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PROSTACYCLIN ACTIVITY IN PORTAL HYPERTENSION 
ABSTRACT
This work was performed between 1979 and 1985 when there was great 
interest in the role of the reœntly identified prostacyclin in vascular function 
and disorders. The discovery of this substance with its powerful vasodilatory 
and platelet anti-aggregatory powers raised the hypothesis that prostacyclin 
might be involved in the pathogenesis of portal hypertension, its associated 
hyperdynamic circulation and typically catastrophic haemorrhage from 
bleeding oesophageal varices.
Partial portal vein ligation in a rat model of portal hypertension was used 
because of its simplicity and absence of hepato-cellular dysfunction. This 
model was found to result in short lived hypertension with return to normal 
pressure by two weeks. Anatomical studies (using venography and corrosion 
casting) of the changes to the portal venous circulation after partial portal vein 
ligation, revealed the development of a dominant portosystemic collateral 
draining into the left renal vein via the left anterior lumbar vein. Ligation of this 
collateral at the same time as partial portal vein ligation gave a reliable model 
of permanent portal hypertension.
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Accurate measurement of prostacyclin proved to be difficult. Initially a bio­
assay of prostacyclin-like activity was used with success. The rat was found 
to produce high levels of prostacyclin well within the range of accurate 
measurement of this assay. Prostacyclin production was shown to increase 
directly with pressure increase in the portal vein. This direct relationship was 
confirmed in the acute model where prostacyclin production fell as the portal 
pressure returned to normal; in the model of chronic portal hypertension, 
prostacyclin production remained permanently elevated.
A radioimmunoassay for 6 ketoPGFI a, the stable breakdown product of 
prostacyclin, was developed to allow measurement of prostacyclin in human 
tissue and serum samples (at this time there were no commercially available 
RIA kits). Initially the Wellcome antiserum was used with accurate 
measurement in incubated human tissue samples. These studies confirmed 
greater intrinsic prostacyclin activity in normal mesenteric and portal vein 
compared to peripheral venous tissues but failed to show any difference in 
tissue or plasma levels of portal hypertensive compared to normal patients.
A second antiserum, the Cardeza antiserum, was then used in the 
radioimmunoassay. Unlike the Wellcome assay, this antiserum did not 
require a prostanoid extraction process. Comparison of the two assays in 
identical samples revealed major differences with large quantities of 6 
ketoPGFI a being measured using the Wellcome antiserum with its extraction 
step compared to virtually none detected using the Cardeza antiserum. The 
extraction step was resulting in production of cross-reacting prostanoid
substances giving falsely high readings. Both radioimmunoassays were 
abandoned at this stage because of the inaccuracy of the first, and the 
inability of the second to detect the low levels of 6 ketoPGFI a in human 
plasma.
The human studies were continued using a highly specific and sensitive assay 
of 6 ketoPGFI a, namely gas chromatography/negative ion chemical ionisation 
mass spectroscopy (GC/NICIMS). At the time of this work, this methodology 
was complex, cumbersome, with limited access and the numbers studied 
were small.
Very low levels of 6 ketoPGFI a were found in peripheral blood of normal and 
portal hypertensive patients who were not bleeding from oesophageal varices. 
In patients without portal hypertension, portal blood levels of prostacyclin were 
higher compared to peripheral levels, confirming the finding in the rat and pig 
that prostacyclin activity is higher in the normal portal circulation compared to 
peripheral vein. Significantly elevated prostacyclin production was found in 
both the peripheral and portal blood of portal hypertensive patients who were 
actively bleeding from oesophageal varices.
Portal prostacyclin production was found to be significantly higher in patients 
with portal hypertension who were actively bleeding compared to normal 
patients undergoing laparotomy for other conditions. These findings in 
bleeding patients support the hypothesis that prostacyclin activity is increased 
in portal hypertension and may play a role in the severity of haemorrhage.
In both the animal and human studies a clear effect of surgical intervention on 
increased prostacyclin production was found.
These studies demonstrated for the first time increased prostacyclin 
production in both developing, and established portal hypertension in both 
the experimental animal situation and in man. High levels of prostacyclin 
production were found in the portal circulation of portal hypertensive patients 
undergoing surgery for uncontrolled variceal bleeding.
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CHAPTER 1: PORTAL HYPERTENSION
1.1 IntrcKluctioii
Portal hypertension is an almost invariable complication of chronic liver 
disease characterised by increased pressure gradients between portal and 
systemic venous circulations. The normal gradient of 5 mm Hg increases in 
portal hypertension and becomes clinically significant when it exceeds 12 mm 
Hg at which level variceal haemorrhage and or development of ascites 
supervenes.
There are two principal factors implicated in the pathophysiology of portal 
hypertension. The first is obstruction to portal blood flow most commonly due 
to diseases of the liver or associated structures. These result in distortion, 
compression or obliteration of the hepatic vasculature giving increased
resistance to portal blood flow leading in turn to portal hypertension. This
obstruction is accompanied by portal venous vasodilation and increased 
mesenteric blood flow, this is known as the hyperaemia of portal hypertension. 
These developments lead to an abnormal systemic cardiovascular status 
namely a hyperdynamic circulation characterised by an increased cardiac 
index and reduced vascular resistance.
Obstruction may occur at different levels. It may be secondary to thrombosis 
in the hepatic veins commonly known as the Budd-Chiari syndrome, within the 
liver parenchyma itself, or in the portal vein. The most common cause of
23
portal hypertension in Europe and North America is cirrhosis which increases 
intra-hepatic vascular resistance by fibrosis, thrombosis and nodular
common but much less frequent cause.
" Ï
regeneration. Portal vein obstruction by thrombosis or extrinsic compression 
is the second most common cause. Hepatic vein occlusion is the third most
A classification of portal hypertension commonly used is by site of obstruction 
namely at the pre-sinusoidal, sinusoidal and post-sinusoidal levels. In pre- 
sinusoidal obstruction, intrinsic liver disease is usually absent and the natural 
history and prognosis of portal hypertension in this group is therefore relatively 
good. In patients with a sinusoidal block, which typically occurs in cirrhosis, 
the degree of hepatocellular damage as a result of the precipitating pathology 
is the most important factor in the natural history of the disease. Death may 
result not only from variceal haemorrhage but also from liver failure, 
malnutrition or infection. Post-sinusoidal obstruction can result in secondary 
hepatocellular damage particularly in Budd-Chiari syndrome where there is 
massive congestion of the liver. In all causes of portal hypertension, the 
underlying degree of hepatocellular damage is the major factor in deciding 
prognosis.
1.2 Anatomical and Physiological Considerations
The portal venous system is entirely devoid of valves and numerous small 
tributaries connect the portal and systemic venous system. In portal 
hypertension these can evolve into major collateral channels, (figs 1.2 (a) & 
(b)) Ï
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Liver
U m bilical  ■ 
vein
Portal vein
Superior  
m esenteric vein 
In ferior
m esenteric vein
R ight an d  left 
gastric veins
S hort 
gastric 
veins
Spleen
Splenic
vein
Fig 1.2(b)
Liver
Inferior vena cava 
Umbilical vein
Transdia
collaterals
Paraumbilical
veins
(caput medusae)
Gonadal vein
Retroperitoneal veins draining 
mainly into the left renal vein 
via left adrenal vein
Portal azygous collaterals 
<oeso(mageal varices)
Short gastric 
vessels
Spleen
Stomach
Left gastric (coronary) 
and right gastric veins
Abdominal wall 
collaterals via 
adhesions, colostomy, 
or ileostomy
Haemorrhoidal veins
Fig 1.2(a) The Portal Circulation & Fig 1.2(b) Portasystemic Shunts
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(from Hamilton.G, Aetiology of Portal Hypertension in Oxford Textbook of 
Surgery, 2"^ Edition, Morris & Wood Eds. Oxford University Press 2000, pp 
1713-25).
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Clinically the most important channel is the left gastric or coronary vein which 
connects the oesophagocardiac venous plexus with the splenic or portal vein.
Numerous other portal systemic collaterals open up at various sites in the 
abdomen, across the diaphragm, and into the haemorrhoidal circulation. In 
addition to these channels, intra-hepatic shunts develop through which a 
significant portion of the portal venous flow can pass. The opening up of 
these channels allows up to 80% of the liver’s blood supply to bypass the 
sinusoidal circulation.
The portal vein normally carries 75% of the blood supply to the liver with an 
average flow of 1,200 ml/min. The hepatic artery supplies the remainder at an 
average flow of 400 ml/min and also supplies 30-40% of the liver’s normal 
oxygen requirement since portal blood is already partly de-oxygenated. In the 
presence of compromised flow to the sinusoids a compensatory increase in 
hepatic arterial inflow takes place to maintain the liver’s oxygen requirements. 
In the presence of intra-hepatic shunting, however, 30% of the hepatic arterial 
flow may bypass the sinusoidal bed and despite the compensatory increase in 
arterial flow, an overall significant reduction in hepatic tissue perfusion can 
occur.
1.3 Haemodynamic Considerations
An appreciation of the basic haemodynamic principles governing flow within 
blood vessels allows a better understanding of the pathophysiology of portal 
hypertension. As in all blood vessels, pressure within the portal system is 
determined by the interaction of flow and vascular resistance. As these 
parameters change, so does portal pressure. This relationship is expressed 
by Ohm’s law.
Ap =  0  X  R
where Ap is the change in Pressure, Q is flow and R is resistance in a vessel.
Resistance is determined by several factors expressed in Poiseuille’s law.
R = 8nL/Trr^
where n is the coefficient of viscosity, L the vessel length, and r the vessel 
radius. Within the liver, viscosity and length of vessel are relatively constant 
and thus changes in the vascular resistance are mainly due to changes in 
radius. Because the relationship is to the 4^  ^ power of the radius, small 
changes in portal vessel diameter will have profound effects on vascular 
resistance. By substitution of the equation for resistance into Ohm’s equation, 
it can also be readily seen that pressure changes will also depend on changes 
in flow.
The normal liver has a very low intra-hepatic resistance which can decrease 
with increased blood flow due to vascular dilatation. This inherent property of 
an extremely compliant hepatic circulation can maintain normal portal 
pressure within a wide range of portal flow. This capacity is lost in liver
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cells. These cells are star shaped with many branching arms and acquire 
contractile properties behaving in a similar manner to vascular pericytes.
1.4 The ‘theories’ of portal hypertension.
■àÿ'
disease with dramatic increases in intra-hepatic resistance. Structural 
disturbances associated with cirrhosis, inflammatory changes in the hepatic 
venous tree and deposition of fibrous tissue around the terminal hepatic
venules and adjacent sinusoids have been described. In cirrhotic livers, intra- 
hepatic resistance may also be affected by proliferation of myofibroblasts 
around the sinusoids and terminal hepatic venules, resulting in increased
contractility which may raise resistance and contribute to portal hypertension 
(Rockey DC, 1997). These myofibroblasts are now known as hepatic stellate %
■I
Thus in response to cytokine stimulated release of vasoactive substances, in 
particular endothelin, these cells by their action on the sinusoids at the 
microcirculatory level can increase the resistance to portal blood flow. Also I
sinusoids may be compressed by hepatocyte enlargement in regenerating 
parts of the liver. This can occur as a result of several toxic, infectious or 
metabolic insults to the parenchyma and may explain the portal hypertension 
seen in non-cirrhotic conditions such as alcoholic hepatitis.
Despite the decompressive effects of the collaterals described above and 
intra-hepatic shunts, with up to 80% of portal blood flow bypassing the liver, 
portal pressure remains elevated. Two major hypotheses have been 
advanced to explain this phenomenon. I
.f
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The “backward” theory postulates that portal hypertension is due to increased 
hepatic vascular resistance which develops as a specific response, so that in 
the presence of normal flow, pressure must increase. Hypertrophy of 
myofibroblasts or stellate cells within the sinusoidal bed is one possible 
mechanism by which this could be achieved. Ohm’s law suggests that portal 
hypertension would only develop if normal liver blood flow was maintained, 
but logically, in the presence of extensive low resistance collaterals, blood 
flow should be diverted away and thus portal pressure should decrease. In 
reality, however, the portal and splanchnic circulation becomes not only 
markedly increased but hyperdynamic, thus negating the likelihood that this 
theory can provide a complete explanation for portal hypertension.
The “forward” theory was initially postulated by Banti in 1883. He suggested 
that splenomegaly, portal hypertension, and cirrhosis were the result of 
increased splanchnic arterial blood flow. The subsequent confirmation of 
increased splanchnic blood flood as a major feature of portal hypertension has 
led to further development of this theory (Vorobioff J et al 1983). This now 
suggests that increased and hyperdynamic flow, together with decreased 
splanchnic pre-capillary resistance, maintain portal hypertension even in the 
face of extensive portosystemic shunting. Since Banti first populated this 
theory, opinions on the relative contribution of increased splanchnic blood flow 
to the development of portal hypertension have varied. In the early 80s when 
the studies for this thesis were performed, there continued to be debates 
regarding the importance of each of these two principal mechanisms. More 
recently Groszmann, (Gupta TK et al, 1997), and other workers have
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increasingly implicated both theories as being involved in the pathophysiology 
of this condition, perhaps coexisting to different degrees in different 
conditions.
It is currently believed that the principal and initial abnormalities previously 
described increase vascular resistance to portal flow and that portal 
hypertension is then maintained by increased blood flow into the portal 
circulation, a phenomenon which has been confirmed conclusively both 
experimentally and clinically. Blood flow to the stomach, spleen, and 
intestines is increased by 50% in portal hypertension. This is achieved largely 
by splanchnic vasodilatation and raised cardiac output.
Cirrhosis and other causes of portal hypertension
i
Increased portal system resistance
i
Portal hypertension
i
Increased production of vasoactive substances
i
Portal collateral formation
i
Peripheral vasodilatation and increased plasma volume
i
Hyperdynamic circulation
30
1.5 Hyperdynamie Circulation of Portal Hypertension
A hyperdynamie systemic circulation is a common feature in patients with 
porta! hypertension. Previously it was thought that the intensity of this 
phenomenon was related to the degree of hepatocellular dysfunction. 
However, this status is also seen in patients with extra-hepatic causes of 
portal hypertension in whom hepatic function is normal. Portosystemic 
shunting and peripheral vasodilatation are the major determinants in the 
pathogenesis of this clinical feature of portal hypertension and are not directly 
related to the status of hepatocellular function. The hyperdynamic circulation 
is characterised by decreased systemic vascular resistance, decreased mean 
arterial pressure, increased splanchnic blood flow, increased cardiac index 
and plasma volume expansion (Murray JF et al, 1958). Three main 
mechanisms have been identified, namely increased levels of circulating 
vasodilators, increased endothelial production of local vasodilators, and 
decreased vascular responses to endogenous vasoconstrictors.
Due to extensive study the pathogenesis of these changes is now becoming 
better understood (Bendis L and Wong F 2001 ). The hyperdynamic changes 
originate in the portal vein and splanchnic venous bed at an early stage 
secondary to increased resistance. In addition to dilation of this vascular bed 
and the development of splenomegaly, portal to systemic shunts develop 
resulting in shunting of portal blood into the systemic circulation. Due to 
ambulatory sub-clinical sodium retention, expansion of all body fluid 
compartments develops. Thus initially the hyperdynamic circulation can be 
detected only after two hours in the supine position probably as a result of
31
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vasorelaxation by suppression of the renin-angiotensin-aldosterone system, 
and redistribution of excess extracellular fluid into the central blood volume. 
Similar changes are found in pregnancy where increased blood volume 
associated with vasodilation and shunting are the fundamental changes which 
will completely reverse post-partum. After liver transplantation however, 
where both portal hypertension and liver function are normalised, the 
hyperdynamic circulation will persist for 6 to 12 months (Piscaglia F et al 
1999). This is probably due to a combination of portal venous remodelling, 
hypertension induced changes to the wall structure of the splanchnic vessels 
and the continuing presence of portasystemic shunts. With deteriorating liver 
function leading to severe decompensation, and major activation of the renin- 
angiotensin-aldosterone system, the systemic hyperdynamic circulation 
becomes evident at all times and postures. A further important feature of
severe decompensation is increasing hyporesponsiveness to increasingly 
elevated circulating vasoconstrictor substances. The aetiology of this 
phenomenon is complex but mainly due to the high levels of vasodilators such 
as nitric oxide and prostacyclin in the systemic circulation acting together with 
changes to the systemic vascular bed. The net result is resistant systemic 
hypotension.
Historically several substances have been implicated as hormonal factors 
which act on both the splanchnic and systemic circulations to produce 
vasodilation and hyperaemia. The most important of these agents are bile 
acids, serotonin, glucagons, adenosine, prostaglandins, in particular 
prostacyclin, and nitric oxide. Elevated levels of bile acids have been
.1
:1,5.1. Endothelial Function in Portal Hypertension
33
i..'
I
demonstrated in patients with liver disease and implicated as promoters of 
splanchnic hyperaemia. Their exact role, however, remains uncertain.
Glucagon is an important splanchnic vasodilator and is elevated in patients 
with portal hypertension and probably accounts for 30% of the increased 
splanchnic blood flow. Indeed the effect of somatostatin in reducing portal 
pressure and blood flow in the clinical situation may in part result from its 
inhibitory effect on the release of glucagon, in addition to its direct vasoactive 
properties. Serotonin has a powerful vasoconstrictor effect on all vascular 
smooth muscle and is normally released into the portal circulation by the 
enterochromaffin cells of the gastrointestinal tract. Experimental evidence 
reveals that selective blockade of serotonin receptors reduces portal pressure 
thus providing evidence for the role of serotonergic mechanisms in the 
pathogenesis of portal hypertension.
At the time that the work for this thesis was undertaken, the role of 
prostacyclin in the aetiology of this phenomenon had not been elucidated. 
Similarly nitric oxide was not identified and studied until later in the 1980s and 
its role in the development of the haemodynamic circulation of portal 
hypertension continues to be investigated. Furthermore, at the time of these 
studies the central importance of endothelium as a modulator of basic 
vascular tone was not realised or implicated as perhaps the most important 
aetiological factor in portal hypertension.
Over the last twenty years or so the importance of endothelium above and 
beyond its traditional role as a barrier between the circulation and the 
interstitial space has been recognised. Endothelium has a plethora of 
important physiological functions both metabolic and regulatory. Through 
balanced control of haemostasis and regulation of vascular tone and blood 
flow, endothelial function is of central importance to the normal function of all 
organs. This balance may be disturbed in many disease states, a condition 
currently known as endothelial dysfunction.
Endothelial dysfunction plays a pivotal role in the pathophysiology of portal 
hypertension. As soon as portal hypertension is triggered complex changes in 
the splanchnic and portal endothelium take place. Mechanical forces, namely 
those of increased pressure and shear stress are sensed by the endothelial
;■
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cell by the process of mechano-transduction. Powerful vasoactive substances 
which affect coagulation and vessel tone by vasodilation and vasoconstriction, 
are released by the endothelial cell to act locally in a paracrine manner within 
the circulation and also by diffusion to act on vascular smooth muscle cells.
As the disease develops humoral factors also will affect the endothelium 
including those described previously. In addition agents produced in large 
quantities by the dysfunctional endothelium will act on other vascular beds in 
an endocrine manner. Endothelial dysfunction is manifest in the acute 
situation in disordered function, and in the chronic situation in long term 
changes to vascular structure.
■ft
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Fig 1.5.1 A simplified schematic of the important mechanisms of 
modulation of vascular tone by the endothelium:
Mechanical stimuli (shear stress & pressure) are sensed by mechano- 
transduction which triggers production of vasoactive substances PGI2 and NO 
(vasodilators) and ET-1 (vasoconstrictor); these substances act locally in a 
paracrine manner on the underlying vascular smooth muscle cells (VSMGs) to 
induce relaxation of the vessel wall and vasodilation, or contraction and 
vasoconstriction. PGI2 acts by increasing levels of c-AMP and protein kinase 
A (PKA); NO acts by raising levels of c-GMP and protein kinase G (PKG); 
endothelin acts by increasing intracellular Ca2+ and protein kinase C (PKC). 
‘Cross-talk’ between ET-1, NO and PGI2 takes place via the ET-b receptor 
and at several levels in both the endothelial and vascular smooth muscle 
cells.
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1.5.1.1 Endothelium derived vasodilators
There are three major vasodilators produced by endothelium, these are 
prostacyclin, nitric oxide and endothelial-derived hyperpolarizing factor.
Prostacvclin (PGI2)
PGI2 is a major product of the cycloxygenase system (COX) in endothelial 
cells but is also produced in smaller quantities by the rest of the vessel wall. 
COX is now known to have two isoforms (COX-1 and COX-2) encoded by two 
separate genes. C0X1 is expressed in many tissues including endothelial 
cells, while C0X2 is not constitutively expressed but is fleetingly but rapidly 
induced in endothelial cells and vascular smooth muscle cells under the 
stimulus of both physical and pre-inf lam matory actions. (Topper J N & 
Gimbrone M A Jr, 1999), (Marnett L J, et al, 1999). These interactions are 
described in more detail in chapter 2 (Prostacyclin) but essentially nitric oxide 
is also released by these same stimuli. The current consensus is that PGI2 
makes a smaller contribution to endothelial derived relaxation than nitric oxide 
but that these two substances act synergistically to inhibit platelet aggregation 
(Stoltz J F et al, 1999).
■iff
Nitric Oxide (NO)
NO is a labile gas produced in endothelial cells from L-Arginine by NO 
Synthase (NOS). Endothelial cells have two isoforms of this enzyme, inducible 
NOS (iNOS) which is calcium dependent, and constitutive NOS (eNOS) which 
is calcium independent and is abundantly released on induction by cytokines 
and endotoxin (Moncada S, 1999).
NO produced by endothelial cells diffuses into vascular smooth muscle cells
stimulating soluble guanylyl cyclase in the cytosol. This leads to increased
levels of cyclic GMP (cGMP), which cause relaxation and vasodilation.
Experimental evidence mainly in the rat model of portal hypertension using 
partial portal vein ligation, has indicated that nitric oxide is important in the 
development of portal hypertension. In man, increased levels of constitutive 
and inducible nitric oxide synthase, secondary to the raised level of 
endotoxins and cytokines found in cirrhosis, are proposed as a mechanism 
resulting in production of nitric oxide and thus vasodilatation. Many groups 
have implicated increased basal production of NO as the major factor in the 
pathogenesis of the portal hypertension. However, this mechanism remains 
unproved in patients with cirrhosis, with contradictory results on the circulation 
found when inhibitors of nitric oxide synthase were administered.
■Whole-body production of NO is increased in portal hypertension and 
increased basal levels of eNOS are found in portal hypertensive animals 
(Cahill PA et al, 2001). The role of iNOS in portal hypertension is less clear
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with most studies unable to localise this enzyme to the splanchnic circulation 
of portal hypertensive animals. Current work has focused on the primacy of 
the rote of NO in the aetiology and maintenance of the hyperdynamic 
circulation and of portal hypertension. However, inhibition of NOS was shown 
not to completely inhibit production of a hyperdynamic circulation (Wu Y et al, 
1993). There clearly is a much more complex interplay of vasoactive 
mediators at work in the pathogenesis of portal hypertension and the 
hyperdynamic circulation.
Recently endotoxins acting within the portal circulation have been implicated 
in the development of increased portal pressure. Endotoxin may play a role in 
stimulating iNOS induction in cirrhosis where portal endotoxaemia is common 
(Chu C J et al, 1997). A new hypothesis implicates endotoxin release from 
bacteria which may act by provoking oxidant stress and formation of reactive 
oxidant species which may be important in the pathophysiology of portal 
hypertension (Goulis J et al, 1999). Recent work performed within this 
department and under co-supervision by the author has provided evidence 
that the hyperdynamic circulation seen in portal hypertension can be 
prevented in the experimental situation by blocking oxidant stress using N- 
acetylcysteine (Fernando B et al, 1998).
Endothelial Derived Hvper-Polarisinq Factor (EDHF)
Endothelium dependent hyper-polarisation and relaxation of vascular smooth
muscle is a vasodilator response to shear stress and humoral factors which is
"I
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different to that from NO and PGI2. (Campbell W B & Harder D R, 1999). The 
exact nature of EDHF is unknown but suspected to be potassium (K^). This 
ion effluxes through channels on endothelial cells resulting in elevated 
myoendothelial K* concentrations which hyper-polarise the IC channels and 
stimulates NaYK^ ATPase activity. Several studies indicate that mechanical 
and/or humoral stimulated EDHF release plays a significant role in modulation 
of the hyperaemia of portal hypertension. (Cahill et al, 2001). Its precise role 
in the aetiology of portal hypertension in relation to NO and PGI2 function 
remains to be elucidated further, however.
1.5.1.2. Endothelium derived vasoconstrictors
The endothelium can cause vasoconstriction either by reduced production of 
vasodilators, or by release of diffusible vasoconstrictor substances such as 
superoxide anions which scavenge NO, thromboxane A2 (TXA2) and 
endothelin (Rubanyi GM. 1991). Several stimuli for endothelial mediated 
vasoconstriction have been identified including hypoxia, the humoral actions 
of acetylcholine, 5-hydroxy tryptamine and ADP, and most importantly the 
production of endothelin. In addition physical stimuli to the vessel wall such 
as pressure and stretch can cause vasoconstriction. Endothelin-1 (ET-1) is 
produced by endothelial cells and acts on local vascular smooth muscle cells 
via surface receptor ET-a causing increased intracellular CA^ "^  and 
vasoconstriction. Circulating ET-1 also acts on ET-b receptors situated on the 
endothelial cell surface to stimulate release of vasoactive substances such as 
NO and PGI2 under normal physiological conditions. This vasoactive effect 
however may be reversed in particular vascular beds in pathological
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1al, 2001).
conditions such as portal hypertension. Elevated circulating ET-1 levels have 
been found both in experimental portal hypertension and in human cirrhotics, 
and increased responsiveness to ET-1 has been found in experimental portal 
hypertension and cirrhosis. ET-1 may therefore have an important role in 
stellate cell contraction and in causing contraction of the portal vein and its 
intrahepatic branches thus causing increased portal resistance (Cahill PA et
A further possible effect is hyporeactivity to the action of vasopressors on the 
splanchnic circulation. There is experimental and clinical evidence for 
decreased responsiveness in portal hypertension and cirrhosis to 
vasoconstrictor substances such as endothelin, noradrenalin, angiotensin II, 
and vasopressin (Bendis L & Wong F. 2001). Thus the balance between 
endogenous vasodilators and vasoconstrictors could be adversely affected in 
different vascular beds and contribute to vasodilation and the production of a 
hyperdynamic circulation.
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1.5.2. Summary
Considerable evidence now exists to support an important and central role for 
endothelial dysfunction in the pathophysiology of portal hypertension and the 
hyperdynamic circulation. The initial increase in pressure within the portal 
system causes a marked increase in mechanical load to the endothelial cell 
which can sense and respond to changes in pressure and shear stress by 
mechano-transduction. The production of vasoactive substances by the 
endothelium is up-regulated leading to over-production. Later changes
40
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expansion which, together with peripheral dilatation, results in the 
hyperdynamic circulation of portal hypertension.
1.6 The Natural History of Portal Hypertension
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mediated by splanchnic vasodilation and imbalance between dilator and 
constrictor vasoactive substances result in permanently increased portal 
venous blood flow. The vasoactive substances produced in the splanchnic 
circulation are then delivered directly into the systemic circulation via the 
portosystemic collaterals which carry 80% of the portal blood flow in portal 
hypertension. These substances remain vasoactive in the systemic 
circulation, thus inducing a global status of endothelial dysfunction. In 
addition the underlying vessel wall changes its pressor response leading to a 
state of vascular hyporesponsiveness. Thus the peripheral systemic 
vasodilatation seen in these patients probably arises in most part from this 
spill-over' effect.
The plasma volume expansion which takes place in these patients probably 
follows directly from the vasodilation induced as described above. The 
proposed mechanism is one of response to the hypovolaemia induced by the 
dilatation of the systemic and splanchnic circulations. This results in a 
decreased central blood volume triggering the renin-angiotensin-aldosterone
I
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.system. The resultant sodium and water retention causes blood volume
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The natural history and prognosis of portal hypertension depends primarily on 
the underlying hepatic functional reserve. Conditions causing presinusoidal 
block but in which hepatocellular function remains good, carry the best
i
prognosis. Where hepatocellular function is very poor, the prognosis is 
dismal. A further factor is the extent of the hyperdynamic circulation in 
different vascular beds which may either increase or decrease as liver disease 
progresses. Portasystemic shunting generally increases with progression of 
liver disease as portal resistance also increases. In well compensated 
cirrhosis portal venous inflow is increased, however in end-stage 
decompensated cirrhosis portal blood flow may gradually decrease. This 
results from the high resistance of a fibrous, shrunken cirrhotic liver which 
together with increased shunting may eventually result in hepatofugal blood 
flow in 15% of such patients (Gaiani S et al 1991 ). Further decompensation of 
liver function results and it is typically in these patients that the severe 
complications of portal hypertension present.
The major lethal complication for all patients with portal hypertension is 
haemorrhage from oesophageal varices. In patients with cirrhosis the overall 
mortality rate from oesophageal variceal bleeding is about 40%. In patients 
who recover from the acute bleed, the risk of recurrent haemorrhage during 
the same hospital stay is 60% and this increases to more than 80% at two 
years. The long-term survival of these patients, therefore, is poor ranging 
from 6 to 36% at five years. It is important to emphasise, however, that only 
about 30% of patients with cirrhosis will ever experience such bleeding. The 
remainder will die of liver failure and infection.
As previously mentioned the outlook in cirrhosis is generally determined by 
the severity of associated hepatocellular disease. A commonly used
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classification of the severity of liver disease was proposed by Child in 1964.
This is based on clinical findings and liver function tests and classified into 
grades A (good liver function), B (moderate impairment of liver function), and 
0 (poor liver function). This classification allows accurate prediction of 
prognosis with the A and B groups having 70-80% survival rates at one year 
after oesophageal variceal bleeding, while only 30% of patients in group 0  will 
survive for a year. During a major oesophageal bleed, as a result of 
hypovolaemia and reduced hepatocellular perfusion, there can be further 
hepatocellular deterioration and commonly a patient in a higher Child’s 
classification can move down into grade C. Thus, variceal bleeding is not only 
an acute life-threatening event, but may cause acute hepatic decompensation 
such that a patient in a good prognostic group will enter a lower Child’s grade.
1.6.1 Oesophageal Varices
Rupture of oesophageal varices, and less commonly of gastric varices, is the 
most dramatic complication of portal hypertension. Elegant anatomical 
studies have revealed in detail the complex and peculiar portasystemic 
connection which occurs in the distal 2-5 cm of the oesophagus precisely in 
the zone where varices develop ( Kitano S et al, 1986).
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Fig 1.6 Venous drainage of the distal oesophagus: (from Hamilton.G, 
Aetiology of Portal Hypertension in Oxford Textbook of Surgery, 2"^ Edition, 
Morris & Wood Eds. Oxford University Press, 2000).
Four distinct layers of veins have been found in this zone, extending from the 
luminal surface to the adventitial layer (fig 1.6). Intraepithélial veins or 
vascular epithelial channels drain into a superficial venous plexus, which lies 
just below the oesophageal epithelium. This plexus is in turn connected to a 
layer of deep intrinsic veins just outside the muscularis mucosae. These deep 
intrinsic veins connect with the outermost external venous plexus coursing 
within the oesophageal adventitia via the perforating veins which traverse the 
muscular layers of the oesophagus. Thus in this distal portion of the 
oesophagus, venous channels are concentrated largely in the mucosa with 
venous channels being present actually within the intraepithélial layer itself. In 
patients with portal hypertension this venous complex situated at the 
watershed between the portal and systemic circulations, dilates dramatically 
and forms varices classically running in 3-5 distinct trunks. The intraepithélial
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channels dilate to form the cherry red spots which can be seen endoscopicaliy 
and the presence of these is recognised as a predictor of impending rupture. 
Less severe variceal bleeds probably result from rupture of the intraepithélial 
channels while torrential haemorrhage results from rupture of the deeper sub­
mucosal high flow intrinsic venous channels. Gastric varices bleed much less 
commonly probably because of their deeper sub-mucosal situation.
1.6.2 Rupture of Oesophageal Varices
Significant rupture occurs in 30% of patients and the causes remain poorly 
understood. Two main theories for variceal rupture are commonly advanced. 
The erosive theory postulates that mucosal damage due to reflux oesophagitis 
causes erosion into the varix and thus haemorrhage. Reflux oesophagitis is 
not commonly seen at endoscopy and control trials have found that H2 
blockade has no advantage over placebo in preventing recurrent variceal 
bleeding. Erosion of the oesophageal mucosa as a cause of rupture therefore 
seems unlikely.
The second theory -  the eruptive theory -  proposes that variceal rupture is 
related to pressure where the varix is in close proximity to the oesophageal 
lumen. Although increased portal pressure is required for variceal 
development, (>12mm/Hg), a direct correlation between portal pressure and 
risk of variceal bleeding has not been found. There is more circumspect 
evidence to support a relationship between the severity of portal hypertension 
and risk of variceal haemorrhage. Portal pressure in alcoholic patients 
following a variceal bleed was higher in those that did not survive. In addition
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angiography and blood volume expansion both of which may increase portal 
pressure, occasionally precipitate haemorrhage. Variceal haemorrhage has 
also been reported to occur after deep inspiration, coughing and following the 
Valsalva manoeuvre, all of which cause an increased pressure differential 
between the oesophageal varix and lumen. Local factors such as variceal 
wall thickness and that of the overlying mucosa are obviously also of 
importance.
%
Variceal size has been reported to be a risk factor for haemorrhage, the larger 
varices being more likely to bleed. There are several studies relating 
frequency of haemorrhage to variceal size. Lebrec et al found increased 
frequency with larger varices, but there was no correlation of variceal size or 
frequency of haemorrhage with the degree of portal hypertension (Lebrec D et 
al, 1980). A study by Witzel et al found that varix size increased significantly 
with the severity of liver disease, and that frequency of haemorrhage also 
increased significantly with increasing size of varices, (Witzel L et al, 1985). 
These and other previous studies suggested that large varices are more likely 
to bleed than small ones, although clinical experience shows that there will be 
exceptions to this rule, (Baker LA et al, 1959 and Dagradi AE, 1972). The 
relationship between risk of bleeding from varices and portal pressure remains 
controversial. Benhamou has proposed that varices develop when portal 
pressure is more than 10-12mm/Hg over the IVC pressure but once 
developed, variceal size is not related to the degree of hypertension, 
(Benhamou JP, 1982). In 1982, Reynolds reviewed the evidence and found 
that although a few studies directly related higher portal pressure to bleeding,
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wmany more failed to show any significant relationship. In these latter studies 
portal pressure was measured in patients with severe liver disease in a variety 
of ways ranging from wedged hepatic venous pressure to trans-hepatic portal 
pressure, and in all, portal vein pressure could not be found to predict the risk 
of bleeding, (Reynolds TB, 1982). The most relevant pressure measurement 
is that of intra-variceal pressure since there may not necessarily be a direct 
relationship with portal pressure. There are two studies where intra-variceal 
pressure was measured by direct puncture of the varix above the oesopho- 
gastric junction. The first study in 1956 showed no correlation between intra- 
varix pressure and bleeding risk, (Palmer AD et al, 1956). A study in the 80s 
by Westaby et al showed a close correlation between intra-abdominal portal 
pressure as measured by wedged hepatic venous pressure and the 
oesophageal varix pressure, and furthermore that rises in intra-abdominal 
pressure caused by direct compression, led to an increased gradient across 
the varix wall. This manoeuvre did not lead to any immediate haemorrhage, 
but this study did not address itself to risk of subsequent haemorrhage from 
variceal puncture because the patients underwent prophylactic injection 
sclerotherapy, (Westaby D et al, 1985). Of great interest is the fact that in 
both studies no significant bleeding resulted from needling of the varices. 
This supports the observation that pressure is indeed not important once the 
varix has developed, and perhaps coagulation in particular local factors may 
be of more importance in bleeding from varices.
The lack of relationship between pressure and variceal size reinforces the 
importance of local factors in varix development however. Polio and
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Groszmann have proposed that variceal wall tension may be the unifying 
predictor of rupture (Polio J & Groszmann RJ, 1986). Tension in the variceal 
wall can be derived from a modification of Laplace’s Law;
T=TP X r/w
were T is tension, TP is transluminal pressure, r is vessel radius and w is wall 
thickness.
Fig 1.6.1 Variceal wall tension: variceal wall tension is greater where radius 
(r) is larger and the wall (w) is thinner despite equal transmural pressure 
(from Hamilton.G, Aetiology of Portal Hypertension in Oxford Textbook of 
Surgery, 2"^ Edition, Morris & Wood Eds, Oxford University Press, 2000)
In oesophageal varices, transluminal tension is the difference in pressure 
between the oesophageal lumen and that of the varix. This tension is directly
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related not only to this pressure difference, but also to the varix radius and is 
inversely related to variceal wall thickness. These three variables correspond
compromise of hepato-cellular function, multiple and complex haemostatic 
defects are invariably present.
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in the clinical situation to variceal size, thickness of epithelium overlying the 
varix and degree of portal hypertension, all of which have been described as
independent predictors of bleeding. When portal pressure is increased the 
more superficial protruding varix will have less supporting connective tissue 
and a larger radius than a deeper varix embedded in supporting tissue which 
is under identical pressure. Wall tension will therefore be higher in these 
superficial varices and rupture will result when this tension is no longer in 
equilibrium with the outwardly directed expansile force of portal pressure. 
When the elastic limit of the vessel has been reached small changes in 
volume or radius will result in large changes in wall tension and imminent 
rupture. Reduction of variceal pressure by shunting, disconnection or by 
pharmacological means will decrease transluminal pressure, vessel radius 
and wall tension. Sclerotherapy by causing dense perivariceal scarring, will 
increase the surrounding supporting tissue strengthening the variceal wall and 
thus decreasing tension.
Once rupture has occurred the severity of haemorrhage will be affected by 
haemodynamic factors and complicated by the disordered haemostasis that 
frequently accompanies liver disease. Portal hypertension is frequently 
complicated by disorders of blood coagulation and haemostasis. The liver 
plays a central role in these functions, consequently where there is severe
I
Hypersplenism is a common accompaniment to portal hypertension, and the 
resulting platelet abnormalities compound the coagulatory disorder. The liver 
is the major site of synthesis of at least 11 blood coagulation proteins, two 
components of the fibrinolytic system and anti-thrombin. In chronic liver 
disease significant derangement of haemostasis is most common in the more 
severe grades of hepato-cellular dysfunction, but with the exception of pro­
thrombin, measurement of various components of haemostasis has failed to 
be useful in prediction of risk of haemorrhage,. Deficiency of the vitamin K 
dependent factors II, VII, IX and X results in abnormalities of both the extrinsic
I:
and intrinsic coagulation pathways and prolongation of the pro-thrombin, and 
partial thromboplastin times, (PT & PTT). Abnormal PT and PTT can be an 
early consequence of liver disease, even in the presence of minimally 
deranged liver function tests, and these tests remain the most useful
'
screening and monitoring measurements for coagulation defects and liver 
disease. Administration of vitamin K and fresh frozen plasma will correct the 
PT and PTT in the majority of cases with improved clotting. A minority of 
patients however continue to bleed despite corrected or improved parameters 
and this area of deficient haemostasis in severe liver disease remains poorly 
understood. Thrombocytopaenia is commonly present in liver disease 
particularly in portal hypertension where hyper-splenism is common, (Toghill 
PJ et al, 1977). This is usually secondary to platelet pooling and 
sequestration within the spleen, but platelet survival is normal. In addition 
platelet function may be deficient in several chronic liver diseases, particularly 
so in alcoholic disease, (Thomas DP et al, 1967, Ballard HS et al, 1976 and 
Cowan DH, 1973). In this disease impaired platelet function with prolonged
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bleeding times has been shown to be as a result of selective inhibition of TXA2 
synthesis and platelet aggregation, (Cowan DH, 1980, Mikhailidis DP et al, 
1986 and Mikhailidis DP et al, 1983).
Another factor in the abnormal coagulation of liver disease is increased 
fibrinolytic activity. The underlying mechanism of this increased activity 
remains controversial, but may result from impaired clearance of circulating 
activators or be secondary to an underlying disseminated intra-vascular 
coagulation, (DIC), (Fletcher AP et al, 1964). DIC may result because of
i
decreased plasminogen synthesis which has been reported to be low or 
normal in liver disease, or because of impaired hepatic clearance of activated 
coagulation productions, (Bloom AL, 1975 and Thomas DP et al, 1970). In 
portal hypertension, endotoxins absorbed from the gut in to the portal blood, 
may bypass the liver via porta-systemic collaterals thus entering the systemic 
circulation unaltered and possibly resulting in platelet aggregation and
1
thrombin formation, (Wilkinson SP, 1977). The importance of endotoxaemia 
is being realised in recent studies but at the time of the commencement of the
work for this thesis in 1980, the importance of endotoxin was not as well 
defined.
Patients with liver disease may show multiple disorders of haemostasis 
including deficient production by the liver of the coagulation proteins, 
thrombocytopaenia secondary to hypersplenism, impaired platelet function, 
and increased fibrinolytic activity. The relative importance of all these factors 
in the clinical situation remains unclear. Haemorrhage generally responds to I
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transfusion of whole, preferably fresh, blood and clotting factors such as fresh 
frozen plasma, cryoprecipitate and platelets. Empirically, haemodynamic 
factors may be most important in the development of rupture, while 
coagulatory factors may be of greater importance once profuse bleeding is 
established.
In 1979 when the experimental studies described in this thesis were first 
begun, the major vasodilatory, and more importantly platelet aggregation 
inhibitory effects of prostacyclin, raised the possibility that excess production 
of this prostaglandin might have an effect at the site of oesophageal variceal 
rupture promoting torrential haemorrhage.
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CHAPTER 2 : PROSTACYCLIN
Prostacyclin (PGI2) is a prostaglandin produced mainly by endothelial cells acting in 
a paracrine manner, and is a very powerful vasodilator and inhibitor of platelet 
aggregation. Most of this chapter describes what was known about prostacyclin 
during the years of my experimental and early clinical studies, that is from 1979- 
1985. Where relevant, up to date knowledge of prostacyclin is reviewed.
2.1 Historical Background
Prostaglandin was a derivative name given to substances initially found in seminal 
fluid in the 1930s which were found to cause contraction of human uterine muscle, 
(von Euler US, 1934). The exact nature of the substance began to be defined with 
advances into the field of lipid chemistry in the 1960s. Several decades before this, 
linoleic and arachidonic acids had been identified as essential fatty acids. In the 
1960s it was established that arachidonate was an important link between the 
essential fatty acids and prostaglandins when biosynthesis of PGI2 from aracidonic 
acid was achieved (Bergstrom S et al, 1964). Prostaglandins were then shown to be 
20 carbon unsaturated carboxylic acids with a cyclopentane ring. By this time 
prostaglandins (PGs) were shown to be present in most body tissues indicating a 
fundamental role at the cellular level. This led to the proposal that the observed 
effects of essential fatty acid deficiency might be due to inadequate synthesis of 
prostaglandins.
The effect of prostaglandins on the circulation was first discovered in 1966 when a 
prostaglandin subsequently named PGEi inhibited ADP-induced platelet aggregation 
in vivo in the rat, pig and man. Furthermore, infusion of PGEi was shown to inhibit
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the transient thrombocytopaenia which usually develops after intravenous infusion of 
ADP (Kloeze J, 1970). In 1973 Smith et al demonstrated that platelets produced 
stable prostaglandins and also that aspirin was able to inhibit selectively 
prostaglandin synthesis in human platelets, (Smith JB et al, 1973 and Smith JB et al,
1971). Since it was already known that aspirin inhibited platelet aggregation, the 
logical conclusion was made that prostaglandins produced by platelets were involved 
in the process of haemostasis, (Weiss HJ et al, 1968).
In 1973 platelets were shown to be generating several prostaglandins when 
aggregation was stimulated by addition of arachidonate, and in addition arachidonate 
was shown to stimulate release of a rabbit aorta contracting substance (RCS), 
(Vargaftig BB et al, 1973). Production of prostaglandins and RCS were shown to be 
suppressed by anti-inflammatory drugs such as aspirin. RCS had been previously 
described by Piper and Vane, (Piper PJ & Vane JR, 1969), as an unstable substance 
produced in anaphylaxis of isolated guinea pig lungs; it was thought to be an 
intermediate in prostaglandin synthesis and possibly the cyclic intermediate 
endoperoxide reported by Samuelsson et al in 1965, (Samuelsson B, 1965). 
Subsequently, prostaglandins G2 and H2 were produced on incubation of 
microsomes prepared from sheep seminal vesicles incubated with labelled 
arachidonic acid. Both of these substances were shown to stimulate platelet 
aggregation in vitro and to contract rabbit aortic strips, (Hamberg M et al, 1974). A 
new metabolite was identified in studies with labelled arachidonate incubated with 
platelets which led to the identification of thromboxane A2 (TXA2) (Hamberg M et al, 
1974 and Hamberg M & Samuelsson B, 1974). TXA2 was shown to be a very potent 
platelet aggregatory agent and vasoconstrictor and also the active component in
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rabbit aorta contracting substance, (Hamberg M et ai, 1975).
C et al, 1971). Subsequently this substance was confirmed to be the main hydrolytic 
product of the unstable compound PGI2.
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Moncada and Vane studied tissues other than platelets which might produce this 
substance and while looking at blood vessel homogenates found an unknown 
prostaglandin which had potent vasodilatory and platelet inhibitory properties which 
was then named PGX, (Moncada S et al, 1976[a] and Bunting S et al, 1976). At 
about the same time, other workers independently found this vasodilatory substance 
PGX on incubation with arachidonate with intact blood vessel preparation (Kulkarni 
PS et al, 1976 and Raz A et al, 1977). PGX was found to have a striking ability to 
inhibit platelet aggregation being 20-30 times more potent than PGEi, and 5-10 times 
more potent than PGD2 making it the most powerful naturally occurring anti­
aggregatory substance known at that time, (Moncada S et al, 1976[b]). It was found 
to be highly unstable with its anti-aggregatory activity disappearing after standing for 
20 minutes at 22°C in tris-buffer or within seconds after boiling. Its activity could be 
prolonged by storage at 0®C or at pHiO and preserved by several days if dissolved in 
dry acetone and stored at -20°C. Its chemical structure was identified as 9-deoxy-6, 
9-alpha-epoxy-delta 5 PGFi alpha and was finally named prostacyclin or PGI2. 
(Whittaker N et al, 1976). This identified PGI2 as the main metabolite of arachidonic 
acid in vascular tissues. PGI2 was probably the same substance identified in 1973 
by Saba et al from human umbilical endothelial cells (Saba SR et al, 1973). Pace- 
Asciak had also previously described a compound called 6-keto PGFi alpha which 
was found to be a product of prostaglandin metabolism in rat stomach, (Pace-Asciak
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2.2 Biosynthesis of PGI.
2.2.2 Synthesis of PGbfrom arachidonate
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2.2.1. Reiease of arachidonate from membrane phosphoiipids
Arachidonic acid is a polyunsaturated fatty acid which is present in cell membrane 
phospholipids and other cellular lipids, and is the precursor substrate for all 
prostaglandins including PGb and TXA2. Its release is initiated by either mechanical 
or biochemical stimulation of the cells by the action of phospholipase C and 
phospholipase A2 and is calcium dependent, being initiated by a rise in intracellular 
Ca^  ^(Lands WE, 1979, Bell RL & Majerus PW, 1980 and Broekman MJ et al, 1980).
î
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There are three pathways for the metabolism of released arachidonic acid, the 
lipoxygenase, cycloxygenase, or cytochrome P450-dependent epoxygenase 
mediated pathways. Cycloxygenase converts arachidonate or other 20 carbon chain 
unsaturated fatty acids into cyclic endoperoxides (prostaglandins and 
thromboxanes), lipoxygenase converts to the leukotrienes, and cytochrome P450 
epoxygenase forms epoxyeicosanoids (Quiroga J, & Prieto J. 1993). These 
essential fatty acids contain 3, 4 or 5 double bonds which will be metabolised and 
designated accordingly into groups of prostaglandins namely PG1 (one double 
bond), PG2 (two double bonds) or PG3 (three double bonds).
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Figure 2.2 Synthesis of prostanoids from arachidonic acid: Arachidonic acid is 
mobilised from phospholopid pools by the action of phospholipase2; COX-1 and 
COX-2 act to convert arachidonic acid to cyclic endoperoxides (1): Thromboxane 
synthase acts at (3) to form TXA2 and prostacyclin synthase acts at (2) to form PGI2; 
the stable end products TXB2 and 6-keto PGFiO are formed by hydrolysis.
Cycloxygenase stimulated transformation of arachidonate into PGH2 is irreversible 
and is therefore a potentially rate limiting step in prostaglandin production 
(Thuresson ED et al, 2000). The endoperoxides PGG2 and PGH2 thus formed are 
mainly converted by prostaglandin synthetase in the endothelial cells into PGI2 or in 
the platelet by thromboxane synthetase in to TXA2.
In vitro it was demonstrated that exogenous endoperoxides could be taken up by
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endothelial cells and metabolised into prostaglandins such as PGI2 which could then 
be released to the exterior (Marcus AJ et al, 1978). This raised the possibility that 
activated platelets might release endoperoxides which could then be metabolised by 
endothelial cells to form PGI2 and thus limit propagation of thrombus formation. 
Several studies in 1979 however, led to the conclusion that under normal 
physiological circumstances platelets do not constitute a significant source of 
endoperoxides for PGI2 synthesis. The main source of endoperoxides is therefore 
endogenous from the arachidonic pool of the endothelial cell, (Baenziger NL et al, 
1979, Needleman P et al, 1979 and Hornstra G et al, 1979).
PGI2 is a major product of the cycloxygenase system (COX) in endothelial cells but 
is also produced in smaller quantities by the rest of the vessel wall. COX is now 
known to have two isoforms (COX-1 and COX-2) encoded by two separate genes. 
COX-1 is expressed in many tissues including endothelial cells, while COX-2 is not 
constitutively expressed but is fleetingly but rapidly induced in endothelial cells and 
vascular smooth muscle cells under the stimulus of both physical and pre- 
inflammatory actions. (Topper J N, Gimbrone M A Jr, 1999) (Marnett L J, et al 
1999). Their products are the same catalyzing a two step reaction producing first 
PGG2 then PGH2. COX-1 is expressed on the endoplasmic reticulum of all cells and 
is responsible for the constitutive production of prostaglandins in most tissues 
including platelets. COX-1 dependent prostaglandin production is currently thought 
to serve physiological housekeeping functions in particular cytoprotection of gastric 
mucosa, modulation of renal function and production of TXA2 in the platelet. Its 
concentration remains relatively stable. COX-2 is virtually undetectable in normal 
conditions but is induced by cytokines, endotoxins, growth factors or tumour
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promoters {Smith WL, Langenbach R. 2001). Thus this inducible conversion of 
arachidonate to PGHg by COX-2 in various pathophysiological settings provides an 
additional rate limiting step in prostanoid biosynthesis.
In addition to inflammatory modulators mechanical forces, in particular shear stress,
-■are now known to induce COX-2 in vascular endothelial cells (Topper and Gimbrone 
1999). Thus increased expression of COX-2 (which is a rapidly occurring 
phenomenon) is being increasingly implicated in the pathophysiology of several 
disease processes and indeed may play an important role in the pathogenesis of 
portal hypertension.
■I
The final step in synthesis of PGb and TXA2 from PGH2 involves two similar
Jisomerases, PGI2 synthase and TXA2 synthase. These act by a haeme-thyolate 
mechanism to rearrange the PGH2 molecule to form the two important vasoactive 
prostanoids with opposing biological properties, PGI2 and TXA2 (Tanabe T, Ullrich V.
1995).
2.2.3. Sites of synthesis of PGb
Moncada et al studied the differential production of PGb by different layers of rabbit 
aorta. It was shown that intima had the greatest PGb activity, the media was 
intermediate and the adventitia had the least activity, (Moncada S et al, 1977[a]). On 
quantification of this activity, the intima, although only 5% by weight, was found to 
produce 40% of the total PGb Later cultured human umbilical vein endothelium and 
bovine aortic endothelium were shown to produce PGb, as were porcine 
endothelium and smooth muscle cells, (Weksler BB et al, 1977 and MacIntyre DE at
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al, 1978). Also cultured endothelial cells produced more PGb than cultured smooth 
muscle cells, (Baenziger NL et al, 1979 and Baenziger NL et al, 1977). In a seminal 
experiment, Elder et al demonstrated cessation of PGb production from the luminal 
surface of rabbit aorta after stripping of the endothelium with a balloon catheter. As 
a new intima of medial smooth muscle cells developed however, so the capacity for f  j
■IPG b production returned and once fully developed the smooth muscle cells
produced as much PGb as normal endothelium, (Eldor A et al, 1981).
Other vessels were subsequently studied, with placenta and umbilical vessels in 
particular demonstrated to have a very high capacity to synthesise PGb. Arteries 
were shown to produce more PGb than veins on a weight per weight basis,
(Johnson AR, 1980). Other cells of non-vascular origin such as macrophages, •£
fibroblasts, mésothélial cells, renal glomerular and gastric fundal mucosal cells were 
shown also to produce PGb but with no conclusive studies of portal or mesenteric 
endothelial PGb activity being reported at the time of commencement of the studies 
to be described in this thesis.
2.2.4 Metabolism of prostacyclin
At physiological pH and temperature, PGb is a very unstable molecule, its hydrolysis 
being inversely proportional to the pH of its environment. At a pH of 7.55, PGb has a 
half-life of 3 minutes in buffer solution, but as a result of albumen binding its half-life 
is greater than 20 minutes in plasma or whole blood at normal pH, (Pifer DD et al, 
1981 and Wynalda MA et al, 1980). PGb is at its most stable at an alkaline pH (>9) 
and at lower temperatures. In physiological media, PGb is rapidly hydrolysed to an 
inactive derivative 6-keto PGFio, (Pace-Asciak C et al, 1971). In vivo studies in
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animals have shown that PGb metabolism follows metabolic pathways similar to 
other prostanoids. The in vivo metabolism in humans has been studied by 
measuring the effect of bolus infusions of PGb or G-keto PGFiO into volunteers, 
(Myatt L et al, 1981). These studies showed that PGb was mainly hydrolysed to 6- 
keto PGFiO with a minor degree of dehydrogenation by 15-hydroxyl-PG- 
dehydrogenase (PGDN) in the lungs. This enzyme inactivates 90% of primary 
prostaglandins after a single passage through the lungs but PGb survives pulmonary 
transit without any loss of biological activity, (Ferreira SH & Vane JR, 1967, Dusting 
GJ et al, 1978 and Bolger PM et al, 1978). In the late 70s, it was reported that the 
lung released PGb into the arterial circulation leading to the suggestion that PGb 
might be a circulating hormone (Gryglewski RJ et al, 1978[a], Hensby CN et al, 
1979[a] and Moncada S et al, 1978[bj). This proposal, highly contentious and 
debated at the time, has since been refuted based on later accurate measurements 
of 6-keto PGFio in human blood.
The major clearance of prostaglandins including PGb, is by the liver but also by the 
kidneys and skeletal muscle, (Dusting GJ et al, 1978). There are many urinary 
metabolites including 2, 3 dinor 6-keto PGFi alpha and 6, 15 diketo, 13-14 dihydro, 
2-3 dinor PGFi a, (Bizzi A et al, 1977 and Blackwell GJ et al, 1977)
2.2.5. Regulation of PGb synthesis
PGb synthesis is primarily regulated in a rate limiting manner by the availability of 
arachidonic acid, the preferred fatty acid substrate, by the induction of COX-2 and 
also by a variety of materials and drugs. COX-2 in turn, is inhibited by 
glucocorticoids and by the recently available COX-2 inhibitor drugs. In this review
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some of the more important factors are described in the regulation of PGI2 regulation 
which at present remains puzzling but undoubtedly forms part of a complex, highly 
efficient system of regulatory pathways in cellular function.
Thrombin induces PGI2 production in human endothelial cells suggesting that this 
might be a physiological mechanism by which the growth of thrombus at the site of a 
vascular injury might be limited, (Czervionke RL et al, 1979 and Weksler BB et al, 
1978). A range of vasoactive substances including bradykinin, histamine, 
angiotensin II and serotonin induce PGb synthesis from endothelial cells. Histamine 
has a potent effect on endothelial cell synthesis of PGb occurring at concentrations 
found during acute allergic reactions. This suggests that this mechanism may play a 
role in the histamine mediated allergic reactions such as hypotension, (Baenziger NL 
et al, 1980 and Baenziger NL et al, 1981). Platelet activating factor (PAF) acting via 
increasing calcium influx has been shown to prime the action of histamine and 
thrombin in increasing PGb production from human umbilical vein endothelial cells in 
culture (Weber C, et al 1993). Angiotensin II similarly has a potent stimulatory effect 
but adrenaline and non-adrenaline do not, (Gimbrone MA, Jr & Alexander RW, 1975, 
Nolan RD et al, 1981). Serotonin induces synthesis of PGb in smooth muscle cells 
and its action is potentiated by PDGF, (Coughlin SR et al, 1980 and Coughlin SR et 
al, 1981). Other plasma substances such as lipoproteins will affect PGb synthesis 
with high-density lipoprotein (HDL) stimulating, and low density lipoproteins (LDL) 
suppressing, PGb synthesis in vascular tissue culture, (Beitz J & Forster W, 1980, 
and Evensen SA, 1979).
Tumour necrosis factor oc (TNFa) has recently been shown to potentiate angiotensin
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Il induced PGb synthesis in vascular smooth muscle cells (Askari B, Ferrerib NR.
2001). Both TNFa and interleukin-1 induce slow release of PGb from cultured
endothelial cells and this mechanism has been implicated as factor in the
hypotension of septic shock (Vane JR, Sotting RM. 1995). Human lymphocytes 
have also been shown to act on cultured human endothelial cells by stimulating
PGb production (Merhi-Soussi F, et al 2000).
Superoxide anions (O2'-) are produced by endothelial cells as part of oxygen 
derived free radical formation and are generally inactivated by scavenging enzymes
'?
such as superoxide dismutase. Superoxide anion interacts with nitric oxide very 
rapidly to form peroxynitrite (ONOO ) which may not only reduce levels of nitric 
oxide but also powerfully inhibits synthesis of prostacyclin by inhibition of PGb 
synthase (Katusic ZS. 1996). Increased production of superoxide anion has been 
implicated in several arterial disease states such as hypertension, resulting in 
vasoconstriction as a result of the inhibition of both nitric oxide and prostacyclin.
There is no data to confirm whether this reaction plays a role in portal hypertension 
but it is implicated as a factor in endothelial dysfunction (Ullrich V et al 2001). Nitric 
oxide in the presence of increased superoxide may also therefore be involved in the 
regulation of prostacyclin synthesis.
Prostacyclin release is significantly stimulated by mechanical forces such as 
transmural pressure, wall tension and shear stress. In recent years prostacyclin 
production has been shown to increase biphasically after shear stress loading of 
HUVECs. This probably results from an initial increased arachidonic acid release 
and a combination of increased expression of both COXs and PGb synthase 
(Okahara K, et al 1998).
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Current knowledge of the regulation of P G b and TXA2 synthesis is revealing a most 
complex interaction involving growth factors, cytokines, other eicosanoids and lipid 
mediators. At the heart of this complexity is the regulatory coupling of PG b -  TXA2 
which is implicated in several disease states. However, in 1980 when the studies to 
be described were carried out, the regulation of PG b synthesis was poorly 
understood but recognised to be multi-factorial and complex.
2.3 Pharmacology of PGIg
The most striking properties of PGb are its potent inhibition of platelet aggregation 
and its vasodilatory activity (Moncada S et al, 1976a). Its ability to inhibit platelet 
adhesion and to disaggregate platelets and disperse platelet clumps both in vitro and 
in the human circulation, has long been recognised (Moncada S et al, 1978[a]) 
(Szczeklik A, et al 1978). It remains the most potent inhibitor of platelet aggregation 
yet discovered, much more potent and longer lasting than PGEi or PGD2.
In 1979 receptors had been demonstrated on platelets and red blood cells with the 
receptor sites on platelets being shared with PGEi, (Siegl AM et al, 1979 and Miller 
OV et al, 1979). The nature of these receptors has been further studied particularly 
with the introduction of TXA2 synthase blockers which surprisingly showed no 
inhibition of platelet aggregation. Prostanoid receptors belong to a group of seven- 
loop transmembrane spanning G-protein coupled receptors. TXA2 has two receptors 
but so far only one receptor for PGb has been found and is named the IP-receptor 
(Ullrich Vetal,  2001).
2.3.1. PGb and cyclic AMP
Acting on these receptors, agents which inhibit platelet aggregation increase cAMP,
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and agents which stimulate platelet aggregation decrease cAMP levels, (Haslam RJ 
et al, 1972, Weiss A et al, 1978, Mills DC et al, 1971 and Salzman EW et al, 1971). 
These observations led to the hypothesis that the biological effects of PGb resulted 
from stimulation of intracellular adenylate cyclase with subsequent elevation of 
cAMP levels. This hypothesis was supported when it was shown that PGb was the 
most potent inducer of platelet cAMP production and at least 10 times more potent 
than PGEi, (Gorman RR et al, 1977 and Tateson JE et al, 1977). Inhibitors of 
adenylate cyclase activation were also shown to prevent the biological actions of 
PGb, (Haslam RJ et al 1978). PGb was shown directly to stimulate adenylate 
cyclase activity in platelet microsomes causing elevation of cAMP levels, activation 
of protein kinases and the phosphorylation of other proteins with the direct 
consequence of inhibition of aggregation (Best LG et al, 1977). It has also been 
shown to stimulate adenylate cyclase in endothelial cells and similarly PGb has a 
much more potent effect than PGEi or other prostaglandins, (Gryglewski RJ et al, 
1978[c]). PGb has also been shown to stimulate cAMP levels in many other types of 
cells including fibroblasts and arterial rings (Claesson HE, 1980 and Baenziger NL et 
al, 1980).
The mechanism by which PGb stimulated elevation of cAMP affects platelet 
aggregability is based on intra-cellular calcium signalling. When TXA2 is formed in 
platelets during activation, calcium irons are released from bound intra-cel I ular sites 
and are then bound to calmodulin to form the calcium/calmodulin complex. This 
complex then stimulates phospholipase A2 activity and activates myosin kinase. 
The activated myosin kinase phosphorylates myosin, which interacts with actin 
resulting in platelet contraction and the release reaction, (Hathaway DR et al, 1979).
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2.3.3 PGb and platelet adhesion
PGb has been shown to inhibit platelet adhesion but only occurring at much higher 
concentrations (>100 nM) than those required for inhibition of platelet aggregation 
(Higgs EA et al, 1978, Weiss HJ et al, 1979 and Adelman B et al, 1981). PGb has 
also been shown to inhibit changes in platelet shape induced by ADP or 
arachidonate, and indeed it has been suggested that this might be the mechanism 
by which platelet adherence is decreased, (Ehrman ML et al, 1980 and Kinlough- 
Rathbone RL et al, 1970). However, the concentration of PGb required to inhibit 
adhesion is much higher than that for aggregation and is much greater than that 
found under normal physiological conditions. It is therefore likely that inhibition of 
platelet adhesion by PGb is not physiologically important in the circulation but it may 
be physiologically important at the level of the platelet endothelial cell interface
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Elevation of cAMP by PGb causes calcium sequestration, decreasing phospholipase 
A2 activation and release of arachidonate, and activating a cAMP dependent protein 
kinase. This kinase phosphorylates myosin kinase, thus decreasing phosphorylation 
of myosin, reducing actin-myosin interaction, and inhibiting the release reaction,
(Hathaway DR et al, 1979).
Î2.3.2 PGb and de-aggregation of platelets
;PGb has the ability to de-aggregate platelets initially demonstrated by Moncada et 
al, who showed reversal of human platelet aggregation by PGb incubated with aortic 
microsomes, (Moncada S et al, 1977[b]). This activity has also been demonstrated 
in vivo in man where PGb infusion decreased the percentage of circulating platelet 
aggregates formed, (Gryglewski RJ et al, 1978[bj).
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where the concentrations of PG b are potentially much greater.
2.3.4 PGb and vascular smooth muscle
PGb is a potent vasodilator relaxing vascular smooth muscle in all mammalian 
species tested. The degree of vasodilation varies with different vascular beds and 
species but both large and small vessels are affected. The exact mechanism by 
which PGb achieves this affect was unclear at the time of the study, but was felt to 
be related to changes in cAMP. It had previously been thought that increases in 
cAMP levels caused smooth muscle cell relaxation while increased cGMP or 
decreased cAMP levels caused contraction, (Andersson R et al, 1972, Broekman MJ 
et al, 1980 and Poch G et al, 1972). However, other studies have shown that 
smooth muscle relaxation is not dependent on raised cAMP levels, (Collins GA et al, 
1975, Diamond J et al, 1975 and Uruno T et al, 1973). PGb like other 
prostaglandins may have a biphasic action on cAMP production dependent on its 
concentrations. PGb has been shown to have a duel effect on isolated human 
ovarian veins with low concentrations causing depression of muscle tone but higher 
concentrations causing increased tone and inducing phasic contractile cycles, 
(Borda ES at el, 1979). So a direct relationship between PGb induced changes and 
cAMP and smooth muscle contractivity could not be demonstrated and at the time of 
this work, it was thought that PGb acted by altering the levels of cyclic nucleotides 
thus in turn controlling intra-cellular free calcium iron fluxes, (Andersson R et al,
1972). It is now recognised that Ca^* mediated phosphorylation of myosin light chain 
is central to relaxation and contraction of vascular smooth muscle (Walsh MP. 1994). 
Increased intracellular Ca^ above basal levels causes formation of the 
Ca^almodulin complex which binds with myosin light chain kinase, enabling
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phosphorylation of myosin light chain subunits. Actin-myosin cross-bridging results 
causing shortening of the muscle fibres and vasoconstriction. Removal of 
intracellular Ca^ causes the to Ca^/calmodulin complex to dissociate, reversing the 
above process by dephosphorylation of myosin light chain subunits, resulting in 
muscle relaxation and vessel dilation.
In the clinical situation, infusion of PGb causes rapid cutaneous flushing, lowers 
mean arterial pressure by lowering diastolic pressure, and causes vasodilatation of 
coronary, coeliac and mesenteric arterial beds, (O'Grady J et al, 1980). These 
effects however occur at very high circulating levels of PGb, which are not present in 
the physiological situation. Thus, on the evidence available at the time of this study, 
the contribution of PGb to normal vascular tone was not clear.
2.4. Prostaglandin Production in Disease
There is substantial evidence that PGb production by vascular tissue may be altered 
in various disease states, and that increased or decreased production is associated 
with a range of diseases including chronic renal disease and atherosclerosis.
Venous stasis and mild ischaemia have been shown to increase PGb production and 
release. This had been demonstrated primarily after temporary peripheral venous 
occlusion with a sphygmomanometer and also in veins after tourniquet ischaemia for 
total knee replacement, (Serneri GG et al, 1980 and Zahavi J et al, 1980). In both 
studies there was a rapid fall in production after release of occlusion. In 1979 a 
plasma factor was found in patients with uraemia and hepatic failure which 
stimulated PGI2 release from rat aortic slices and in a separate study a factor was
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found in uraemic plasma which stimulated normal endothelial cells to produce PGb. 
(Van Hoof A et al, 1979 and Defreyn G et al, 1980). In acute and chronic uraemia, 
vascular tissue was found to have increased PGb activity leading to the suggestion 
that this might be a factor in the severe haemostatic deficiency found in renal failure, 
(Remuzzi G et al, 1978[a]). This effect of uraemia on PGb production by endothelial 
cells has been confirmed in vessels from rats with experimentally induced uraemia, 
(Silberbauer K et al, 1978).
A congenital deficiency of thromboxane synthetase has been demonstrated in three 
generations of a family with consequent redirection of arachidonic metabolism to 
formation of PGb and PGDg. All affected members were found to have prolonged 
bleeding times with defective platelet function, (Defreyn G et al, 1981). Familial 
cycloxygenase deficiency has also been reported characterised by a bleeding 
tendency but paradoxically in this case, both PGb and TXA2 production were 
deficient, (Pareti FI et al, 1980).
Bartter’s syndrome, (hypertension, hypokalaemia, elevated plasma renin and 
aldosterone secretion, diminished response to pressor agents), was a focus of a 
great deal of attention when these patients were shown to have increased urinary 6- 
keto PGFi alpha excretion (Gill JR et al, 1976). In these patients it was shown that 
there was a plasma factor which had PGb like inhibition of platelets, (Gullner HG et 
al, 1979 and Jackson EK& Goodman RP, 1981). Treatment with indomethacin, an 
inhibitor of prostaglandin synthetase, successfully corrected both the blood pressure 
and platelet aggregation abnormality, (Stoff JS et al, 1980).
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Pace-Asciak et al reported increased PGb production by aortic rings from 
spontaneously hypertensive rats in whom an increased incidence of stroke was 
shown when PGb synthesis was blocked, (Pace-Asciak C et al, 1976 and Okuma M 
et al, 1979). In man decreased 6-keto PGFia and PGE2 have been reported in 
essential hypertension but whether this represents production of these metabolites 
by the kidney or urinary excretion of metabolites from systemic vascular production 
is not clear, (Grose JH et al, 1980, Tan SY et al, 1978).
Decreased PGb production appears to be present in arteriosclerosis. In 
experimentally induced arteriosclerosis in the rabbit, PGb synthesis is decreased in 
aortic rings, (Dembinska-Kiec A et al, 1977, Sinzinger H et al, 1979 and Gryglewski 
RJ et al, 1978[c]). In experimental hypercholesteraemia the time taken by aortic 
neo-inti ma formed after endothelial trauma to resume PGb synthesis was prolonged 
when compared to normal (Eldor A et al, 1982). In man both LDL and lipid peroxides 
similar to those found in atheroslerotic plaques have been shown to inhibit PGb 
synthesis in normal endothelium, (Nordoy A et al, 1978). In diabetes mellitus 
reduced PGb synthesis has been demonstrated in man and also in experimentally 
induced diabetes in rats (Silberbauer K et al, 1979, Davis TM et al, 1981, Harrison 
HE et al, 1978 and Carreras LO et al, 1980). In diabetic patients, TXA2 synthesis by 
platelets has also been shown by several workers to be increased with plasma 6- 
keto PGFi a levels appearing to be normal or slightly decreased, (Davis TM et al, 
1981, Johnson M et al, 1979, Davis TM et al, 1979 and Halushka PV et al, 1981).
In pre-eclampsia and chronic placental insufficiency syndromes in general, PGb 
production by the placenta, umbilical artery and the foetus is reduced, (Downing I et
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al, 1980, Remuzzi G et al, 1980[a], Remuzzi G et al, 1980[b] and Stuart MJ et al, 
1981). Deficiency of a plasma factor stimulating PGb production has been reported 
in the haemoiytic uraemic syndrome and in thrombotic thrombocytopaenic purpura, 
(Remuzzi G et al, 1978[b], Webster J et al, 1980, Hensby CN et al, 1979[b], Remuzzi 
G et al, 1979, Jorgensen KA et al, 1981, Wiles PG et al, 1981 and Chen YC et al, 
1981). Reduced PGb activity had also been reported in systemic lupus 
erythematosus, (McVerry BA et al, 1980).
Prostacyclin has been used as a therapeutic agent in several disease states with 
some success. Prostacyclin infusion (or inhalation) successfully lowers pressure in 
patients with primary pulmonary hypertension, can significantly improve rest pain in 
patients with end-stage peripheral vascular disease and relieve the symptoms of 
Raynaud’s disease (Vane RJ and Botting RM, 1995). This therapeutic success in 
disorders where endothelial dysfunction is a central feature suggests that 
prostacyclin production is impaired in these disease states.
Thus at the time of this study, there was a considerable volume of data implicating 
abnormalities of PGb production in vascular and other diseases. There had been 
very little work on the role of PG b in liver diseases and in particular in hepatic failure 
and portal hypertension. These observations and other disease states led to the 
hypothesis to be tested in this thesis.
9
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HYPOTHESIS TO BE TESTED
Alterations in PGb production in portal hypertension may contribute not only to the 
pathophysiology of portal hypertension but also to deficient haemostasis resulting in 
the catastrophic haemorrhage which so commonly complicates oesophageal varices.
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CHAPTER 3: MEASUREMENT OF PROSTACYCLIN 
3.1 Introduction
Because of the evanescence and production in small quantities of most prostanoids, 
their measurement in the 1970s and 1980s, posed particular difficulties. PGb’s very 
short half- life made assay of this prostanoid even more problematical.
PGb was initially assayed by measurement of its biological effects, namely relaxation 
of vascular smooth muscle and inhibition of platelet aggregation. There are two 
commonly used applications of these properties in PGb assay. In the cascade 
perfusion assay PGI2 is detected by its effect on smooth muscle contractility when 
continuously perfused with blood or perfusate. Platelet nephelometry on the other 
hand, measures PGI2 by the effect of tissue extracts or perfusates on platelet 
aggregation. More recently, PGI2 has been assayed by physico-chemical rather than 
biological methods, namely radio-immunoassay (RiA) and gas chromatography/ 
mass spectrometry (GC/MS). Both techniques measure 6-keto PGFia the stable 
breakdown product of PGI2.
Over the duration of the study, different assays were used as they became available. 
Initially a bio-assay was used, then RIAs were developed and applied and in the final 
part of the study plasma measurements were made using GC/MS. In this chapter 
the development and application of these assays to PGI2 measurement are 
described. With the exception of the GC/MS measurements, this work took place in 
the Katharine Dormandy Department of Haemophilia at the Royal Free Hospital.
I was fortunate to have access to measurement of PGI2 working with Dr Rose Chow 
(who at that time was a Research Scientist in the department) and under the direct 
supervision and direction of Dr Ron Hutton, Principal Biochemist and expert in
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haemostasis.
3.2 Bioassays 
3.2.1 Cascade Perfusion
Superperfusion of tissues is a widely used technique for the bioassay of biologically 
active substances and it was indeed with this technique that Vane first detected PGX 
or PGI2, (Bult H et al, 1977 and Vane JR, 1969). The basis for this assay is the 
smooth muscle relaxing or contracting effect of prostanoids on various animal 
tissues. PGI2 characteristically contracts a range of tissues such as rat stomach 
strip, but relaxes vascular tissue such as rabbit aorta, (Moncada S et al, 1976[a]). 
This assay's great advantage is the ability to make continuous and instantaneous 
measurement of a perfused tissue's production of PGI2 There are several major 
disadvantages however. Identification of PGI2 is dependent on an appropriate 
selection of a range of tissues to be perfused, which will respond in a manner 
particular to PGI2, and in order to exclude possible interference from other vaso­
active substances appropriate antagonists need to be used. Furthermore accurate 
measurement of absolute concentrations was not possible. For all these reasons, 
plus the lack of expertise at the Royal Free Hospital or the Royal Free Hospital 
School of Medicine in this technique, cascade superfusion was not used to assay 
PGI2.
3.2.2 Platelet Nephelometry
This assay exploits the principle that the optical density of platelet rich plasma (PRP) 
will decrease as platelets aggregate. Born first applied this concept in the 
development of the platelet aggregometer, (Born GVR, 1962). A modern version of 
this machine, the Payton dual channel aggregometer, was used in these
• Î
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experiments. The study was based on methods described and validated by 
Moncada et al, (Moncada S, 1977[b]). Essentially, the fall in optical density of a test 
solution containing a fixed amount of platelets after addition of an aggregatory agent
■:
is compared to the maximum fall in density occurring in a buffer containing control 
(fig 3.2.2). The amount of PGb in the sample is calculated by comparing the 
percentage inhibition measured with a standard curve as described by Hutton et al,
1980.
3.2.2.1 Method
a. Preparation of platelet rich plasma
50ml of blood was taken from the ante-cubital vein of normal subjects who 
had not taken any prostaglandin synthetase inhibitors (i.e. aspirin or non­
steroidal anti-inflammatory drugs) for two weeks. Platelet rich plasma (PRP) 
was prepared as outlined in Appendix A.
b. Aggregating agents
Adenosine phosphate (sodium salt ADP, Sigma Pharmaceuticals) was used 
exclusively throughout the study; the final concentration varied from 2 to 10pM 
made up in Owren’s buffered saline, pH 7.35 (Appendix A).
c. Anti-aggregation assay
0.4ml of PRP was incubated at 37°C for 60 seconds in a siliconised glass 
cuvette in the Payton aggregometer with 0.05ml of test solution or 0.05ml of 
control (Tris buffer pH 8.0). 0.05ml of ADP (lOpM final concentration) was 
added and the following optical density registered on a Rikadenky pen 
recorder (see figure 3.2.2). After 3 minutes the fall in optical density of the 
PRP was measured from the tracing and expressed as a percentage of that
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seen in the buffer control.
PRINCIPLE OF A ’BORN-TYPE" PLATELET AGGREGOMETER.
source
Heated block Tube containing
at 37®c PRP + mixing flea
Rotating 
U-magnet
Ptiotoelectric cell 
connected to a 
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Fig 3.2.2 The Payton Aggregometer exploits the principle that the 
optical density of stirred plasma decreases as platelets aggregate under 
the effect of various aggregating agents.
In order to confirm that the inhibitor present was PGI2 and not another 
physiologically active substance, all test samples were incubated at 37°C for 
20 minutes. This effectively destroys PGI2 while not affecting other more 
stable prostaglandin inhibitors or ADP degrading enzymes (ADP-ases). These 
samples were assayed as above to confirm loss of inhibitory activity.
d. Standard dose response curve for PGI2
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This assay was applied to a range of known concentrations of PGIa and 
inhibition for each concentration was plotted to make a standard dose 
response curve. Fresh prostacyclin standards were prepared by dissolving 
crystalline PGb sodium salt in Tris buffer (pH 8.0) at a concentration of 120 
ng/ml and serial dilutions with Tris buffer were made. A range of dilutions 
were therefore made as follows: 0.12, 0.3, 0.6, 1.2, 3.0, 6, 9, 12, 60 and 120 
ng/ml. These standard solutions were kept at 4°C to preserve prostacyclin 
activity.
e. ADR degrading activity
The action of ADP-ases could possibly exist in biological fluids and therefore 
affect the results. Because ADP was used as the aggregatory agent ADP-ase 
activity was measured in each sample as follows.
2.0ml of neat or diluted tissue extract was incubated at 37°C with an equal 
volume of ADP (100pM/l). At 30 to 60 second intervals, 0.1ml of the 
incubation mixture was added to 0.04ml of PRP, and platelet aggregation by 
residual ADP was measured as before. A further volume of this incubation 
mixture was assayed for residual ADP at each interval, using the modified 
firefly luminescence methods, (Holmsen H et al, 1966 and Hardisty RM et al, 
1970).
f. Calculation of PGI2 Activity
From the aggregation tracing (in the absence of any ADP-ase activity) the 
percentage inhibition was calculated from the formula
77
% aaareaation in test sample at 3 min x 100 
% aggregation in control at 3 min
With this value the amount of PGI2 activity in the test sample was calculated 
from the standard curve.
3.2.2 2 Results
The standard dose response curve is shown in figure 3.2.2.2. The lower limit of 
sensitivity was found to be 1 ng/ml. No ADP-ase activity was found.
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Fig 3.2.2 2 Typical dose response curve for PGI2
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3.2.2 3 Discussion
This method has the major advantage of providing a dynamic physiological assay of 
biological activity which is relatively straightforward and gives rapid results. There 
are several problems with the assay however which limits its usefulness.
Firstly the assay specificity is limited, 1 ng/ml being the minimum concentration of 
PGI2 detectable. Furthermore inhibition of platelet aggregation is not specific to PGI2 
and many other physiological inhibitors such as PGA2, PGEi, PGD2, adenosine and 
ADP degrading enzymes could be present in biological fluids. By testing for ADP- 
ase activity and by incubating samples to destroy PGI2, this possibility can be largely 
although not totally excluded. A theoretical alternative approach to the problem of 
specificity would be to use PGI2 production inhibitors (such as Indomethacin, 15- 
hydroxy-peroxy-arachidonate [15HPAA] and tranylcypromine) during control 
incubation of samples to ensure that the substance produced was indeed PGI2
Because of the above concern about specificity , the results for PGI2 
measurements were expressed as units of PGb-like activity.
There were technical problems related to the need for immediate assay because 
of the lability of PGI2. Consequently, the number of samples that could be assayed 
at any one time was significantly limited. Because of these difficulties and of the 
need to measure PGI2 in plasma, a radio-immunoassay (RIA) was also developed.
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PHYSICO-CHEMICAL ASSAYS OF 6-keto PGF, qc
3.3.1 The Radio-immunoassay of 6-keto PGF^  qc
A RIA for 6-keto PGFi a, the stable breakdown of PGb, was developed initially using 
an anti-serum kindly donated by Dr J A Salmon of the Welcome Laboratories. This 
work was done in collaboration with and under the direct supervision of Dr Rose 
Chow and Dr Ron Hutton, Department of Haemophilia at the Royal Free Hospital.
3.3.1.1 Sources of antisera and liquids
Antiserum was donated by Dr J A Salmon of the Wellcome Research Laboratories, 
Beckenham, Kent. Later in the study a second antiserum was supplied by Dr P B 
Smith of the Cardeza Foundation, Philadelphia, PA, USA. Both Dr Salmon's 
antiserum and that from Cardeza were raised against 6-keto PGFiq conjugated to 
bovine serum albumin and supplied in freeze dried form, (Salmon JA, 1978). 
Tritiated 6-keto PGFiO was purchased from the Radiochemical Centre, Amersham, 
UK.
3.3.1.2 Dilution of the antiserum
The working concentration of an antiserum is normally chosen to give 40-60% 
binding of a radioactive antibody in the absence of the unlabelled antigen, 
(Granstrom E et al, 1978). The use of too much antibody results in an assay with 
diminished sensitivity because there are too many available binding sites. On the 
other hand, too dilute an antiserum results in a narrowing down of the working range 
of the standards. It is generally accepted that the greatest sensitivity is obtained if 
the expected level of the unknown cold ligand or antigen is taken into consideration.
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The final working of the serum dilution chosen would be that resulting in maximal 
displacement between anti serum curves with and without the expected antigen load. 
The best antiserum dilution for this RIA was determined in the following experiment.
3.3.1.3 Method
A modification of Salmon’s method was used, (Salmon JA, 1978), and in order to 
establish maximum assay sensitivity a loading dose of 100pg 6-keto PGFio was 
Included in the assay. A stock solution of 0.5mg/ml of the antiserum was made up in 
0.1% gelatin tris buffer pH 7.5 (GTB, Appendix A) and a series of dilutions from 1/10 
to 1/1000 were made. Duplicate 0.1ml aliquots were mixed in plastic tubes, (LP3 
Sarstadt), with 0.1ml of (H^) 6-keto PGFiO (ca 10,000 dpm, Appendix A) and either 
0.1ml GTB alone or 0.1ml GTB containing lOOpg unlabelled 6-keto PGFio; total and 
blank samples were included. After mixing, the mixture was stored at 4°C for 24 
hours. 1ml dextran coated charcoal (DCC) was added, mixed and incubated for 10 
minutes. After centrifugation at 3,000g and 4®C for 15 minutes, 1.0ml of the 
supernatant was transferred to a vial containing 7.5ml of scintillation liquid (Appendix 
A) and counted for 10 minutes in a LKB p scintillation counter. This procedure was 
repeated using different antiserum dilutions and the concentration resulting in the 
greatest displacement of bound label was determined.
3.3.1.3 Results
The results are shown in figure 3.3.1.3 where percentage bound labelled 6-keto 
PGFi Q was plotted against concentration of antiserum with and without the loading 
dose of lOOpg unlabelled 6-keto PGFio. A dilution of 0.0.4mg/ml was found to
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produce the greatest displacement between curves at percentage binding of 
between 32-50%. This was therefore chosen as the anti serum dilution yielding 
greatest sensitivity.
70i
60
50-
40-
No Load 
100 pg LoadCD 30-
20-
10-
0.70.1
Freeze dried antiserum (mg/ml)
0.01
Fig 3.3.1.3 Dilution curve for the Wellcome antiserum with and without iOOpg 
unlabelled 6 keto PGFia load
3.3.1.4 Standards
Essential characteristics of a standard should be stability and purity. The levels
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.where K is the affinity constant of the antiserum.
3.3.1.4.1 Estimation of affinity constant of the antiserum
The affinity constant (Ka) of an antiserum is derived from the assumption that the 
rates of association (binding) and disassociation of antigens (Ag) to and from 
antibodies (Ab) reaches a steady state of equilibrium (i.e. the law of mass action).
K1
Ag + Ab -  Ag/Ab complex 
K2
Ka = —K,
where Ki = the rate of association of Ag/Ab complex 
K2 = the rate of disassociation of Ag/Ab complex
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should be chosen to cover the range of values within which the substance to be 
measured is expected to fall. Antiserum unlabelled antigen concentration should be 
chosen accordingly and should ideally concentrate on the most sensitive part of the 
standard curve, but still extend over the entire range. In addition, upper and lower 
detection limits should be included in order to identify the range of sensitivity. 
Sensitivity is measured according to the following principle:
Sensitivity =
where Sigma = errors and K = affinity constant, (Ekins RP, 1974).
From this, the lowest amount of antigen that can be accurately measured may be 
derived. Assuming that the relative experimental error Sigma remains constant (i.e.
coefficient of variation = 1 ), then the least detectable amount of antigen = —K.
:,:S
In this case where the antiserum is a heterogeneous mixture of antibodies, each with 
its own Ka, and the specific activity of the antiserum is not known, the affinity 
constant was estimated from a saturation curve of bound against free antigen by a 
method which exploits the Michaelis-Menton equation (Thorell J et al, 1978). From 
this the Ka in litres/mole (I/M) can be derived from the following equation:
Ka = (FA/MW)xD
where FA = pg free antigen at 50% of total load bound 
MW = molecular weight and D = dilution
3.3.1.4.2 Method
Tritiated 6-keto PGFioc was diluted with GTB pH 7.5 to make a series of 
concentrations from 4.8 to 81.7pg/ml 6-keto PGFiO. 0.1ml of each dilution was 
incubated in duplicate with 0.2ml GTB and 0.1ml of antiserum (Appendix A). 
Duplicate total and blank samples were included for each dilution of labelled antigen. 
The samples were incubated at 4°C for 24 hours and then 1ml of DCC was added, 
incubated for a further 10 minutes and centrifuged at 3,000g for 15 minutes to 
separate the bound and free fractions. 1 ml aliquots of supernatant were counted. 
The experiment was repeated several times at different dilutions of antiserum to 
obtain a good spread of points on the saturation curve.
3.3.1.4.3 Results
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Fig 3.3.1.4.3 Affinity constant of the Wellcome antiserum as determined from 
the saturation curve
The saturation curve obtained is shown in figure 3.3.1.4.3. A true plateau was not 
reached: this was therefore assumed to have occurred at the 80pg level. Therefore, 
30.5pg free antigen was present at 50% binding of the total load. Thus
1x10'"Ka = (30.5/380)x2500/ 
1x10'"
I/M
200.7
Therefore, the least amount detectable, 1/Ka 
= 200.7 X 10'^  ^M/L
I/M
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= 762.7 X 10 ■ '^'g/0.1ml 
= 7.6x10-'^g/0,1nnl
Thus the lower amount of antigen detectable with this assay was just under lOpg 
and consequently this was the lowest concentration used in making up the
Several prostanoids could theoretically cross react with 6-keto PGFioc. Salmon found 
that the majority of prostaglandins and their metabolites did not cross react with 6- 
keto PGFioc antiserum, but did report significant cross reaction with PGEi (11%), 
PGEz (4.8%), PGFioc (7.5%) and PGFzoc (5.4%), (Salmon JA, 1978). Using a 
different antiserum, another worker found much less cross reactivity (PGEi 0.09%, 
PGE2 0.16%, PGFzoc 0.8%), (Mitchell MD, 1978).
3.3.1.5.1 Method
PGA2, PGEi, PGE2, PGF20C (obtained from Sigma Pharmaceuticals) and 6-keto
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3.3.1.5 Specificity of the Antiserum
Specificity of an assay is defined as the extent of freedom from interference by 
substances other than that intended to be measured, (Midgley AR, Jr et al, 1969). 
RIA supposedly has the major advantage of great specificity but several factors may 
act adversely to affect this. Non-specific factors such as pH, osmolality, the 
presence of binding proteins, enzymes and certain cations may affect the antigen- 
antibody reaction or concentration of available binding sites. Thus the ability of the 
antibody to detect a particular antigenic determinant may be affected and possibly 
result in increased cross reactivity with structurally similar substances. It is therefore 
important to assess the specificity of the antiserum used.
PGFia were prepared in concentrations of 100,000pg, 10,000pg, 1,000pg, 100pg 
and 50pg in GTB. Each was incubated with 0.1ml antiserum, 0.1ml -  6-keto
PGFi alpha (ca lO.OOOdpm) and 0.1ml GTB. Duplicate samples were made and 
processed as above. On a separate occasion the method was repeated for PGb.
3.3.1.5.2 Results
Standard curves for each agent were plotted using the percentage of total bound 
ligand against the concentration of ligand used and are shown in figure 3.3.1.5.2 a.
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Fig 3.3.1.5.2 a Inhibition of binding of tritiated 6 keto PGFia to the Wellcome 
antiserum by unlabelled prostaglandins: antiserum / prostaglandin cross­
reactivity is calculated from the intercept with the horizontal axis at 50% total activity
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From the above figure the relative cross-reactivity between antiserum and ligands 
can be calculated from the following formula
% cross-reaction = concentrations at 50% total binding.bgand
The data was also plotted using the Logit Plot method which straightens the curves 
allowing easier comparison (Rodbard D et al, 1970). This method is based on the 
following equation:
Logit (Y) = log e [ - ^ 11 — I
where Y = b/bo
b=fraction of tracer bound, and bo=maximal binding in absence of unlabelled antigen 
These results are shown in figure 3.3.1.5.2 b.
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Fig 3.3.1.5.2 b Plots of Logit B/Bo for 6 keto PGFia and other prostaglandins 
using the Wellcome antiserum
Calculations of relative cross reactivity are shown in Appendix 0 and tabulated in 
table 3.3.1.5.2.
Ligand Relative Cross-Reaction 
From curves From Lc
6ketoPGFia 1 1.0
PGp2a 0.03 0.0032
PGEi 0.0009 <0.000004
PGAz 0.0007 <0.000004
PGEs 0.0003 <0.000004
PGI2 0.546
Table 3.3.1.5.2 Specificity of the BketoPGFi» Antiserum (See Appendix 0  for 
the calculations of the relative cross-reaction to the SketoPGFia antiserum).
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Logit plots comparing 6-keto PGFiO and PGb are shown in figure 3.3.1.5.2 c (6.5).
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Fig 3.3.1.5.2 c Plot of Logit B/Bofor SketoPGFia and PGb using the Wellcome 
SketoPGFia Antiserum
3.3.1.5.3 Conclusion
The relative cross-reactions were found to be higher when calculated by the 
standard curves rather than by the logit plot method. This difference could 
be due to the more subjective fitting of the standard curves giving the 
potential for less accurate measurement of zero binding of the label.
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3.3.1.6 Correlation Between 6-keto PGFio RiA AND PGIg Bioassay
Once established the 6-keto PGFioc RIA was correlated with the bio-assay for PG 12- 
like activity. This correlation was made using human tissue, namely human umbilical 
vein which was a readily available and fresh source of vascular tissue.
3.3.1.6.1 Method
Five fresh umbilical cords from normal deliveries were obtained (Ethical Committee 
Approval and consent obtained) and 10 arteries and 5 veins dissected from them. 
Vessel rings were prepared as previously described an incubated in TBS pH 7.5 at a 
concentration of 200pg/ml for 3 minutes at room temperature. The incubation fluid 
was immediately assayed for PGb-like activity by bio-assay. At the same time, 
aliquots of this fluid were stored at 4°C and 6-keto PGFi alpha assayed by RIA at a 
convenient time.
3.3.1.6.2 Results
The linear regression plot between these two assays is shown in figure 3.3.1.6.2.
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Fig 3.3.1.6.2 Linear regression plot between PGb and 6 keto PGFia in artery 
and vein
3.3.1.6.3 Conclusion
There was excellent correlation found between these two assays (R = 0.97), 
indicating that biological activity measured immediately correlated well with the 
presence of PGb’s breakdown products measured at a convenient time later. Thus, 
RIA for PGFioc using the technique described above is a convenient and reliable 
method for measuring PGb production in tissue incubates.
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3.3.1.7 Discussion
A RIA for 6-keto PGFioc was developed because of several expected advantages 
over other methods. The major benefits included greater sensitivity and specificity 
than platelet nephelometry, a lower detection limit and greater precision and 
accuracy. A further expected advantage was the possibility of carrying out analyses 
on multiple samples at a convenient time without the need for immediate assay.
In fact, from the above experiments the following criteria for this RIA were 
established.
a. Maximal sensitivity was achieved at an antiserum concentration of 0.4 
mg/ml.
b. The affinity constant Ka of the antiserum was found to be 5 x 10  ^ I/M, with 
a lower detection limit of 10pg/ml.
c. PGF2=c was the only prostanoid of those tested that had any substantial 
cross reactivity (only prostanoids described at that time as having 
significant cross-reactivity were studied). The relative cross reaction was 
low at 0.003 using the Logit Plot method, thus the antiserum was proved to 
be highly specific for 6-keto PGFi alpha.
d. There was very good correlation between 6-keto PGFioc and biological 
activity as measured by platelet nephelometry.
The obvious disadvantage of the RIA is that it does not directly measure PGb but 
one of the 2 possible breakdown products. Although 6-keto PGFi^ is the main 
metabolite, it remains unknown whether the balance of metabolites is maintained
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Iunder non-physiological conditions. A further problem is that the assay is 
immunologically based and does not reflect the dynamic physiological function of the 
substance being measured. Practical disadvantages of the assay were limited to the 
methodology which proved laborious, and could not be completed within one working 
day.
The demonstration of the high specificity and excellent correlation between 6-keto 
PGFioc and biological activity suggests that these possible disadvantages were not of 
critical importance in the application of the RIA.
SUMMARY
From this work a highly specific RIA for 6-keto PGFioc was developed. In the use of 
this assay during the study the following method and incubation system was adopted 
for the RIA of 6-keto PGFi alpha using the Wellcome antiserum.
0.1ml gelatin tris buffer pH 7.5
0.1 ml standard or sample
0.1ml (H®) 6-keto PGFi« (ca 10,000dpm)
0.1ml 6-keto PGFioc anti serum (0.4mg/ml)
Standards ranged from lOpg to 10,000pg cold 6-keto PGFioc. Total gelatin content 
was 0.1% with addition of sodium azide 0.1% to inhibit bacterial growth in the gelatin 
solutions. The samples were stored at 4°C for 18 to 24 hours before the addition of 
1.0ml DCC and a further incubation of 10 minutes at 4°C. The samples were then 
centrifuged at 3,000g at 4°C for 15 minutes and 1.0ml of the supernatant removed by
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aspiration for counting.
This RIA provided an accurate and specific method for measuring PGb activity in 
vascular tissues which formed the basis of the study at this time.
3.3.2 MEASUREMENT OF 6-keto PGF.oc BY RIA IN PLASMA
Introduction
Ethically it is difficult to collect human clinical tissue samples either on a single 
occasion or particularly repeatedly over a period of time for prostaglandin 
measurements. The ease of collection of peripheral venous samples with the added 
logistical advantage of repeated sampling made plasma measurement of crucial 
importance.
■U-
An alternative way of measuring prostaglandin production was by assay of urinary 
metabolites. However, this method only allows measurement of total excretion over a 
specified period of time (usually 24 hours) and is therefore unable to detect 
fluctuations in production. At the time, this was felt to be a disadvantage and thus 
inappropriate to the proposed clinical studies. Furthermore, of more importance to 
this study, was the inability of this method to determine the source of production of 
PGb For these reasons, urinary PGb metabolites were not measured.
In this section, the modification and eventual application of the RIA to plasma 
measurement that took place in this study is described. Ethical Committee approval 
from the Royal Free Hospital Ethics Committee was obtained for studies using blood 
samples from volunteers and patients.
Blood Collection
Blood was collected by antecubital venepuncture using 21G needles into plastic 
tubes containing sodium EDTA and Indomethacin in tris buffer pH 7.5 at final 
concentrations of 2mg/ml and 10pM respectively. Sodium EDTA, a calcium 
chelating agent was included to anticoagulate and prevent further activation of the 
arachidonata pathway while Indomethacin, an inhibitor of cyclo-oxygenase, was 
used to prevent further formation of PGb or other prostanoids. Blood was collected 
only from volunteers or patients who had not taken aspirin or non-steroidal anti­
inflammatory drugs for 2 weeks prior to sampling. Anti-coagulated samples were 
stored in tubes placed in iced water for transport. After centrifugation at 3,000G at 
4°C for 15 minutes, plasma was collected in 1.0ml aliquots into plastic tubes and 
stored at -40°C until assayed.
3.3.2.1 Measurement of 6-keto PGFioc in Plasma without an 
extraction step
Because of the small quantities of prostanoids typically present in plasma extraction 
steps are commonly used to concentrate the substance being studied sufficiently to 
give levels measurable by the RIA. At the beginning of the study it was not clear 
whether prostacyclin was present in sufficiently high concentrations to allow 
measurement in plasma without an extraction step. In order to establish whether the 
step would be required the following experiments were carried out;
3.3.2.1.1 Experiment i; Direct plasma measurement
Blood was collected from 10 healthy volunteers and processed as above. 0.01ml of
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plasma was assayed for 6-keto PGFioc using the standard incubation system. This 
procedure was repeated using 0.2ml plasma (i.e. double volume) with omission of 
GTB to maintain an equivalent total volume of 0.04ml; the final gelatin concentration 
was made up to 0.1%.
Result
6-keto PGFioc levels were all below 10pg/ml even when using the double volume 
sample.
3.3.2.1.2 Experiment ii: pre-loading plasma before measurement
In an attempt to increase the detection limits of the assay, the RIA was performed in 
the standard manner but with prior addition of 60pg of cold 6-keto PGFioc in a volume 
of 0.01ml to each sample; the same volume of GTB was added to the standard.
Result
6-keto PGFioc levels were once again below the lower detection limit of lOpg/ml.
3.3.2.1 Conclusion
From these results, it was clear that this assay could not directly measure 6-keto 
PGFioc in plasma. It was therefore necessary to include an extraction step in the 
assay.
3.3.2 2 Extraction of Prostanoids from Plasma
Extraction and further purification steps are very commonly used in RIA of 
prostanoids. As always this process has disadvantages as well as advantages. The 
ideal advantage of the extraction process would be in achieving concentration of the
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prostanoid in the sample to bring it within the range of the radio-immunoassay. 
Furthermore, extraction might result in disassociation of most of the prostanoid from 
the prostanoid/albumin complex which binds most of these substances in plasma, 
and there was a further perceived potential advantage of removal of unknown factors 
which might interfere with the RIA.
There are many disadvantages with the extraction process however, including the 
fact that the recovery of prostanoid can be frequently low and inconsistent, the 
extraction process itself may modify related substances in the plasma to cross react 
with the antibody resulting in falsely high results, and impurities in the reagents may 
be introduced by this step which could interfere with the RIA. Finally, the whole 
assay procedure becomes more laborious, time consuming and expensive thus 
severely limiting the number of samples which can be simultaneously processed, 
(Granstrom E et al, 1978). Many extraction methods for prostaglandins are 
described, all based on the principle that acidification will render fatty acids insoluble. 
Prostaglandins are cyclic fatty acids, and as such, the carboxyl group can be altered 
by changing the pH of the medium. Carboxylic acids have a pKa (negative logarithm 
of the dissociation constant) of between 4 and 5.
High pH >
Prostanoid -  COOH o  prostanoid -  COO" +
< Low PH
At low pH the carboxyl moiety is intact and thus insoluble, while at high pH, 
dissociation into its ionic form takes place and thus becomes soluble in aqueous 
media. Thus acidification will render the fatty acids insoluble, allowing extraction by 
organic solvents.
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3.3.2.2.1 Standard Method to Extract Plasma
The development of the extraction process presented numerous problems such as 
émulsification of the samples, poor and variable recoveries and difficulties with 
extract re-suspension after evaporation. Extraction without further purification by thin 
layer chromatography (TLC) was used because the recovery was significantly lower 
after TLC.
Sample number
Recovery after 
TLC (%)
[A]
Recovery without 
TLC (%)
IB]
6ketoPGF1a 
pg/ml using RIA 
on [B] samples
1 37.9 73.1 101
2 30.1 62.9 102
3 43.4 60.2 169
4 47.6 85.7 91
5 41 71 167
6 39.9 74.6 91
7 38.1. 69.3 175
8 32.7 72.3 118
9 36.1 64.2 98
10 33.6 68.9 98
Table 3.3.2.2.1 Comparison of recoveries from 10 normal human plasma 
extractions with and without Thin Layer Chromatography (TLC)
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As a result, the method used throughout this part of the work, was as follows:
1 ml of plasma was added to a polypropylene tube containing 2m! acetone at - 
20°C; 0.1ml of 6-keto PGFi«: (ca 2,000dpm) was added and the sample 
vortexed for 30 seconds, centrifuged at 2,000G for 3 minutes, and the 
supernatant collected into another tube containing 2ml hexane. The protein 
precipitate was re-extracted with another 1ml of acetone at -20°C. The 
second collection of supernatant was added to the first, the sample vortexed 
for 60 seconds and centrifuged. The top hexane layer was then discarded. 
0.06ml citric acid (2.87M) and 2ml chloroform were added and the sample 
vortexed for 60 seconds and centrifuged. The upper layer was aspirated into 
another tube containing 2ml chloroform and the extraction repeated. The 
combined bottom layers of chloroform were evaporated with nitrogen at room 
temperature in a fume cupboard. The residues were re-dissolved in 0.3ml 
GTB and assayed for 6-keto PGFioc.
3.3 2.2.2 Discussion
The levels measured in the 10 samples of normal human plasma (see table 
3.3.2.2.1) were 121 +/- 33.1 pg/ml (mean +/- SO) which were within the range of 
values reported by other workers at that time (Mitchell MD, 1978) (Machin SJ, et al 
1981). This assay was therefore applied to measurement of 6-keto PGFIa in plasma 
studies. However as these studies progressed certain problems with this technique 
were encountered.
3.3.2 2.3. Problems with the RIA and Extraction Process
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As experience with this plasma assay grew, certain inconsistencies and results were 
found which called into question the reproducibility and variability of the method. 
Initially, sample extractions were not done in duplicate, but when this was eventually 
done, the results for duplicate extracted samples were sometimes found to differ 
markedly. As a result the co-efficient of variation and the reproducibility of the 
process were determined.
Determination of co efficient of variation
A large volume of plasma was collected from a normal volunteer. 20 1ml aliquots of 
plasma was simultaneously extracted and submitted to assay. A corrected 
measurement of 6-keto PGFioc was derived by converting the value to 100% 
recovery (i.e. RIA measurement divided by recovery for that sample x 100). Out of a 
total of 0.3ml of extract for each sample, only 0.1ml was assayed, thus the result was 
multiplied by 3 to obtain the full corrected quantity per 1 ml sample. The co-efficient 
of variation was then calculated as follows;
Co-efficient of variation (%CV) = 100 (standard deviation / mean)
3.3.2.2.3.1 Results
Sample recovery, RIA readings and corrected readings are shown in table 
3.3.2.2.3.I.
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Sample recovery % SketoPGFia
Reading from RIA
(pg/ml)
Corrected
1 7.7 19.0 81
2 68.2 12.0 53
3 70.7 13.0 55
4 69.2 15.5 67
5 62.1 14.5 70
6 74.3 12.5 50
7 68.2 17.5 77
8 70.7 12.5 53
9 71.7 22.0 92
10 64.2 13.5 63
11 65.1 16.5 76
12 65.1 25.5 118
13 71.7 11.5 48
14 64.2 17.5 82
15 69.2 20.0 87
16 62.1 16.5 80
17 65.6 16.0 73
18 80.9 16.5 61
19 76.3 20.5 81
20 76.8 11.5 45
Table 3.3.2.2.3.1 6ketoPGFi« in Twenty Samples of the Same Plasma. Each 
sample contained 1ml Plasma.
There was poor correlation between recovery and the original reading with a 
correlation co-efficient of -0.39. Recoveries varied from 62.1% to 80.8% (mean
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69.4%, SD 5.1). The co-efficient of variation was therefore 7.3%. The corrected 
levels of 6-keto PGFiO varied from 45 to 118pg/ml (mean 70.6, SD 17.9). The co­
efficient of variation for 6-keto PGFioc measurement was therefore 25.4%.
3.3.2.23.3 Conclusion
From these results it was clear that there was much variation in the measured levels 
of replicate extracted samples. The high CV for 6-keto PGFioc measurement (CV 
should not exceed 10%) suggested that the assay system in extracted plasma was 
likely to be inaccurate.
3.3.2.2 4 Assessment of reliability of the RIA on extracted plasma
This was done by addition of known amounts of unlabelled 6-keto PGFu to plasma 
before extraction and assay.
Plasma from 6 normal volunteers was pooled. 1m! samples of the pooled plasma 
were extracted in the standard manner but with prior addition to the samples of 
known different amounts of cold 6-keto PGFioc in tris buffer (amounts added: 400pg, 
600pg, and 1,000pg). Triplicate samples of each concentration of 6-keto PGFioc or 
control plasma were then extracted and assayed for 6-keto PGFioc.
3.3.2.2.4.1 Results
The results are shown in table 3.3.2.2.4.I.
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6ketoPGFia load Recovery % 6ketoPGFia pg/ml plasma
(pg) Corrected mean
0 87.0 293
83.3 286 300
77.6 321
400 75.0 482
84.0 361 402
84.0 364
600 84.3 365
83.0 380 405
81.7 471
1000 85.7 410
73.6 554 454
77.6 398
Table 3.3.2.2.4.1 6ketoPGFia Levels in the Same Sample of Pooled Plasma 
Where Some Had Known Amounts of Cold 6ketoPGFi« Added
The mean 6-keto PGFioc level in control pooled plasma was higher than that found in 
the initial study on 10 normal volunteers (see section X; 300pg/ml -v- 121 pg/ml 
respectively); this elevated level may have been the result of the longer time to 
collect and pool the blood from the 6 volunteers to provide the pooled sample. Mean 
6-keto PGFioc levels in the loaded samples were 402, 405, and 454pg/ml for the 
loads of 400, 600, and 1,000pgs respectively. Assuming the mean control level to 
be correct, then only 102, 105 and 154pg of 6-keto PGFi« were recovered from
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samples containing 400, 600, 1,000pg respectively.
3.3.2.24.2 Conclusion
These results confirmed the high variability and unacceptable reliability of this RIA 
applied to extracted plasma.
3.3.3 A second RIA using a different antiserum to 6-keto PGF^ ^
At this point in the study the application of another RIA technique not requiring an 
extraction step was explored because of the results obtained previously. An 
antiserum for 6-keto PGFioc of such high affinity and specificity that an extraction step 
was not necessary, had been developed at the Cardeza Institute, Philadelphia, USA 
by Smith and colleagues, (Smith JB et al, 1978). A small supply of this antiserum, 
hereby denoted Cardeza antiserum, was obtained for comparison with the Wellcome 
antiserum.
3.3.3.1.1 Method
Previous work with this antiserum had involved reagent measurement in pM rather 
than pg. For simplicity, this convention was observed with the Cardeza antiserum 
(conversion factor from pM to pg is 370.47; i.e. 1 pM = 370.47pg).
6-keto PGFioc standards ranging from 0.025pM to 5pM in 0.1ml were prepared in tris 
buffer containing 1% plasma gamma globulin as a protein carrier (Appendix A). 
0.1ml of plasma sample or standard was incubated with 0.1ml of tritium labelled 6- 
keto PGFioc (ca 10,000dpm). After mixing, 0.05ml of Cardeza antiserum (8pg/ml) 
was added, mixed and incubated at 37°C for 1 hour. 0.25ml of saturated ammonium
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sulphate solution was added to each tube and then centrifuged at 3,000g for 15 
minutes. The entire supernatant containing 6-keto PGFioc of each tube was 
decanted into a scintillation vial, 7.5ml of scintillation fluid was added and then 
counted. A standard curve was derived from counts per minute (cpm) of each 
standard against 6-keto PGFioc concentration.
This new RIA method was applied to a range of different samples and results 
compared to those obtained using the Wellcome antiserum for RIA following 
extraction.
The following samples were assayed; 2 plasma samples from normal human 
volunteers, 2 plasma samples from a dog taken before and immediately after 
pancreatic surgery, and 2 supernatant fractions from fresh rat portal veins 
(normotensive rats; vein segments incubated at 20°C for 3 minutes at a tissue 
concentration of 50mg/ml tris buffer).
3.3.3.1.2 Results
A typical sigmoidal standard curve was produced by this RIA, from which results for 
the above test samples could be read (figure 3.3.3.1.2).
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Fig 3.3.3.1.2 Typical standard curve for 6 keto PGF1o RIA using the Cardeza 
antiserum
The results of 6-keto PGFioc levels in the various plasmas using both Cardeza and 
Wellcome antisera are listed in table 3.3.3.1.2.
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Sample SketoPGF ia pg/ml 
Wellcome 
antiserum
(mean of duplicate 
samples) Cardeza 
antiserum
Normal human plasma 1* 171 0
Normal human plasma 2* 134 0
Dog plasma before surgeryO 238 180
Dog plasma after surgery 0 386 227
SNF from rat vein 1 0 128 126
SNF from rat vein 2 O 160 167
Table 3.3.3.1.2 Comparison of the 6ketoPGFia Measured In Various Samples 
Using the Wellcome and Cardeza Antiserum In the RIAs. SNF = Supernatant 
Fraction from 3 Minutes Incubation.
* Extracted samples were used when assayed by the Wellcome antiserum.
O Unextracted samples.
3.3.3.1.3 Conclusion
Using the Cardeza antiserum, no 6-keto PGFioc could be detected in normal human 
samples, while using the Wellcome antiserum and extracted plasma these same 
samples seemingly measured large amounts of 6-keto PGFioc (171 and 134pg/ml 6- 
keto PGFi alpha). Interestingly both assays were able to measure 6-keto PGFioc 
without an extraction process in both dog samples, but the values obtained were 
lower using the Cadeza antiserum. In both, more 6-keto PGFioc was found after 
surgery than before. In the rat vein supernatants however, there was good 
agreement between values obtained with both antisera without an extraction step 
with 6-keto PGFioc being present in ng quantities in these specimens. These results 
imply that both assays were capable of measuring 6-keto PGFioc without an 
extraction step where the concentrations of 6-keto PGFioc are high, but that the
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Cardeza antiserum was much more specific.
3.3.3 2 Estimation of lower detection limits of Cardeza antiserum 
RIA
Since no 6-keto PGFioc could be measured in human plasma in the initial study, two 
experiments were performed to establish the detection limit of the assay in plasma.
3.3.3.2.1 Experiment 1
This experiment was designed to confirm that the Cardeza antiserum was capable of 
detecting small amounts of 6-keto PGFioc in plasma.
The assay system was set up as follows;
0.1ml standards in tris buffer or plasma 
0.05ml tris buffer
0.05ml (H^) 6-keto PGFioc (ca 10,000dpm)
0.05ml Cardeza antiserum 
The mixtures were well mixed after addition of the tracer. On addition of antiserum, 
the samples were vortexed, incubated at 37° for 2 hours, then precipitated with 
0.25ml of saturated ammonium sulphate solution. Tris buffer control standards and 
normal pooled plasma standards of 6-keto PGFioc were made up and assayed as 
before.
3.3.3.2 2 Experiment 2
In order to test whether plasma proteins interfered with RIA, tris controlled standards 
and plasma standards were set up as above. However, after addition of saturated 
ammonium sulphate solution, 0.1ml of plasma was added to the tris standards and
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0.1ml of tris buffer was added to the plasma standards. All samples were 
centrifuged and the free tracer in the supernatant fraction was counted.
3.3.3 2.3 Results
6-keto PGFioc standard curves made in tris buffer or plasma are show in figure 
a.3.3.2.3.1.
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Fig 3.3.3.2.3.1 6 keto PGFIa standard curves made in plasma and tris buffer
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standard curves from the second half of the experiment where the standards were 
corrected with plasma or tris buffer are shown in figure 3.3.3.2.3 2.
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Fig 3.3.3.2.3 2 6 keto PGFIa standards in plasma or tris buffer corrected with 
tris or plasma respectively, immediately after addition of ammonium sulphate
In both experiments, displacement of plasma standards to the left was found 
particularly at lower concentrations of 6-keto PGFioc. The recoveries were all 100%, 
and of note there was more recovered at 0% binding (i.e. when no 6-keto PGFioc 
was added).
I l l
3.3.32.4 Conclusions
These results suggest that plasma interferes with binding of antiserum. This could 
result from the presence of non-specific binding factors in the plasma, or from 
endogenous 6-keto PGFioc being already present in the plasma. More importantly 
the assay was shown to be capable of measuring small quantities of 6-keto PGFioc 
but it is likely that the plasma proteins do interfere with this assay to a certain extent.
3.3 3.3 Measurement of 6-keto PGFioc from plasma after PGIg 
Infusion
A clinical test of the performance of the RIA presented itself shortly after its 
development. Plasma from patients having PGI2 infusions for trial management of 
renal transplant rejection by this treatment was collected for assay. This study was 
performed with prior approval from the Ethical Committee of the Royal Free Hospital. 
Peripheral venous samples were collected from one of these patients at intervals 
before, during and after PGI2 infusion at the rate of 4ng/Kg/min. Plasma was 
processed in the standard way and stored at -40°C until RIA was performed using 
the Cardeza antiserum.
3.3.3.3.1 Results
These are shown in table 3.3.3.3.1.
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Sample (from time of 
infusion of PGI2)
6ketoPGFia pM/0.2ml Equivalent pg. 
6ketoPGFia/ml. Plasma
Pre 1 hour 0.0 0.0
Pre 30 min 0.0 0.0
Pre 10 min 0.0 0.0
Pre Omin 0.0 0.0
Post 1 hour 0.011 20.4
Post 2 hour 0.011 20.4
Post 3 hour 0.011 20.4
Post 4 hour 0.0105 19.4
Control on following day 0.0 0.0
Table 3.3.3.3.1 6 ketoPGFia in Plasma Samples Collected from a Patient 
Receiving PGI2 Infusion.
No 6-keto PGFioc was detected in any of the samples before PGI2 infusion. During 
the infusion approximately 20pg/ml plasma was detected throughout, but 24 hours 
post cessation of the infusion, 6-keto PGFioc was again undetectable.
3.3.3 3.2 Conclusion
These results clearly show that this RIA is capable of measuring small quantities of 
6-keto PGFioc directly from plasma during a PGI2 infusion. The complete absence of 
detectable 6-keto PGFioc before and after the infusion confirms the previous findings 
in normal human plasma.
3 3.3.4 Comparison of the 2 RIAs in extracted plasma
This experiment was performed to compare performance of both assays in extracted 
plasma samples.
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3.3.3.4.1 Method
Duplicate samples of 8 different plasma samples were extracted and resuspended in 
the standard way. 0.1ml of each extract were subjected to RIA with both antisera.
3.3.3.4 2 Results
Percentage recovery, absolute and mean values of 6-keto PGFioc are shown in table 
3.3.34.2.
Recovery %  Corrected 6ketoPGFiq (pg/ml)________________
Wellcome Antiserum Cardeza Antiserum
Absolute Mean Absolute Mean
71.4 126 193
64.3 119 123 534 364
72.6 107 157
67.9 203 155 142 149
70.2 120 145
73.8 185 153 323 234
76.2 177 48
83.3 109 143 187 118
71.4 170 279
71.4 151 161 341 310
76.2 228 248
75.0 116 172 138 193
71.4 103 182
70.2 218 161 410 296
83.3 155 313
86.9 165 160 383 348
Table 3.3.3.4 2 6 ketoPGFia from 8 Extracted Plasma Samples as Measured by 
the Two RIAs.
3.3.34.3 Conclusion
6-keto PGFioc was detected by both methods but the Cardeza antiserum measured
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more 6-keto PGFioc in most samples than the Wellcome anti serum. There was 
greater variation in measurements with the Cardeza antiserum. These results 
further confirmed the unreliability introduced to two different assays by the extraction 
process.
3 .3 .3  5 Discussion
Direct measurement of 6-keto PGFioc and plasma using the Wellcome antiserum 
proved unsuccessful. Modifications such as increasing the plasma volume and 
loading of the samples with known amounts of cold 6-keto PGFioc failed to improve 
the sensitivity of this assay.
An extraction process to concentrate the amount of 6-keto PGFioc before submission 
to assay was developed but a variety of technical problems were experienced from 
the start. Initial problems of émulsification and difficulty in resuspension of the 
extract after evaporation were overcome by the use of cold acetone and inclusion of 
a second extraction of the protein precipitate. The use of hexane gave better 
extraction and elimination of neutral lipids from the organic layer, and addition of 
gelatin to the tris buffer made resuspension of the lipid extract easier. The best 
recoveries of 6-keto PGFioc were obtained with chloroform extraction despite the 
theoretical objection that because of its polarity, 6-keto PGFioc should not easily 
extract into this non-polar solvent.
Incorporation of these modifications appeared to give recoveries within 60-80%, 
which compared well with those reported by others, (Machin SJ et al, 1981 and
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Salmon JA, 1978). Furthermore 6-keto PGFioc levels measured in normal human 
plasma fell within a similar range to those previously reported using RIA, (Mitchell 
MD, 1978 and Machin SJ et al, 1981), and also using measurement by TLC and gas 
chromatography/mass spectrometry, (Hensby ON et al, 1979 and Hensby ON,
1981). On the basis of these correlations, the Wellcome antiserum was applied to 
clinical studies reported later in this thesis. After prolonged use of the assay 
however, certain discrepancies in measurements of duplicate samples lead to 
questions about the reproducibility of the procedure. Several experiments confirmed 
this suspicion. The extraction process was found to affect accuracy of 6-keto PGFioc 
measurement, with an unacceptably high coefficient of variation. Furthermore there 
was little correlation between recoveries and levels of 6-keto PGFioc. in fact it was 
often found that when recoveries were high the measurements were low, and vice 
versa. These findings suggested that uneven resuspension of the extracted material 
was taking place.
It therefore became clear that the extraction method caused major interference with 
the assay, resulting in poor accuracy and reproducibility in plasma 6-keto PGFioc 
measurement. At about the same time other workers began to report similar 
problems with the assay, (Greaves M et al, 1982). In retrospect, perhaps the 
reproducibility and variability of the assay should have been checked before 
embarking on these clinical studies but at the time it was the only technique available 
to undertake these measurements.
Further information to implicate the extraction process subsequently became 
available. Smith et al using the high affinity Cardeza antiserum could not detect any
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6-keto PGF10C in un-extracted serum, but did measure sizable quantities in 
conventionally extracted plasma. If the currently reported levels of 100pg/ml 6-keto 
PGF10C were correct, then this high affinity antiserum should have been able to 
detect significant amounts in 0.1ml plasma without prior extraction. Other workers 
reported that unextracted plasma treated by TLC always formed a single peak of 
radioactivity, but that extracted plasma formed 1 to 5 peaks, (Mitchell MD et al, 
personal communication). This suggested that during the extraction process several 
related substances to 6-keto PGFioc were formed. The likeliest mechanism in 
formation of these substances is the acidification step. This is known to convert
I
some prostanoids to those of another series, e.g. PGE to PGA compounds,
(Granstrom E et al, 1978).
In our laboratory, the high affinity of the Cardeza antiserum was confirmed, with 
direct measurement of known added amounts of 6-keto PGFioc to plasma, and in 
samples taken during PGb infusion. Again, no 6-keto PGFioc could be directly 
detected in normal human plasma, confirming the findings of Smith et al. Of some 
concern was the greater than 100% recoveries commonly obtained which suggested 
that plasma proteins did interfere with this RIA to a certain extent.
All these findings confirmed that all measurements on extracted plasma had to be 
reassessed. Without question, the levels of 6-keto PGFioc so measured are 
inaccurate. This data was not totally discarded however since the levels were a 
reflection of 6-keto PGFioc either in a modified or closely related form. Subsequent 
measurements were made with the Cardeza antiserum, accepting the possible 
interference, albeit minor, by plasma proteins. It became clear that 6-keto PGFioc is
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not detectable in pg quantities in normal human peripheral plasma.
1
In conclusion, 2 RIAs were applied to 6-keto PGFioc measurements in this work. 
Initially the Wellcome antiserum RIA was used until its inaccuracy in extracted 
plasma was confirmed. Further measurements were made with the reliable and 
accurate Cardeza antiserum RIA directly on plasma (peripheral and portal venous). 
Because of the very small levels of 6-keto PGFioc detected, and to a lesser extent, 
because of potential interference by plasma proteins at the limit of sensitivity of this 
assay, this too was abandoned in the final part of this study.
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3.4 Measurement of 6-keto PGFioc by Gas Chromatography /Mass 
Spectrometry
Gas chromatography/mass spectrometry (GC/MS) is generally accepted at the 
present time as the most sensitive and specific method available for measurement of 
prostanoids present in small quantities. In view of the considerable problems 
experienced with the RIAs, plasma 6-keto PGFioc measurements in the final stage of 
this study were made using a more specific and sensitive variation of this method. 
Essentially this technique became available for use in this study in 1983 in 
collaboration with Dr Sue Barrow, Clinical Pharmacologist at the Royal Post 
Graduate Medical School, Hammersmith Hospital, London and by kind permission of 
Sir Colin Dollery.
3.4.1 Gas Chromatography / Negative Ion Chemical Ionisation Mass 
Spectrometry
The sensitivity of standard GC/MS in 6-keto PGFioc measurement can be adversely 
affected by technical problems. These are difficulty in separation of 6-keto PGFioc 
from other endogenous prostanoids, and of the occurrence of extensive mass 
spectral fragmentation, (Barrow SE et al, 1982). Furthermore GC/MS assays for 6- 
keto PGFioc operate close to the limit of sensitivity, (Hensby CN et al, 1979[cJ). The 
range of plasma concentrations measured by such assays (20 to 400pg/ml) was 
found to be at variance with estimated normal PGb production. Based on urinary 
excretion rates of 2 of the metabolites of PGb, plasma levels were estimated to be in 
the low pg/ml range, (Oates JA et al, 1981). Professor Dollery's group at the Royal
Post Graduate Medical School, London, concluded that a more specific and sensitive 
method than standard GC/MS was needed. Thus such an assay based on capillary 
column gas chromatography coupled with negative ion chemical ionisation mass 
spectrometry (GC/NICIMS) was developed by this group, and is well described by 
Blair et al, (Blair IA et al, 1982).
Method of blood collection
Blood was collected by venepuncture of using a 21G needle with prior approval from 
the Ethics Committee of the Royal Free Hospital. 20ml of blood was collected into 
ice cold heparin tubes and centrifuged within 15 minutes of collection at 4°C at 
1,000g. After separation of plasma by aspiration, an internal standard of 2ng of tetra 
deuterated 6-keto PGFioc (3, 3’, 4, 4’-2H4-6-keto PGFi alpha) was added to an 
extracted volume of plasma (usually 5 or 10ml). Samples were then stored at -20°C 
until extraction, derivatisation and assayed by capillary column GC/NICIMS.
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3.4.2 Method of GN/NICIMS assay
The method is described in detail by Professor Dollery’s group (Blair IA et al 1982) 
and summarised as follows. After extraction utilising SEP-PAK columns, the residue 
dissolved in methanol was treated with methoximation of the 6-keto function, then 
subjected to TLC purification. The purified methoxyamine derivative was submitted 
to estérification and trimethylsilylation of the 3 hydroxyl groups. Standard curves for 
6-keto PGFioc in the range 0 to lOpg/ml were prepared by addition of appropriate 6- 
keto PGFioc concentrations to 20ml normal pooled plasma and by processing 
through the assay procedure. Concentration of 6-keto PGFioc was plotted against 
peak height ratios of protium and deuterium ions to construct calibration curves. A
linear regression equation was calculated to allow determination of the unknown 6- 
keto PGFioc concentrations from the slope of the curve.
3.4.3 Results
A calibration curve for 6-keto PGFioc extracted from pooled plasma is shown in figure 
3.4.3.1.
0.15-
£UloX 0.05-
0.00 1086420
Plasma GketoPGFIa (pg/ml)
Fig 3.4.3.1 Calibration curve for 6 keto PGFIa extracted from pooled plasma.
y = 0.014x +0.017 ; r^= 0.995 ( from Blair IA et al 1982)
Typical mass chromatograms for 6-keto PGFi a extracted from plasma are shown in 
figures 3.4.3 2 and 3.4 3.3.
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Fig 3.4.3 2. Limited mass chromatograms for 6-keto PGFiO extracted from 
plasma. ( from Blair IA et al 1982)
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Fig 3.4.3.3. NICI spectra of a) 6-keto PGFiO and b) radio-labelled 6-keto PGFiO
( from Blair IA at al 1982)
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Recovery from this assay was 50%. The assay was shown to be highly accurate 
with measurements of 0.82pg/m! and 4.92pg/ml being made from plasma samples 
containing known concentrations of 1 pg/ml and 5pg/mi respectively (n = 5). The 
lower limit of sensitivity of the assay was O.ôpg/ml. Plasma levels in 20 normal 
volunteers were found to be within a range of < 0.5 to 2.49 pg/ml, (Blair lA et al,
1982).
3.4.4 Conclusion
This assay based on capillary column gas chromatography coupled with negative ion 
chemical ionisation mass spectrometry is highly specific and sensitive with a much 
lower detection limit that the Cardeza antiserum (<0.5pg/ml -v- lOpg/ml). The two 
levels of 6-keto PGFioc in peripheral blood are shown to be much lower than 
reported with RIA or standard GO/MS measurements.
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#SUMMARY OF MEASUREMENT OF PGI^
A constant feature in the history of studies on prostaglandins in general and PGI2 in 
particular, was the great problem encountered in accurate measurement of these 
evanescent substances. Assay of tissue extracts or plasma from species such as 
the rat which produce PGb in relatively large quantities, has been reasonably 
straight forward. Unfortunately man produces PGb in very small quantities and the 
literature on human PGb assay is characterised by a constant search for more 
accurate methodology. As more accurate assays have been developed, accepted 
normal human plasma levels have steadily fallen from nanogram to picogram to less 
than picogram quantities.
Measurements in this study began with platelet nephelometry on rat tissue extracts 
which, because of the high production of PGb by the rat proved to be acceptably 
reliable and accurate. The assay however could only measure PGb-like activity.
The development of the RIA for 6-keto PGFioc allowed accurate measurements in 
tissue extracts with good correlation between RIA measurements and PGb-like 
activity. It was only after a considerable period of time that awareness of the 
inaccuracy of RIA on extracted plasma dawned, both in our laboratory and in the 
wider scientific community. The development of a more specific anti serum which 
obviated the need for plasma extraction allowed accurate measurement of 6-keto 
PGFioc. However, the levels found in plasma were found to be around or below the 
lower level of detection of this method.
r
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The final part of this study made use of GC/NICIMS for plasma measurements. This 
is the most accurate and sensitive method currently available but is extremely 
laborious and time consuming with a typical assay taking a week to complete. This 
assay was carried out in the laboratories of Professor Colin Dollery at the RPMS with 
heavy demands on their technical expertise and time from many other sources. For 
these reasons, application of the assay was limited necessarily to relatively small 
numbers of samples in the final part of the study.
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CHAPTER 4: EXPERIMENTAL STUDIES IN PROSTACYCLIN 
ACTIVITY AND PORTAL HYPERTENSION
Introduction
Haemorrhage is the major complication and cause of death in portal hypertension. 
As has previously been discussed (chapter 1), once portal hypertension is 
established a major and important factor in variceal haemorrhage is deficient 
coagulation. Prompt and massive replacement of clotting factors and blood will 
Improve and even correct the bleeding diathesis as measured by prothrombin time 
(PT) and activated partial thromboplastin (aPTT). There are situations however 
where massive bleeding continues despite these measures often even in the 
presence of normal or near normal clotting studies. In such circumstances, other 
mechanisms in addition to those of deficient synthesis of coagulation factors, 
increased fibrinolytic activity and thrombocytopaenia may be of primary importance.
The discovery of prostacyclin's important role in the platelet vessel wall interaction 
and its function in counteracting the pro-aggregatory property of TXA2 led many 
workers to investigate its possible role in many diseases. Alterations in the PGI2 
stimulating or inhibiting activity of plasma from patients with haemorrhagic or 
thrombotic complications were described in 1978 (Remuzzi G et al, 1978[b]). At 
about this time van Hoof, Chamone and Vermylen observed that some patients with 
liver or renal disease had a raised level of PGb stimulating factors in their plasma, 
(Van Hoof A et al, 1979).
These findings led us to the following hypothesis: in portal hypertension excessive
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production of PGb might occur thus contributing to the haemostatic defect which is a 
major factor in the severity of haemorrhage from oesophageal varices.
I II'
To investigate this hypothesis further, an experimental model of acute portal 
hypertension was needed. This can be achieved in a variety of ways including 
occlusion of the portal vein using cellophane, by injection of silica or microspheres 
into the portal vein, portal vein injection of schistosomiases, by various models of 
induced cirrhosis, and by partial ligation of the portal vein, (Sherlock 8, 1981). I 
chose to use partial ligation of the portal vein in the rat as the simplest technique for 
inducing portal hypertension without the complicating presence of liver disease in the 
majority of studies, with microsphere injection used in one set of experiments to 
mimic pre-sinusoidal obstruction.
4.1 Methods
4.1.1 Experimental Animals
In all experiments, male Sprague-Dawley rats weighing between 150-200g were 
used. These animals were bred by, and obtained from, the Comparative Biology 
Unit at the Royal Free Hospital. They were kept in standard cages with a 
maintenance diet and water ad libitum. Previous studies in our laboratories had 
shown that the normal portal vein of these animals produced significant levels of 
PGb as measured by bioassay.
4.1.2 Operative Procedures
All surgical procedures were carried out under tight ether anaesthesia (unless 
otherwise stated) between 0800-1400hrs. The peritoneal cavity was opened by an 
upper midline incision and abdominal closure was by mass suture of the peritoneum
127
and muscle layers using 0 chromic catgut, and skin closure with continuous 2/0 silk.
4.1.3 Measurement of Portal Vein Pressure
Pressure was measured by simple manometry and expressed as cm of water, taking 
the level next to and outside the portal vein at the porta hepatis and at the site of 
insertion of the needle as 0cm (fig 4.1.3). The portal vein was cannulated with a 25G 
butterfly needle via a 3-way tap to the manometer and to a reservoir of normal saline 
at room temperature. Portal pressure was then measured once the hydrostatic 
column had stabilised. This simple technique proved reliable and without major 
complication. Haemorrhage after withdrawal of the needle, even from hypertensive 
veins, was easily controlled by gentle pressure with a gauze swab, and with these 
precautions was always minimal.
PORTAL VEIN PRESSURE MEASURED 
IN A ll A N im iS  AT INITIAL PROCEDURE 
AND BEFORE REMOVAL OF PORTAL VEIN
Mwn PV Pressure 
IcmHzOJ
AT INITIAL LAPAROTOMY - Id  4+2.4IS. D. ) 
US2 AFTER P. V. LIGATION -  Id  6 ^ L 7SIS. D. )
<p<Q01)
Fig 4.1.3 Portal vein pressure measurement
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4.1.4 Induction of Portal Hypertension
The portal vein was mobilised in a standard manner by incision of the peritoneum
Iover the portal structures and careful dissection of the portal vein from the 
surrounding structures, namely the common bile duct, the hepatic artery and the 
peri-portal tissues. Portal hypertension was induced by a technique of partial ligation
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previously described by Halvorsen and Myking, (Myking AO et al, 1973). A metal 
tube of standard diameter (1.2mm) was placed alongside the portal vein (typically 
between 2 and 3 mm in diameter) and a 2/0 polyamide ligature (non-absorbable) 
was tied firmly around both as close to the liver as possible but taking care to keep 
below the bifurcation of the portal vein. The tube was then gently removed from the 
ligature leaving the vein constricted to a standard diameter of 1.2mm ( figures 4.1.4 
a, b, c and d). This is equivalent to inducing a stenosis of >50% of the original 
diameter. No antibiotics or other drugs were given. Other operative techniques are 
fully described in the relevant sections.
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Fig 4.1.4 a. Partial portal vein ligation using 1.2 mm tube
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Fig 4.1.4 b. Operative display of the rat portal vein:
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mFig 4.1.4 c. Mobilised portal vein and 1.2 mm diameter needle encircled just 
below the liver with the non absorbable ligature
13%
Fig 4.1.4 d. Portal vein partially ligated to diameter of 1.2 mm after removal of 
the needle
13?
b). Human Veins
With prior Ethical Committee approval and patient consent, samples of mesenteric 
and omental veins, 2-3cm in length, were collected at abdominal surgery as
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4.1.6 Harvesting and Preparation of Tissues
Segments of portal vein obtained from animals or patients were used to generate 
PGb-like activity. This was measured by bioassay or when it had become available, 
by measurement of 6-keto PGFio using a RIA. All tissues and the tris-buffer in which 
they were suspended were kept at 4®C prior to testing in order to minimise loss of 
activity due to the instability of PGb.
a). Rat Veins
In rats the portal and superior mesenteric veins and the abdominal inferior vena cava
(IVC) were harvested after measurement of pressure. Harvesting was by dissection 
from surrounding structures and tissues and excision of a 2-3cm section of vein.
The specimen was immediately placed in a petri dish at 4®C. After removal of 
adventitial tissue and fat, the vein was washed with 4®G tris buffer pH 8 (appendix A 
for preparation of buffer). The vein was then chopped into 1 mm rings. These were 
quickly blotted on filter paper, weighed and re-suspended in the appropriate volume 
of tris buffer (50mg of tissue /1ml  buffer), and then incubated at 20*C for three 
minutes. After removal of the rings, the resultant tris buffer solution was stored at 
4°C and tested as soon as possible by the platelet anti-aggregation bio-assay, or 
kept at -40®C until analysed by the 6-keto PGFi alpha RIA. All assays were 
performed within a month of collection of the sample.
:
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atraumatically as possible. These samples were collected into ice and immediately
.-■1transferred to the laboratory where they were processed in the same manner as rat 
veins. The rings were re-suspended in tris buffer pH 7.5 at a concentration of 25- 
200mg/ml depending on the amount of tissue available. The suspension was then 
incubated at 20^*0 for three minutes using a vortex mixer to maximise mixing during 
the first 15 seconds of this incubation period. The fluid was then removed by 
aspiration and either tested immediately or stored at -40*^0 for later assay.
. 5
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Three further control groups of 10 rats each (groups 3, 4 and 5) were set up to 
investigate the effect of surgical manipulation on portal vein pressure and PGb 
production. In all these three control groups, the duration of anaesthesia was 
standardised at 20 minutes and portal pressure was measured in the routine 
manner.
I
4 .2  EXPERIM ENT 1
4.2.1 Introduction
In this set of experiments, portal vein PGb activity was compared in groups of rats 
that had portal hypertension induced, with various sham operations and controls.
In group 1, 20 rats were anaesthetised with ether, the peritoneal cavity opened in the 
standard manner and portal vein pressure measured by simple manometry. The 
portal vein was mobilised, the standard metal tube, 1.2mm in diameter laid alongside 
the vein and a non-absorbable suture tied firmly around both. The tube was then 
removed leaving a constriction of 1.2mm. Having ensured haemostasis, the 
abdomen was closed and the animals allowed to recover.
A further group of 10 rats (group 2) were anaesthetised as before but did not 
undergo any surgical manipulation or incision. Anaesthesia was maintained for 20 
minutes, which is approximately the same time taken for the surgical group’s 
intervention, and the animals then allowed to recover. This group provided baseline 
control.
■I,;
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Group 3 - Ten rats underwent anaesthesia and laparotomy without any 
manipulation or dissection of the portal vein other than that required for portal vein 
pressure measurement.
Group 4 - Ten rats underwent anaesthesia, laparotomy and dissection of 
the portal vein from the porta! structures without ligation.
Group 5 - Ten rats underwent anaesthesia, dissection of the portal vein 
and ligature constriction exactly as described for group 1 but the ligature was 
removed after 60 seconds, (i.e. a sham ligation).
anatomically equivalent section in the non-ligated animals. The rat was then killed 
by opening the thoracic cavity and transecting the IVC. The specimens were 
immediately collected and prepared for generation of PGb like activity. To minimise 
observer bias, the samples were coded after harvesting and identified during the 
assays only by the code number.
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In two additional groups of six animals each (groups A and B), group A underwent 
permanent partial ligation of the portal vein, and group B underwent laparotomy and 
portal vein dissection alone. All groups were allowed to recover and were kept under 
identical conditions for one week.
In each group, seven days after the original procedure, the following was carried out. 
Under ether anaesthesia a laparotomy was performed noting in particular the state of 
the liver and intestines. Portal pressure measurement was carried out in the 
standard manner, and 2-3cm of the portal venous system was excised taking care 
not to take the hepatic artery or the bile duct, and excluding the ligatured area. The 
section excised was the hypertensive part where this had been induced or the
-a:
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Samples from groups A & B were similarly prepared but in addition to bioassay, 6- 
keto PGFiQ was measured by RIA as described previously (chapter 3.3.1). ADP-ase 
activity was determined in each sample as described (chapter 3.2).
The results were analysed by Wilcoxon’s two-sample test and by linear regression. 
The results from groups A & B however were analysed using Student’s paired t test.
4.2.2 Results
At laparotomy no abnormalities were noted in the liver or intestines, (e.g. necrosis, 
congestion etc.), in any of the rats. The only consistent finding was a minor degree 
of adhesion formation around the porta hepatis in all groups.
4.2.2.1 Portal Pressure
Time Group 1 Group 2 Group 3 Group 4 Group 5
Day 1 10.4 (2.4) ---- 9.8(1) 10.1 (1) 10.2 (1.3)
Day 7 16.6(1.8) 10.4 (0.9) 10(2.2) 10.1 (2.3) 10.5(2.4)
Table 4.2.2.1.Portal pressure (cm H2O) In surgical groups (mean +/- (SD)) Group 
1 -  permanent partial portal vein ligation; Group 2 -  GA alone; Group 3 -  laparotomy 
without portal vein manipulation; Group 4 -  portal vein dissection alone; Group 5 -  
temporary portal vein ligation (60 seconds).
In the control groups which had undergone laparotomy without permanent ligation of 
the portal vein, i.e. groups 3, 4 and 5, there was no difference in portal pressure at 
seven days when compared to the original pressure reading. Neither was there any
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difference in the group (group 2) which had undergone anaesthesia alone. In the 
rats with permanent partial portal vein ligation (group 1 ) however, there was a highly 
significant increase in pressure from 10.4 (+/- 2.4) to 16.6 (+/-1.8) cm H20 (mean +/- 
SD) after 7 days (p<0.01). (see table 4.2.2.1)
4.2.2.2 PG IHike Activity
40n
^  20
Group 1 Group 2 Group 3 Group 4 Group 5
Fig 4.2.2.1 a. PGI2 like activity in rat portal veins after 7 days (mean & SD):
Group 1 partial portal vein ligation (22.7 +/- 9.8); Group 2 GA alone (4.2 +/- 2.6); 
Group 3 laparotomy alone (9.2 +/- 5); Group 4 portal vein dissection without ligation 
(12.3 +/- 4.2); Group 5 partial portal vein ligation and removal of ligature after 60 
seconds (12.3 +/- 4.8).
PGb-like activity in the portal veins of the rats which had undergone general
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anaesthesia alone, (group 2), had the lowest levels. Compared to this group, all 
animals which had undergone laparotomy with or without portal vein procedures, 
(groups 3, 4 & 5), had significantly higher levels of PGb-like activity (P<0.01 in each 
group) (see fig 4.2.2.1 a). Between these groups there were no significant 
differences but group 5 had the highest level of activity. In the animals with 
permanent portal vein ligation and portal hypertension, (group 1), the greatest PGb- 
like activity of all groups was found, the levels being significantly higher than in any 
of the four control groups (p<0.01).
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Group A Group B
Fig 4.2.2.1 b. Rat portal vein PGbJike activity measured by Bio-assay and RIA 
(mean & SD).
Gp A partial portal vein ligation (RIA 4.4 +/-1.6; Bioassay 8.5 +/- 3.3)
Gp B sham portal vein ligation (RIA 2.5 +/-1.3; Bioassay 4.9 +/- 0.8)
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Increased production of 6-keto PGFiO as well as PGb-like activity was found in the 
animals with portal hypertension (see fig 4.2.2.1 b). The results from groups A and B 
revealed a strong correlation between PGb-like activity measured by bioassay and 
measured by RIA as 6-keto PGFio (see fig 4.2.2.1 c).
15-1
Y=0.55X-0.52, n=14, r=0.88, p<0.001
00
151050
P G I2 like activity (ng/50 mg)
Fig 4.2.2.1.C. Relationship between PGIHike activity measured by bio-assay 
and 6-keto PGFiO levels in rat portal vein.
Inhibition of platelet aggregation disappeared after incubation at 37®C for 20 minutes, 
thus ADP-ase activity could not be detected in any of the extracts.
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substances, (Moncada S et al, 1977 and Moncada S & Vane JR, 1978).
that produced by portai hypertension (p<0.01). The extent of surgical manipulation 
did not seem to be important since there was no real difference in PGb-like activity 
between the three non-hypertensive surgical groups.
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4.2.3 Discussion
Partial ligation of the portal vein proved to be an effective and reliable technique for 
production of portal hypertension at seven days with minimal morbidity and mortality. 
Manipulation of the portal vein, including transient ligation, did not result in any
Iincrease of pressure above the normal range.
Established porta! hypertension of seven days duration was accompanied by a 
highly significant increase in the production of PGb-like activity by the hypertensive 
segment of the portal vein. Because this activity was destroyed by incubation of the 
sample at 37°C for 20 minutes, and because there was no ADP degrading activity 'S'
detected in any of the samples, the conclusion was made that this was true PGb-like
activity. This observation was confirmed by the strong correlation found between 
PGb-like activity and 6-keto PGFi alpha (R=0.8B, p<0,001). The low production of 
other prostaglandins with similar activity to PGb by vascular endothelium supports 
the conclusion that the activity detected was due to production of the PGb-like
Controls set up to differentiate the effect of the trauma of laparotomy and more 
importantly of manipulation of the portal vein, from the effect of hypertension, also 
showed significantly increase PGb-like activity compared to animals which had not 
undergone any surgery at all. This Increase however was significantly lower than
:f
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These results indicate that surgery alone results in increased portal vein PGb 
production. The explanation for this response is not clear but one can speculate that 
this may be a non-specific inflammatory response to the trauma of laparotomy, 
handling of the intestines and dissection of the portal vein. Cannulation of veins is 
known to stimulate release of PGb and another possible explanation is the insertion 
of the manometry needle into the portal vein.
Over and above this non-specific response to surgery however, there was a 
significant increase in PGb production by the portal vein associated with portal 
hypertension. Similar increases in PGb production have been demonstrated in 
aortic extracts from spontaneously hypertensive rats when compared to 
normotensive animals (Pace-Asciak CR et al, 1978).
It may be that increased production of PGb by hypertensive vascular tissue is an 
adaptive response to hypertension, and this would explain the increased activity 
seen in this model of portal hypertension. Increased local release of PGb would 
exert a local vasodilatory response, thus tending to reduce hypertension. However, 
this raises the possibility that the increased production of PGb might also affect 
platelet function by increased inhibition of platelet aggregation.
In summary, the results of this first experiment supported the hypothesis that 
increased portal vein PGb production occurs in portal hypertension and raised the 
possibility that increased inhibition of platelet aggregation resulting from this might 
contribute to a haemostatic defect.
•
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4 .3  EXPERIM ENT 2
be as a result of inflammatory responses within the portal vein alone.
It is also possible that hepato-cellular function might be compromised in this 
experiment as a result of diminished portal inflow to the liver. This possibility must
activity to hypertension alone.
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4.3.1 Introduction
In experiment 1 portal hypertension was successfully achieved by the technique of 
partial ligation of the portal vein. This unavoidably entails direct mechanical trauma 
to the portal vein which as a result of the ligature could be chronic and result in 
inflammatory changes in the porta! vein wall. Prostaglandins are known mediators of
the inflammatory response and although the role of PGb in this process is not 
defined, it is possible that the increased PGb activity seen in the experiment could
be investigated because major clearance of PGb is probably by the liver as well as
by the kidneys and skeletal muscle. Altered hepato-cellular function could result in 
reduced clearance of several vasoactive prostanoids with increased levels being the 
outcome. In addition, hepato-cellular dysfunction might affect levels of various 
substances produced by the hepatocyte such as bile acids, and other vasoactive 
substances known to promote splanchnic hyperaemia which are metabolised by the
liver (glucagon, serotonin etc). These potential effects on vasoactive substances 
which modulate splanchnic blood flow may be involved in the regulation of PGb
synthesis. It is therefore important to exclude any adverse effect on hepato-cellular 
function in this model of portal hypertension before attributing changes in PGb
a
1
0.22pm pore filter to remove any gelatin aggregates,
b) microsphere suspension
2.352G of Ballotini glass beads 40 microns mean diameter, (British Glass UK), were 
suspended in the 2% gelatin buffer. This preparation resulted in concentration of
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Using portal injection of microspheres, a second mode of portal hypertension was 
developed which involved minimal trauma to the portal vein. Inflammatory change 
was assessed by histological and electron microscope scanning analysis, and 
hepato-cellular function was measured in both models of portal hypertension with the 
specific aim of assessing the contribution of direct trauma, inflammation and hepatic 
function to changes in PGb production that was measured.
Î
4.3.2 Method: Portal hypertension Induced by Injection of microspheres
With the collaboration of Dr Russell Woods, Research Scientist in the Academic 
Department of Surgery at the Royal Free Hospital School of Medicine, an alternative 
model of portal hypertension was developed. This was achieved by injection of a 
suspension of glass microspheres -  40 microns of mean diameter -  which would 
result in partial obstruction to portal flow at the pre-sinusoidal level.
4.3.2.1 Preparation of the microsphere suspension
a) buffer
2% gelatin suspension In 0.1M sodium chloride solution was prepared to pH 7.35 
using 0.05M potassium diphosphate buffer. The solution was then filtered through a
4.
approximately 600,000 spheres/ml as counted on a haemocytometer.
■I
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4.3.2.2 Procedures
13 male Sprague-Dawley rats (weight 150-200g) were anaesthetised with ether and 
the peritoneal cavity opened. Using a 3-way stopcock, portal venous manometry 
was carried out and then the 2% gelatin/microsphere suspension was injected into 
the portal vein until portal vein pressure >15cm of water was achieved and confirmed 
by repeat manometry after five minutes. The abdomen was then closed and the 
animals allowed to recover. A second group of six rats underwent laparotomy alone 
and a third group of six rats had partial portal vein ligation, and were allowed to 
recover.
Seven days later, under ether anaesthesia, the animals underwent laparotomy and 
any congestion or necrosis of the liver or intestines was noted. Portal venous 
manometry was then carried out prior to excision and processing for bioassay of the 
hypertensive segment of the portal vein exactly as described in experiment 1. A 
segment of liver was also taken for histological analysis by H & E staining. The 
animal was then killed.
Portal vein pressure and PGb-like activity in these rats were compared with levels 
measured in laparotomy only and partial portal vein ligated animals. Statistical 
analysis was by Wilcoxon’s paired sample test.
4.3.2.3 Measurement of serum hepatic enzyme levels
Blood samples were taken from the tail vein under light ether anaesthesia from three 
groups of rats. The first group of six rats had undergone laparotomy alone, the 
second group of six had undergone partial portal vein ligation, and the third group of 
six had undergone portal injection of microspheres. The samples were collected into 
lithium heparin tubes before the procedure and at one, three, five and seven days
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afterwards. Serum aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) levels were measured using an ‘optimised standard method’ U-V system kit 
(Boehringer Mannheim Gmbh Diagnostica).
4.3.2 4 Assessment of inflammatory response to partial ligation of portal vein
Six male Sprague-Dawley rats underwent partial ligation of the portal vein under 
ether anaesthesia and were allowed to recover. At seven days after the procedure, 
the portal vein was excised and for the purpose of histological and scanning 
electron microscope analysis was divided into three sections as follows:
a) proximal to the ligature, i.e. the non-hypertensive segment closest to the liver
b) around the ligature, i.e. the segment immediately around and including the
ligature
c) distal to the ligature, i.e. the hypertensive segment
These specimens were collected into formalin and coded. Histological analysis was 
carried out in a ‘blinded’ manner by Dr Margaret Chappell, at that time Lecturer in 
Pathology at the Royal Free Hospital, now Consultant Pathologist at the Southend 
General Hospital.
4.3.3 Results
Using this technique of microsphere injection, a significant elevation of portal 
pressure was obtained at one week (p<0.01) (see fig 4.3.3 a). The degree of 
hypertension was less than that obtained with partial ligation although this difference 
was not significant.
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Laparotomy PV Ligation PV Microspheres
Fig 4.3.3.a Rat portal vein pressure comparing laparotomy alone (n=6; 9.7 +/- 
1.1), partial portal vein ligation (n=6; 16.6 +/-1.8) and portal vein microsphere 
injection (n=10; 13.7 +/- 3.3) (mean & SD).
There were several problems with this technique however. The main problem was of 
high mortality -  three rats died of venous infarction of the gut in the immediate post­
op period, presumably as a result of complete occlusion to the portal inflow by 
injection of excess numbers of microspheres. There were also technical difficulties 
in maintaining the microspheres in suspension for longer than 15 minutes after 
preparation thus severely limiting the time available for induction of anaesthesia, 
dissection and manometry. More importantly because of this problem the number of 
animals operated on at any one ‘sitting’ had to be limited.
PGIHike activity was significantly elevated in this group when compared to the group 
which had undergone laparotomy alone (p<0.01) (see fig 4.3.3 b). This increase was 
comparable to that in the group which had hypertension induced by partial ligation,
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and statistically there was no difference in PGb-like activity between the two groups.
40n
Laparotomy PV Ligation PV Microspheres
Fig 4.3.3.b Rat portal vein PGIz -  like production after laparotomy (9.8 +/- 5), 
partial portal vein ligation (22.7 +/- 9.5) and portal vein microsphere injection 
(20 +/- 7.9) (mean & SD).
Serum AST levels were elevated on day one in both the laparotomy and partial 
ligation groups, but thereafter returned to normal (see fig 4.3.3 c). Serum ALT levels 
showed no elevation at all at any stage after either of these two procedures. In the 
group which had undergone microsphere injection however, there was striking 
elevation of both enzymes at day one, but the levels gradually fell approaching 
normality at day seven. In the animals that did not survive death occurred within 
hours of microsphere injection and before any post procedure samples could be 
obtained.
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Fig 4.3.3.C SGOT & SGPT levels during first 7 days after laparotomy, partial 
portal vein ligation or portal vein microsphere Injection (mean & SEM)
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4.3.3.1 Histological analysis
Histological analysis of the portal vein seven days after ligation showed no significant 
inflammatory change either in the intima or other areas of the wall of the portal vein, 
either proximal, distal to or around the ligature (see fig 4.3.3.1 a & b). There was 
resolving inflammation of the surrounding connective tissue however, which was 
compatible with recent dissection.
I
Histological analysis of liver sections from rats injected with microspheres showed 
mild inflammatory reaction around the glass microspheres but otherwise normal 
architecture in the majority of animals (see fig 4.3.3.1 c). In two rats however, very 
severe chronic inflammatory changes with a prominent lymphocytic reaction and 
dilated sinusoids were seen. There was no recognisable normal liver tissue seen 
and haemosiderin laden macrophages were noted, (see fig 4.3.3.1 .d)
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Fig 4.3.3.1.a H&E preparation of partial ligated rat portal vein at site of ligature:
arrow marks the fibres of the polyamide ligature; there is perivascular inflammatory 
and fibrotic activity but the portal vein shows intact morphology with little 
inflammation.
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Fig 4.3.3.1.b H&E preparation of liver in partial portal vein ligated rat at 7 
days: essentially normal liver structure.
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Fig 4.3.3.1.C H&E preparation of rat liver 7 days after portal vein injection of 
glass microspheres; mild inflammatory reaction around the microspheres but 
otherwise normal liver architecture was found in most rats.
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Fig 4.3.3.1.d Very severe liver damage seen in 2 rats 7 days after portal vein 
microsphere injection
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4.3.3 2 Scanning electron microscopy of partial ligated rat portal vein
Scanning electron microscopy confirmed patency at the site of partial portal vein 
ligation. The hypertensive part of the vein was dilated but with normal structure. 
The endothelium was intact with no denudation seen in any of the specimens (see 
figs 4.3.S.2 a & b).
Fig 4.3.3.2.a SEM at site of partial portal vein ligation in the rat after 7 days:
the ligature is seen with a constricted but patent vein and downstream dilation; wall 
structure is normal.
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Fig 4.3.3.2.b SEMs showing intact layer of endothelium in the partial ligated 
portal vein at the ligature (upper scan) and in the hypertensive part (lower 
scan)
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4.3.4 Discussion
injection of microspheres proved to be an effective means of inducing portal 
hypertension, but was technically cumbersome and time-consuming. There was an
" I I
associated high mortality and morbidity as reflected in the elevated serum hepatic
4
enzymes and in the severe liver changes seen in two of the animals.
A similar increase in PGb-iike activity was found in this model of portal hypertension 
to that seen after partial portal vein ligation. This finding gives further support to the 
hypothesis that the increased activity is primarily a response to hypertension. Also 
the lack of significant inflammatory response within the portal vein wall or 
endothelium, effectively excludes inflammation as a factor in this activity.
Hepato-cellular function as measured by serum hepatic enzymes, remained normal 
after the first day in the partial ligation group. This finding effectively excludes 
hepato-cellular dysfunction as a contributory factor to the increased PGI2 activity 
seen in this model of experimental portal hypertension. The degree of hepato­
cellular dysfunction seen in the group with microsphere injection is not surprising 
considering the severity of liver damage seen on histology in a minority of the
'I
animals, but even in this group serum enzymes had returned to normal by the time of
%the PGb-like activity assay at seven days. It is unlikely even in this group that 
hepato-cellular dysfunction played any role in the elevated PGl2-like activity.
These studies supported the belief that the increased PGb-like activity seen in portal 
hypertension was not related to ligature trauma, inflammation of the portal vein, or
'"I
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hepato-cellular dysfunction. Further support to the hypothesis that increased PGI2 is 
directly related to the increase in pressure was provided by these studies.
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4 .4  Experim ent 3
4.4.1 introduction
Preliminary studies on various vascular tissues in the rat had suggested that a tissue 
specific gradient of PGb-like activity might exist with least activity found in low 
pressure vessels such as the IVC, and most in high pressure vessels such as the 
aorta. These observations together with the conclusions from the preceding 
experiments, pointed to a theory of PGb production by vascular endothelium being 
directly related to the pressure within that vessel. Thus, in normotensive vessels 
there would be a degree of PGb production specific to the pressure within that 
system, but if hypertension developed within that particular system, the vascular 
endothelium would respond by increasing its PGI2 production above normal levels 
and to a degree relative to the pressure increase.
In the first instance, to investigate this possibility that a tissue specific gradient of 
PGI2 production might exist, a range of vascular tissues from the rat and pig were 
assayed for PGI2 production by bioassay. An attempt was also made to induce 
hypertension in the rat IVC and the effect of this on PGI2 production within this vessel 
was studied.
4.4.2 Methods
4.4.2.1 Assessment of PG^-like activity in various vascular tissues
2-3cm segments of the infra-renal IVC, the aorta, and of the portal vein of Sprague- 
Dawley rats weighing 150-200g were excised under ether anaesthesia and
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processed as previously described for PGb-iike activity. This was measured by 
platelet nephelometry and the activities compared.
Segments of the following vessels were removed ante-mortem, from eight pigs which 
had been used as donors for an experimental liver transplantation programme -  
portal vein, superior mesenteric vein, pulmonary artery and vein and abdominal IVC. 
These pigs were 25kg halothane resistant White pigs and had undergone full 
Inhalational anaesthesia with halothane/Û2 induction, intubation and maintenance on 
N20/air and halothane mixture with atracurium paralysis. The tissues were harvested 
from sections of vein which had not been clamped or traumatised during dissection, 
and collected and processed for bioassay in the standard manner.
4.4.2.2 Induction of hypertension in the IVC in the rat
Under ether anaesthesia, 13 male Sprague-Dawley rats weighing 150-200g 
underwent partial ligation of the infra-renal IVC (normal diameter 3 to 4.5 mm) to a 
standard constriction of 1.2mm using the technique of partial ligation described for 
the portal vein. A control group of seven rats underwent laparotomy and dissection 
of the IVC without ligation and a third group of six rats underwent general 
anaesthesia alone. All operated animals had IVC manometry carried out after 
opening the abdomen. The rats were allowed to recover and one week later under 
ether anaesthesia, pressure In the infra-renal IVC was measured prior to excision of 
the infra-renal IVC down to the iliac veins. Tissues were collected and processed as 
previously described and PGb-like activity measured by bioassay. The results were 
analysed by Wilcoxon’s two sample test.
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4.4.3 Results
4.4.3.1 PGb-llke activity in various normotensive vessels
In the rat, PGb-like activity was found to be much greater in the aorta than in the 
portal vein or IVC. Portal vein PGb-like activity was greater than in the IVC but this 
difference was not statistically significant (see fig 4.4.3.1 a).
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Fig 4.4.3.1.a PG b- like activity in various normal rat vessels (mean & SEM) 
(Aorta: 47.5 +/- 4); (IVC: 1.4 +/- 0.3); (Portal Vein (PV): 4.4 +/- 2.5).
In the pig, PGb-like activity was lowest in the IVC with significantly greater activity in 
the portal vein, superior mesenteric vein and hepatic veins (p<0.01). Although lower 
than in either the portal or superior mesenteric veins, PGb-like activity in the hepatic 
vein was not statistically different. Activity in the pulmonary circulation was also
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significantly greater than the IVC, (p<0.01), the artery having significantly more 
activity than the vein (p<0.01) (see fig 4.3.3.1 b).
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Fig 4.3.3.1.b PGb-like activity in various normal pig vesseis (mean & SD):
SMV is the superior mesenteric vein (46 +/-11); PV is the portal vein (39.6 +/- 9.3); 
HV is the hepatic vein (32.8 +/- 7.4); IVC is the inferior vena cava (3 +/- 0.7); PUV is 
the pulmonary vein20.7 +/-10.3); PUA is the pulmonary artery (47 +/-11.7).
4 4.3.2 Experimental hypertension in the IVC
The basal mean pressure in the IVC (2.3 +/- 2.1 ) was less than in the portal vein (9.7 
+/- 1.1) [cm H2O: mean +/- SD]. One week after partial ligation, the IVC pressure 
was significantly increased (7.9 +/- 0.8cm H2O) when compared to rats which had 
undergone anaesthesia alone (2.2 +/- 1.9cm H2O), or laparotomy alone (2.0 +/- 
1.6cm H2O). (p<0.01) (see fig 4.4.3 2). Portal vein pressure at one week after IVC 
ligation remained at basal levels in all groups (mean and SD).
PGb-like activity was significantly raised in the hypertensive IVC when compared to
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non-operated rats (p<0.01). PGb-like activity was also significantly increased in the 
normotensive portal veins of rats which had undergone laparotomy alone (p<0.01 ). 
The trend was to greater activity in the hypertensive compared to normotensive 
veins but this difference was not statistically significant (see fig 4.4.3.2).
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Fig 4.4.3.2 Pressure and PGb - like activity in rat IVC (mean & SD): GA is
anaesthesia alone (pressure 2.3 +/- 2.1; PGb 5.4 +/- 3.2) ; SL is sham IVC ligation 
(pressure 2 +/- 1.6: PGb 7.1 +/- 6); PL is partial IVC ligation (pressure 7.9 +/- 0.8; 
PGb 11.3+/-2.6).
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4.4.4 Discussion
Arteries have been shown to produce more PGb than veins on a weight per weight 
basis, (Johnson AR, 1980). This finding is corroborated by the results of these 
studies showing maximal activity in arterial tissues in two species. Furthermore, in 
the normal rat there is indeed a marked and significant difference between high and 
low pressure systems such as the aorta and IVC. The portal system, also a low 
pressure vessel, had much less activity than the aorta but showed a trend towards 
greater activity than in the IVC although this did not reach statistical significance in 
this small number of animals studied.
Of great interest in the pig was the demonstration not only of significant differences 
in PG b activity between different veins, but also that the activity reflected the 
pressure, being greatest in the high pressure veins, (portal, superior mesenteric and 
pulmonary). The exception to this observation was the relatively high level of PGb  
production by the hepatic vein which would be at a pressure only 1.2mm/Hg greater 
than the IVC. Because of the size of the rat, it was not possible to measure PG b  
activity in veins smaller than the portal, and it remains unknown whether the hepatic 
vein in this species is similarly active. If the hepatic vein in man also has the 
property of high production of PGb, perhaps deficiencies in this activity might 
theoretically be a factor in hepatic vein thrombosis.
These findings in normal animals point to the existence of a gradient of PG b activity 
in venous systems directly related to the ambient pressure. The significance of this 
finding requires further elucidation but one could postulate that PGb's potent 
vasodilator property might play a role in the regulation of vascular tone.
165
alteration to the tone of the IVC resulted from the modest increase in pressure.
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Hypertension in the IVC was produced successfully by the technique of partial 
ligation although the pressure obtained was relatively low at 7.9 +/- 0.8cm HgO (mean 
+/- SD), which is lower than the normal portal venous pressure. This was a result of 
the opening up of a rich collateral circulation fed by the many major branches of the 
infra-hepatic IVC.
Significant and similar increases in PGb production were observed in comparison 
with non-operated animals in both the hypertensive and normotensive IVCs of 
operated animals but disappointingly, there was no significant difference between 
the hypertensive and non-hypertensive groups. This effect was presumably mainly 
as a result of the surgery since this has been shown previously to increase PGb 
production in the portal vein. A possible explanation for this lack of response is that 
the increase in pressure in the IVC was not great enough to elicit the response of 
increased PGb production. The IVC is a capacitance vessel capable of great dilation
and drains many potential collateral vessels. Possibly, insufficient stretch and
In summary, the studies in this section have demonstrated a gradient of PGb activity 
in normal vascular tissues which is directly related to the ambient pressure. Surgery 
was shown to increase significantly PGb production in the IVC, an effect which has 
been demonstrated in the portal vein. A significant though modest increase in IVC 
pressure did not result in a correspondingly significant increase in PGb activity.
4 .5  Experim ent 4
4.5.1 Introduction
In experiments 1 & 2, increased PGb activity was found seven days after induction of 
pre-hepatic portal hypertension by two different methods. The study was now 
directed towards establishing the rapidity of onset and duration of this increased 
activity. Of the two models for portal hypertension, partial ligation was chosen for 
these further studies because of the simplicity, reliability and lack of significant 
morbidity and mortality associated with this technique.
Anti-aggregatory activity was measured in portal hypertensive and control rats at 
different time intervals over a six week period. An unexpected fall in portal pressure 
was found after two weeks, and to identify the causes of this fall, splenic venography 
and subsequently resin cast analysis of the porta-systemic collateral circulation was 
carried out.
4.5.2 Methods ;:;r
4.5.2.1 Investigation of onset & duration of PGi2 response
Portal hypertension was induced in six groups of six rats each. A further six groups 
of six rats each underwent laparotomy without portal vein ligation, and formed the 
control groups. The standard technique of ether anaesthesia, abdominal incision 
and closure was used in all animals. Laparotomy, portal vein manometry and 
excision of 2-3cm of portal vein was carried out in the ligated and non-tigated groups 
after 24 hours (group A), four days (group B), seven days (group C), two weeks
■'1
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4 5.2.2 Splenic venography
Splenic venography was carried out on six rats. The first was on a normal rat, and 
the remaining five at intervals of 1, 2, 3, 4 and 6 weeks after partial ligation of the 
portal vein.
168
(group D), four weeks (group E), and six weeks (group F). The portal vein samples 
were collected as described previously, coded and processed immediately for 
measurement of PGb-like activity by platelet nephelometry.
The results were expressed as mean and SD for each group, ligated and control, 
and the portal vein pressures and PGb-like activity charted. Statistical analysis was 
by Wilcoxon’s unpaired two sample test. PGb-like activity was correlated with portal 
vein pressure with measurements taken at 4-7 days after the procedure when PGb-
Ilike activity had previously been shown to be maximal. This data was analysed by
?calculation of the regression equation for these variables.
The rats were anaesthetised with intra-peritoneal urethrane, (0.6ml / lOOg body 
weight of 25% solution of urethrane), a long-acting agent allowing transfer of the 
animals from the laboratory to the Radiology Department without the need for ether 
anaesthetic and equipment. The abdomen was opened via a left sub-costal incision 
and the spleen delivered into the wound. 5m! of 45% Hypaque contrast medium was 
injected into the splenic pulp via a 23g Butterfly needle and serial radiographs taken 
immediately. These rats were not recovered and were not used for PGb 
determinations.
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4.5 2.3 Resin corrosion cast studies
i:'
Corrosion casts were made with the help of Mr Hugh Rogers FRGS, Surgical
C.iResearch Fellow at that time, by a modification of the method described by
fNorthover, (Northover JM et al, 1980). Under ether anaesthesia, 10ml of resin was
il
injected into the superior mesenteric vein in rats at a monitored pressure of 100 mm 
Hg, at intervals from five days to five weeks after partial ligation of the portal vein.
Four normal un-operated rats were also studied. Injection was carried out wtille ttie 
circulation was still intact. The animal was killed and after the resin had set, an en-
Ibloc resection of the thoraco-abdominal trunk was carried out. The specimen was 
placed in a bath of 20% NaOH at 37°C and kept in a constant temperature hot room 
at 37°C. The NaOH solution was renewed at regular intervals until digestion of the
itissues was maximal, usually after 2 to 3 weeks. . Using a fine jet of warm water, the 
cast was then carefully dissected free of residual tissue and the vascular anatomy 
analysed and compared with the normal.
4.5.3 Results
4.5.3.1 Portal vein pressure
30
— Laparotomy alone 
5— PV Ligation
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Time (weeks)
Time Laoarotomv alone PV Uoation
24 hours 9.9 (0.9) 25.3 (1.3)
4 days 8.9 ( 0.9) 15.7 (1)
7 days 9.4 (0.9) 17(1.1)
2 weeks 9.1 (0.8) 15(1.3)
4 weeks 10.7 (0.4) 11.6 (0.6)
6 weeks 10 (0.4) 12.4 (0.3)
Figure 4.5.3.1 Portal vein pressures in partial portal vein ligated rats and 
controls over a 6 week period (mean & SD)
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Mean portal vein pressure measurements are plotted in fig 4.5.3.1. In the control 
groups, no significant change of portal venous pressure from the normal was found. 
There was a significant increase in portal pressure from 24 hours to two weeks 
which was maximal between 24 hours and seven days (p<0.01). After two weeks, 
the pressure began to fall to the level seen in the control group and had stabilised at 
normal pressure by six weeks.
4
I
I?
5
...s
I
171
4 5.3.2 PGl2-like activity
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Time Laoarotomv alone PV Lioation
24 hours 14.9 (1.7) 21 (0.7)
4 days 10.6 (1.5) 30.8 (3.6)
7 days 10.9 (1.5) 30 (3)
2 weeks 13.2(2.3) 18.3 (3.8)
4 weeks 11.3 (1) 15 (2.3)
6 weeks 8.1 (2) 11.1 (0.6
Figure 4.5.3 2 PGk-like activity in partial ligated and control rat portal veins 
over a 6 week period (mean & SD)
172
Mean PGb-like activity measurements in the portal veins of all the groups are plotted 
in figure 4.5.3.2. These results show significantly increased activity in animals with 
partial portal vein ligation when compared to control groups between the 24 hour to 
two weeks period (p<0.01). Thereafter, PGb-like activity diminishes approaching 
that of the control animals. This increase was maximal between the fourth and 
seventh days with a return to control levels by the fourth week.
4.5.3 3 Correlation between portal vein pressure and PGiz-iike activity
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Fig 4.5.3 3 Correlation between portal vein pressure and PGb-like activity
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3From the results above it is obvious that as porta! pressure falls, so does the PGb- 
like activity. This relationship is demonstrated in figure 4.S.3.3. Linear regression 
analysis gives a correlation co-efficient of + 0.76 and demonstrates a strongly 
positive correlation between pressure and PGb-like activity in the portal vein.
4.5.3 4 Splenic venography
Splenic venograms are shown in figures 4.5.3.4 a-d. Venography demonstrated 
minimal collateral circulation at one week, but progressive development of porta- 
systemic collaterals after that time. By the second week, spleno-renal, 
retroperitoneal and peri-oesophageal collaterals are seen. At four weeks, there is a 
large and well developed collateral circulation with a prominent large spleno-renal 
vessel draining in to the left renal vein. This collateral was also prominent at six 
weeks and was found on retrospective analysis of the earlier radiographs.
\W
Fig 4.5.3.4.a Splenic venography showing the normal portal system; in all
portagrams contrast was injected into the spleen
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Fig 4.5.3.4.b Splenic portagram in rat one week after partial portal vein 
ligation: the arrow shows the site of ligature
Fig 4.5.3.4.C Splenic portagram in rat 2 weeks after partial portal vein ligation
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Fig 4.5.3.4.d Splenic portagram in rat 4 weeks after partial portal vein ligation:
the arrow marks the site of the ligature; the very large collateral (a hypertrophied left 
adrenal and anterior lumbar vein) draining the portal bed into the left renal vein and 
on into the I VC, is easily seen.
4.5.3 5 Corrosion cast studies
In all animals a major porta-systemic collateral pathway was found draining the
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gastric, splenic and duodenal veins into the left anterior lumbar vein (LALV).
Figure 4.5.3 5 Anatomy of retroperitoneal collaterals found by corrosion cast 
studies demonstrated on splenic portagram of established portal hypertension 
in the rat. The white arrow shows the left anterior lumbar vein which was universally 
found to be the major collateral draining the portal to the systemic circulations.
The left adrenal vein drains into this vessel just before the LALV drains in to the left 
renal vein. This was found to be the major collateral pathway and all other collateral 
complexes were much smaller. The LALV was present in the normal rats although 
of much smaller calibre then in the hypertensive animals. This was the collateral 
pathway which developed in the portal hypertensive rats and is seen developing in
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the splenic portograms (see figures 4.S.3.4 b, c and d).
4.5.4 Discussion
Using the technique of partial portal vein ligation, significant portal hypertension was 
established within 24 hours. Thereafter, there was a steady decline in portal 
pressure with a return to control levels by four weeks. Splenic venography §
confirmed that over this period a porta-systemic collateral circulation became 
established and over the same time period portal pressure fell to normal levels, 
presumably as a result of the opening up of this alternative circulation. These 
findings are in accordance with those of Orda and Ellis who, using a similar model Iwith a constriction of 1.1mm, found that portal hypertension lasted only 10-14 days 
over which period of time a collateral circulation was shown to have developed,
(Orda R et al, 1978).
PGb-like activity was significantly increased from day one to week two with the 
maximal response being between days four and seven. Of great interest is the 
gradual fall in PGb-like activity after day seven which strikingly parallels the fall in
portal hypertension. This simultaneous fall, and the demonstration of a strongly
kpositive correlation between the two parameters during the time of maximal pressure 
and PGb activity, provides further strong evidence to support the hypothesis that
increased PGb production results when hypertension is induced. The observation of 
similar responses related to spontaneous and experimentally induced arterial 
hypertension in rats leads to the conclusion that increased PGb production by 
vascular endothelium may be a physiologically important adaptive response. This 
would result in vasodilation and a tendency to reduction in pressure. In portal
__
hypertension, PGb may well promote the opening up of collateral channels of 
embryonic origin, thus also leading to a reduction in pressure.
Splenic venography and the corrosion cast studies demonstrated the development of 
collateral vessels and in particular the dominant system draining via the LALV into 
the left renal vein. This pattern of collateral circulation has been described 
previously in the rat, the dog and man in portal hypertension, (Moritz E et al, 1973, 
Rousselot LM et al, 1976 and Halvorsen JF & Myking AO, 1974). The LALV in the 
rat and the supra-renal vein in man are vestigial remnants of the posterior cardinal 
veins in the embryo, which on the left side largely regress, and on the right side form 
the I VC, (Grays Anatomy, 1980). In man however, collaterals connecting the gastric, 
gastro-epiploic and splenic veins to the left renal vein have been demonstrated 
angiographically in the absence of portal hypertension, (Wexler MJ et al, 1975). This 
evidence suggests that this collateral pathway results from dilation of pre-existent 
though vestigial vessels, and not by formation of new channels. While these vessels 
will dilate as a result of hydrostatic ‘back’ pressure alone, increased PGb production 
by its potent vasodilatory effect may have an important role to play in the 
development and maintenance of the collateral circulation.
I
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4 .6  Experim ent 5
4.6.2 Methods
4.6.2.1 Development of model of chronic portal hypertension
Under ether anaesthesia and via an upper midline incision, portal vein manometry 
then partial ligation of the portal vein as previously described was carried out in six 
rats. The LALV was then dissected and completely ligated with a non-absorbable 
ligature just above its junction with the left renal vein 9see fig 4.6.2.1). Under ether 
anaesthesia, portal vein pressure was then measured at 9, 17, 25 and 33 days.
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4.6.1 Introduction
A positive correlation between PGb activity and portal vein pressure has been 
demonstrated. Portal hypertension induced by the technique of constriction to a 
diameter of 1.2mm is short-lived lasting just over two weeks. In order to study the 
effect of prolonged hypertension on PGb production, a model of chronic portal 
hypertension is necessary.
As a result of the identification of the LALV as the main collateral circulation in the 
rat, a model of chronic portal hypertension was developed. Chronic portal 
hypertension was also induced by using a greater degree of constriction of the portal 
vein. Having established these models PGb-like activity at four weeks was 
assessed by bioassay.
Fig 4.6.2.1 Ligation of the left anterior lumbar vein to cause chronic portal 
hypertension: the suture shown by the arrow completely ligates the left anterior 
lumbar vein which normally drains into the left renal vein which can be seen below 
the ligature
In a further group of six rats, partial portal vein ligation alone was carried out but 
using a 0.8mm rather than the previously used 1.2mm tube, therefore resulting in a 
greater degree of portal vein constriction. These rats also underwent portal vein 
manometry at the same time intervals above. A control group of six rats underwent 
laparotomy and dissection of the portal and LALV veins without ligation, and
16%
underwent portal vein manometry at ttie same time Intervals.
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Because of the repeated laparotomies and portal vein punctures to measure portal 
pressure, veins from these animals were not harvested for PGb assay.
4.6 2.2 Chronic portal hypertension and PGb activity
Ten rats underwent laparotomy, portal vein manometry and then partial ligation of 
the portal vein. The LALV was dissected at its junction with the left renal vein and 
completely ligated. A further group of 10 rats underwent laparotomy, portal vein 
manometry and then partial ligation of the portal vein to a diameter of 0.8mm. The 
LALV was not ligated in this group. A third group of 10 rats underwent laparotomy 
alone.
All animals were randomly allocated to these three groups prior to the procedure, 
allowed to recover afterwards and kept under identical conditions for 28 days after 
surgery.
On the 28 *^ day, all animals underwent laparotomy and any areas of necrosis or 
congestion of the liver or intestines was noted. After portal vein manometry, 2-3cm 
of hypertensive portal vein (or the anatomically equivalent segment in the control 
group) was excised, collected onto ice and processed in the standard way for 
immediate for bioassay.
The results were tabulated, and analysed by Wilcoxon’s unpaired two sample test.
'.ÿ
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4.6.3 Results
4.6.3.1 Models of chronic portal hypertension
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Time Control Single PVL Double PVL
9 days 13 (2.2) 21.8(2.5) 26.8 (4.2)
17 days 13.2 (1) 13.5(2) 24.3 (2.2)
25 days 14(1.5) 18.2(4) 26.5 (2)
33 days 13.5 (1) 21.5 (5.5) 22.5 (4)
Fig 4.6.3.1 Portal vein pressure over 33 days; single PVL are rats undergoing 
portal vein ligation to 8mm diameter; double PVL are rats undergoing portal vein 
ligation to 1.2mm and ligation of the LALV; control animals did not have any vein 
ligation.
184
Partial ligation of the portal vein with ligation of the LALV resulted in significant portal 
hypertension from days 9-33 (see fig 4.6.3.1). Partial ligation of the portal vein alone 
to a diameter of 0.8mm resulted in a similar increase in portal pressure at day 9. The 
pressure then fell significantly by day 17 when compared to the double ligation group 
(p<0.01). After this however, the pressure in this group steadily rose until by day 33 
there was no significant difference between the two groups which were both 
significantly hypertensive (p<0.01). As expected, the pressure in the laparotomy 
only group remained stable at normal levels throughout.
185
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4.6.3 2 PGb-like activity in chronic portal hypertension
These results are shown in figure and table 4.6.3.2.
Single PVL Double PVL 
■■I PV Pressure ■
Control 
PGI2 like activity
GrouD Portal vein oressure Portal vein PQIy-like activitv
(cm H20) (ng/SOmg tissue)
Control 12.3 (0.9) 8.4 (1)
Single PVL 21.3(4.7) 18.2(6.2
Double PVL 26.7 (2.8) 17.8 (6.8)
Fig 4.6.3 2 Portal vein pressure and PGb-like activity in chronic portal 
hypertension of 28 days duration and controls: single PVL are rats undergoing 
portal vein ligation to 8mm diameter; double PVL are rats undergoing portal vein 
ligation to 1.2mm and ligation of the LALV; control animals did not have any vein 
ligation.
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There was no significant difference in portal pressure between the two ligated groups 
but both developed significantly elevated porta! pressures when compared to the 
control non-ligated animals (p<0.01 in both). Also, there was a similar degree of 
PGb-like activity in both hypertensive groups with no statistical difference between 
the two on analysis. Each of these hypertensive groups however, had significantly 
increased PGb-like activity when compared to the normotensive control group
(p<0.01).
There were no deaths in any of the groups. There was no significant congestion or 
necrosis of intestines or liver noted.
4.6.4 Discussion
Two satisfactory models of chronic portal hypertension lasting beyond 28 days were 
developed. Partial portal vein ligation with complete ligation of the LALV resulted in 
immediate hypertension which persisted at the same levels throughout. Using the 
greater degree of constriction (0.8mm), partial ligation alone resulted in a transient 
hypertension present at nine days followed, as expected, by a fall towards control 
levels by 17 days. Most surprisingly however, the pressure steadily rose thereafter 
reaching significant hypertension by 33 days.
■f,;
This interesting finding is probably best explained by the increasing size and weight 
of the rat over this period. The initial fall in pressure at 17 days is similar to that seen 
when using a 1.2mm constriction and is secondary to the development of the porta- 
systemic collateral circulation. As the rat grows beyond this time with the more
"a#;
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■critical portal vein constriction of 0.8mm, the collateral circulation becomes unable to Icompensate further. Therefore, with increasing splanchnic flow against the critical 
resistance of the portal constriction, the collateral circulation no longer compensates 
and the portal pressure rises. Myking and Halvorsen found that a portal vein 
constriction of 0.9mm in rats weighing 355g (+/- 91 g; SD) resulted in a greater than 
90% mortality, but that a constriction of 1.2mm was associated with a 75% survival,
(Myking AO & Halvorsen JF, 1973). Furthermore, these authors were able to ligate 
completely the portal vein after a delay to allow a porta-systemic collateral circulation 
to develop. The rats I used in these experiments weighed only between 150-200g 
and this explains the lack of mortality with such a severe constriction. By the time 
the rats had doubled in weight, death did not occur because of the already 
established collateral circulation, but hypertension did supervene.
Most importantly, PGb-like activity was shown in both groups of hypertensive rats to 
remain significantly elevated in parallel with the pressure at up to 28 days. This 
evidence confirms the previous finding of a strong correlation between portal vein 
pressure and PGb release. This effect has been shown to be unrelated to surgical 
trauma or inflammatory changes within the portal vein itself and persists well after 
the collateral circulation has become established.
Summary
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The results from these experimental studies strongly support the hypothesis that 
increased PGb production is an adaptive response of vascular tissue to the stimulus 
of increased intra-luminal pressure. If this response exists in man, PGb production 
would be elevated in portal hypertension and possibly play a role in the increased 
splanchnic blood flow commonly seen in this condition. Increased PGb production 
could also possibly adversely affect the haemostatic mechanisms at a local 
endothelial interface level and therefore play a role in the severity of haemorrhage 
seen in bleeding oesophageal varices.
CHAPTER 5: CLINICAL STUDIES
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Introduction
Having obtained experimental data to support the hypothesis that prostacyclin 
activity in the portal vein is related to pressure, evidence of any clinical relevance 
was now sought. Clinical studies were focused on patients with portal hypertension 
in comparison to control groups with normal portal venous pressure. Initially venous 
tissue samples were studied and once the radioimmunoassay was developed, 
attempts at measurement of serum levels of prostacyclin were made. Latterly, blood 
levels were measured using gas chromatography / mass spectrometry.
'■hAll clinical studies were performed with the prior consent from the patient and 
approval of the Ethics Committee of the Royal Free Hospital.
f
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5.1 Human vein PGig production measured by bioassay
6.1.1 Introduction
In the rat and pig measurable quantities of PGb-like activity were found in a variety 
of venous tissues (chapter 4). The bioassay for this activity was applied to venous 
tissues obtained from patients undergoing general surgical procedures and from 
those undergoing surgical procedures in treatment of portal hypertension. Patients 
who had taken aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) within two 
weeks were excluded from the study.
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5.1.2 Methods
5.1.2.1 Processing of tissue samples
Tissue samples harvested during surgery were immediately placed in ice for transfer 
to the laboratory. Processing of samples was exactly as for the animal tissues 
(chapter 4 introduction). Essentially the vascular rings obtained were re-suspended 
in tris buffer at pH 7.5 or 8.0 at a range of concentrations depending on the amount 
of tissue available (range 25-200mg/ml). This was then incubated for 3 minutes at 
20°C after initial mixing with a vortex mixer. After centrifugation at 1500g for 30 
seconds, PGb-like activity in the supernatant was measured using the anti-platelet 
aggregation assay. Aggregation was induced using ADP in concentrations of 2, 5 
and 10pm. PGb-like activity was calculated as before (chapter 3).
5.1.2.2 Tissue samples collected
Venous segments from 4 groups of patients (groups 1 to 4) undergoing surgical 
procedures under full general anaesthesia were obtained from the following sites:
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1. Superficial veins from the hip region in patients undergoing total hip 
replacement (n=19)
■S3
2. Proximal long saphenous vein branches in non portal hypertensive 
patients with varicose veins undergoing ligation of the sapheno-femoral 
junction (n=7)
192
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3. Mesenteric or omental veins in non portal hypertensive patients 
undergoing cholecystectomy (n=6)
4. Segments of portal vein, mesenteric vein and IVC from patients with portal 
hypertension undergoing porto-caval shunting or oesophageal transection 
for bleeding oesophageal varices (n=6); the vein segments were of 
equivalent diameter (2-3mm) and length (2cm)
5.1.2.3 Additional tests performed on the tissues
Anticipating low production of PGb-like activity from human tissues, the following 
tests were performed on some vein segments:
1. Incubation with arachidonic acid
Arachidonic acid was added to maximise PGb production in the 
presence of any increased tissue PGb-like activity. Vein segments 
were re-incubated for 30-120 minutes at 37°C in tris buffer pH 8.0 
containing 1 mg/ml arachidonic acid. PGb-like activity was measured in 
supernatant specimens.
4:
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5.1.3 Results
After simple incubation in tris buffer, no anti-platelet aggregatory activity could be 
demonstrated in any veins from groups 1, 2 or 4. Two of the mesenteric veins from 
group 3 (i.e. non portal hypertensive patients undergoing cholecystectomy), 
produced PGb-like activity equivalent to 3ng PGb/1 OOmg of tissue. No activity was 
found in incubates performed at higher tissue concentrations up to 200mg/ml.
1. Incubation with arachidonic acid
No PGb-like activity could be found in two veins incubated with 
1 mg/ml arachidonic acid for 30, 60, 90 and 120 minutes. Fifteen 
further veins were incubated with the same concentration of
193
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3?:?■2. Incubation in plasma or platelet rich plasma fPRP)
Plasma factors, which stimulate PGI2 production, have been reported 
(Defreyn G et ai, 1981, MacIntyre DE et al, 1978). Also platelets may 
provide a source of endoperoxides for PGb synthesis, (Baenziger NL 
et al, 1977 and Moncada S et al, 1976). Therefore, after prior 
incubation in tris buffer pH 8.0 at 37®C, vein segments were further 
incubated with normal plasma and PRP and PGb-like activity 
measured in the supernatant specimens.
3. Rapid freeze thawing of blood vessels 
Mechanical stress and trauma were thought to stimulate prostanoid 
production in blood vessels. Vein ring samples incubated in tris buffer 
at 100mg/ml were rapidly frozen using dry ice and then thawed at 
37®C, each cycle being repeated three times. The incubation medium 
was then tested for PGb-like activity.
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arachidonic acid for 60 minutes at 37°C. Four of these produced 
slight PGb-like activity equivalent to 30% inhibition of platelet 
aggregation or <0.7ng/100mg tissue/60 minutes.
2. Incubation in plasma or PRP 
Five samples were incubated with normal plasma and PRP after 
prior incubation in tris buffer. One sample incubated in plasma 
contained 40% anti-platelet aggregatory activity equivalent to 
0.8ng/100mg tissue/10 minutes. The remaining four plasma and 
five PRP incubated samples did not demonstrate any activity.
3. Rapid freeze thawing of blood vessels 
Only one sample out of five tested, produced any inhibition of 
platelet aggregation. This was equivalent to <1ng PGb/1 OOmg 
tissue/15 minutes.
5.1.4 Discussion
With the exception of two normal mesenteric vein samples, no PGb-like activity 
could be detected in tris buffer incubated veins even at higher tissue concentrations.
Further attempts to stimulate PGb release by the additional steps outlined failed to 
shown any appreciable production as measured by the bioassay method. It is well 
established that arachidonic acid is the primary substrate for PGb in cultured 
endothelial cells and arterial microsomes, (MacIntyre DE et al, 1978, Weksler BB et 
al, 1977, Bunting S et al. 1976, Moncada S et al, 1976 and Raz A et al, 1977). |
Human arteries and veins have subsequently been shown to produce substantial 
amounts of PGb when incubated with endoperoxides but not with arachidonic acid,
(Moncada S et al, 1977). This finding is corroborated in part by this study and
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perhaps could have been predicted. At the time of this experiment however, cyclic 
endoperoxides were not obtainable for these incubation studies which could only be 
performed with arachidonic acid.
From all of these studies it became obvious that PGb-like activity is not as prolific in 
human tissue as that in the rat or pig. Also it became clear that the bioassay itself 
was not sufficiently sensitive in detecting this lower level of human PGb-like activity.
The plasma and PRP incubation studies were prompted by the suggestions that 
there are factors present in plasma which could stimulate PGb production, 
(MacIntyre DE et al, 1978). No such effect was demonstrated in this study. Platelet 
derived endoperoxides could form a significant source of substrate for PGb 
production, (Moncada S et al, 1978[a] and Bunting S et al, 1976), but this also was 
not found to any significant extent. An explanation for this could be that only when 
thromboxane synthetase is inhibited can sufficient platelet derived endoperoxides 
accumulate to become available as substrate for endothelial PGb production, 
(Baenziger NL et al, 1979, Needleman P et al, 1979). In this study, neither the 
patients nor the tissue specimens had been treated with TXA2 synthetase inhibitors 
thus possibly explaining the lack of PGb production. Similarly disappointing results 
were found with tissues treated by rapid freeze thawing, a treatment which acts 
usually by stimulating enzymatic activity although sometimes inhibition may occur 
instead.
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5.2 Human Vein PGIs Production Measured by Radio­
immunoassay
6.2.1 Introduction
Having defined the major limitations of the PGb bioassay in human tissues, its use 
was abandoned. The timely establishment of a radio-immunoassay for 6-keto PGFio 
at the Royal Free Hospital made possible further study of PGb activity in human 
vascular tissue. Vein samples were collected from the portal systems of patients 
with and without portal hypertension. In addition, venous tissue samples from the 
systemic circulation were collected for measurement of PGb production.
Contemporaneously plasma samples, both peripheral and portal, were collected for 
6-keto PGFiq measurement but these studies on blood samples will be described 
later in this chapter.
5.2.2 Methods
5.2.2.1 Collection of veins
In all cases vein samples 1-3mm in diameter and 2cm in length were harvested with 
minimal surgical trauma prior to harvesting. In all the laparotomies, the segments 
were harvested before extensive handling of the tissues. Patients who had taken 
aspirin or NSAIDs within the preceding two weeks were excluded. The samples 
were immediately kept ice cold for transfer to the laboratory for processing in the 
standard manner.
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group I Veins from the hip region in 25 patients undergoing total hip
replacement for osteoarthritis; none had taken NSAIDs within two
weeks of surgery and there was no concurrent portal hypertension
group II Mesenteric veins from 17 patients undergoing cholecystectomy with no
concurrent medical problems or portal hypertension.
group IV Mesenteric veins from six patients undergoing surgery for bleeding 
oesophageal varices secondary to portal hypertension. These patients 
were undergoing the procedure of oesophageal transection to arrest 
the haemorrhage.
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5.2.2.2 6-keto PGF1a measurement
6-keto PGFio was measured In the supernatants obtained after tissue incubation at 
20°C for three minutes. The method is described in chapter 3 and the Wellcome 
antiserum was used without an extraction step, (Saba SR et al, 1973). Results were 
expressed as mean and standard deviation (SD) and in units of picograms 6-keto 
PGFio /I OOmg tissue (pg/IOOmg tissue).
5.2 2.3 Vein samples collected
Sections of veins were collected from four clinical groups of patients as follows:
Agroup III Mesenteric veins from nine patients with intra-abdominal malignancy 
with no portal hypertension (carcinoma of stomach, pancreas or colon)
I
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5.2.3 Results
These results are shown in fig 5.2.3.
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Fig 5.2.3 Scattergram with means of 6-keto PGFiQ measurements for the 
various groups; group I = 25 hip veins (mean 88); group II = 17 normal mesenteric 
veins from cholecystectomy patients (mean 350); group III = 9 mesenteric veins from 
patients with abdominal malignancy (mean 600); group IV = 6 portal hypertensive 
mesenteric veins (mean 393).
Hip veins (group I) had a mean 66-keto PGFiq level of 88 +/-74 pg/IOOmg tissue 
which was significantly lower than in any of the three other clinical groups, (gp I -v- 
gp II, p<0.001; gp I -v- gp III, p<0.01; gp I -v- gp IV, p<0.00001). The mesenteric 
veins in groups II, III and IV showed no statistically significant differences, and 
specifically no difference between normotensive and hypertensive veins. The 
standard deviations for values in the normotensive groups were high with a very
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small standard deviation found for the mesenteric veins from patients with portal 
hypertension.
5.2.4 Discussion
The radio-immunoassay using the Wellcome antiserum was clearly sensitive enough 
to measure 6-keto PGFio in incubates of both peripheral (hip) and portal 
(mesenteric) vein segments. As expected from the studies using the bioassay, the
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level of PGI2 activity in man is considerably lower than in the rat and pig, and 
considerably below the lower threshold of sensitivity for the bioassay.
The striking finding in this study is the highly significantly increased PGI2 production 
by mesenteric veins when compared to those from the hip. This finding suggests 
that there may also exist in man a gradient of PGb activity across the various venous 
beds. Disappointingly, no difference was found between the hypertensive and 
normotensive mesenteric veins although there was a marked difference in the range 
of these values between the two. In fact, the range of 6-keto PGFio levels found in 
the six hypertensive mesenteric veins was remarkably consistent about the mean of 
380pg/100mg. These samples were taken from patients actively haemorrhaging 
from the portal system but who had all been resuscitated to normal systemic 
pressures to allow the surgery to take place.
The anaesthetic agents used were standard for all of these procedures with all
'patients being paralysed and ventilated. The portal hypertensive group, (gp IV), was 
different from the other groups, having had haemorrhagic shock, resuscitation and 
transfusion with blood, fresh frozen plasma, and in addition treatment with
j.
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vasopressin at variable times before the vein harvesting. None of the patients in 
group IV were on Propranolol for treatment of portal hypertension. There are clearly 
many clinical differences between group IV and groups II and III and perhaps only a 
much bigger study with more patients in each group would reveal any underlying 
difference. The logistics of obtaining a sufficient number of patients with portal 
hypertension requiring open abdominal surgery are major, thus making a 
significantly large study impossible.
The trauma sustained by the tissues during harvesting may be another significant 
factor in explaining the differences. Mesenteric vein harvesting involved equivalent 
levels of trauma to the tissues in all groups. Technically there is a clear difference in 
harvesting hip vein however which could help explain the significant difference in 6- 
keto PGFiq levels found in these veins. However, the degree of trauma sustained in 
hip vein harvesting is likely to be greater than that of mesenteric vein and 
subsequently higher rather than lower levels of 66-keto PGFiQ would have been 
expected. Assessment of the degree of trauma remains highly subjective and 
impossible to quantify accurately in this sort of study. Measurement of PGb 
production in the plasma within these vessels would avoid these confounding factors 
of trauma from tissue dissection.
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5.3 Plasma 6-keto PGFla Levels Measured by Radio­
immunoassay
5.3.1 Introduction
It is logistically and ethically preferable to measure PGb production from blood rather 
than tissue. This is particularly true in peripheral blood measurements where 
repeated sampling can be performed over a time period with minimal inconvenience 
and trauma to the patient. With the development of the RIA in our laboratory, this 
methodology was applied to human studies on samples from peripheral and portal 
blood samples. Initial work was concentrated on peripheral blood measurements in 
the peri-operative period, then on the first 7-10 days after surgery. Having made 
these baseline studies, levels in normal portal and hypertensive portal blood were 
measured.
Most of this work was carried out using the Wellcome antiserum with an extraction 
step. In the latter part of this study it became clear that the extraction process was 
resulting in inconsistent results as was previously described. Consequently, a 
different antiserum was employed which did not require the extraction process.
5.3.2 Methods
5.3.2.1 Studies using the Wellcome antiserum RIA
Samples were collected using 21G needles after the first 2ml of blood were 
discarded. Only peripheral veins which had not been previously cannulated were 
used and in porta! venous sampling, blood was taken directly either from a
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mesenteric, omental or portal vein at the beginning of the operative procedure with a 
view to minimising possible trauma to the intestines and portal system. The blood 
was collected into plastic tubes containing sodium EDTA and Indomethacin. Plasma 
was prepared from these samples, collected into 1.0ml aliquots in plastic tubes, and 
stored at -40®C until assayed.
Extraction was carried out as outline in chapter 3 (Baenziger NL et al, 1979). The 
residues were re-dissolved in 0.3ml GTB and assayed for 6-keto PGFi alpha using 
the Wellcome antiserum.
S.3.2.2 6-keto PGFia levels In peripheral blood of patients undergoing 
laparotomy or hip replacement
In this initial study blood samples from the antecubital veins were collected from 15 
patients without portal hypertension undergoing laparotomy for benign disease, 
(cholecystectomy, vagotomy). Samples were collected before induction of 
anaesthesia, 24 hours after surgery and on days 2, 3, 4 and 7 post operation. In 
collaboration with the orthopaedic surgeons, a similar study was performed on 11 
patients undergoing total hip replacement; peripheral venous samples were collected 
pre-operatively and on days 1,2, 3, 4, 7 and 10.
5.3.2 3 6-keto PGFia levels In peripheral and portal blood of non portal 
hypertensive patients undergoing laparotomy
Blood samples were collected before induction of anaesthesia from 15 patients 
undergoing laparotomy, 11 for cholecystectomy and four for carcinoma. During the 
first part of the laparotomy and with minimal disturbance to the intestines, a sample
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of portal venous blood was taken from a suitable vein as previously described. 
Finally peripheral samples were taken 24 hours after the operation.
5.3.2 4 Comparison of 6-keto PGFio levels in peripheral and portal vein blood 
using the Wellcome and Cardeza antisera
Because of marked differences of 66-keto PGFiO activity found with the two antisera, 
comparison was made using both methods in the same samples. Blood was 
collected before induction of anaesthesia in five patients who did not have portal 
hypertension undergoing laparotomy for benign conditions. Portal samples were 
collected as previously described and peripheral samples obtained 24 hours after the 
operation.
Two 1.0ml aliquots from each sample were prepared, one assayed using the 
Wellcome antiserum after an extraction process, and the other directly assayed 
using the Cardeza antiserum without the extraction step.
5.3.2.5 6-keto PGFia levels in portal blood using the Cardeza antiserum
Portal venous samples were obtained at laparotomy from 12 patients undergoing 
cholecystectomy and three undergoing procedures for bowel carcinoma, all of who 
did not have portal hypertension. Portal venous samples were also obtained from 
five patients with portal hypertension undergoing laparotomy for treatment of 
oesophageal variceal haemorrhage.
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5.3.3 Results
204
5.3.3.1 6-keto PGFia levels in peripherai blood of patients undergoing
laparotomy or hip replacement
Using the Wellcome antiserum after extraction, detectable levels of 6-keto PGFiO in 
peripheral blood samples of patients undergoing laparotomy (general abdominal 
surgery) were found (see fig 5.3.3.1). Overall these ranged from 9 -  196pg/ml of 
plasma with a pre-operative baseline range of 105 -  181pg/ml. A fall in 6-keto 
PGFi a was found on the second post-operative day in the majority and on the third 
day in one patient, which was significant (p<0.05, Wilcoxon paired rank sum test). 
By one week after surgery, the levels had returned to pre-operative values.
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General
Abdominal
Surgery
142(17) 128 (28) 104(15) 127(13) 149(11) 122(12)
Fig 5.3.3.1 Apparent 6-keto PGFiO levels in peripheral blood of patients having 
Total Hip Replacement (THR) or General Abdominal Surgery (GAS) Mean & 
(SD)
Similar baseline levels of 6-keto PGFiO were found in the cohort of patients 
undergoing total hip replacement. There also occurred a similar significant fall in 6- 
keto PGFiO on the second post-operative day (p<0.05, Wilcoxon paired rank sum
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test). Also by day seven, these had returned to the pre-operative levels.
S.3.3.2 6-keto PGFia levels in peripheral and portal blood of non portal 
hypertensive patients undergoing laparotomy
Using the Wellcome antiserum major differences were found in 6-keto PGFi alpha 
levels between peripheral and portal venous samples (table 5.3.3.2). This 
difference was ten to twenty fold with mean portal levels of 3901 (+/- 2304) pg/ml in 
comparison to mean pre-operative and 24 hour post-operative levels of 182 (+/- 76) 
and 194 (+/- 130)pg/ml respectively. There was no difference in peripheral plasma 
6-keto PGFi alpha levels before or one day after surgery, confirming the findings of 
the preceding study.
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Surgical group Pre-operation Post operation Intra-operation
peripheral peripheral portal
cholecystectomy 113 302 3830
171 264 5122
161 160 5122
217 334 5036
349 107 552
180 199 979
233 77 5325
55 291 1054
142 140 6043
159 43 3858
142 89 4071
Carcinoma 97 61 1356
268 236 8271
165 514 1652
273 94 5522
Mean 182 194 3901
SD 76 130 2304
Table S.3.3.2 Apparent 6-keto PGFio measured using the Wellcome antiserum 
in extracted peripheral and portal plasma from patients without portal 
hypertension undergoing abdominal surgery
5.3.3 3 Comparison of 6-keto PGFia levels in peripheral and portal vein blood 
using the Wellcome and Cardeza antisera
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A striking difference in levels of 6-keto PGFiO detected with the two assay methods 
was found. As in previous studies considerable quantities were detected with the 
Wellcome antiserum in extracted samples but no 6-keto PGFiO at all could be 
detected with the Cardeza antiserum in non-extracted peripheral specimens (table 
5.3.3.3). Low levels of 6-keto PGFiO were found in four out of five of the portal 
samples using the Cardeza antiserum with none at all found in the fifth. This 
difference in levels found between the two assays was of several orders of 
magnitude with a mean 6-keto PGFi a of 5955pg/ml in the Wellcome assay versus a 
mean of 9.34pg/ml in the Cardeza assay.
Patient Plasma
sample
Wellcome antiserum with 
extraction
Cardeza antiserum without 
extraction
1 Pre-op 217 0
Post-op 334 0
Portal 5036 13
2 Pre-op 113 0
Post-op 302 0
Portal 3830 10.4
3 Pre-op 268 0
Post-op 236 0
Portal 8271 13.7
4 Pre-op 349 0
Post-op 107 0
Portal 552 0
5 Pre-op 142 0
Post-op 140 0
portal 6043 9.6
Table 5.3.3 3 6-keto PGFiO (pg/ml) measured in peripheral and portal blood 
using both Wellcome and Cardeza antisera
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5 3.3.4 6-keto PGFia levels in portal blood using the Cardeza antiserum
Measurable but much reduced levels of 6-keto PGFiO were found in all portal 
samples using this assay (table 5.3.3.4). Levels in the portal hypertensive group 
were similar to those found in patients with normal portal pressure, i.e. mean 19.9 
(+/- 6.7) pg/ml versus 15.5 (+/-10.4) pg/ml for the cholecystectomy patients and 20.5 
(+/-16.1) pg/ml for the three patients with carcinoma.
Cholecystectomy
N=12
Portal hypertensive patients 
N=5
Patients with carcinoma
N=3
2.9 11.5 8.9
3.7 14.1 13.7
9.6 21.8 38.9
9.6 25.9
10.3 25.9
11.5
12.2
13
21.8
26.8
29.6
35.2
15.5 (10.4) 19.9 (6.7) 20.5 (16.1)
Table 5.3.3 4 6-keto PGFiO levels (pg/ml) in portal plasma obtained at surgery 
measured using the Cardeza antiserum: mean and standard deviation shown in 
bottom row.
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5.3.4 Discussion
Peripheral venous plasma samples contained measurable quantities of 6-keto PGFio 
using the extraction process and the Wellcome antiserum. Studies on orthopaedic 
and general surgical patients showed a similar pattern of significantly falling 6-keto 
PGFiq on the first and second days after surgery with rapid return to normal by seven 
days. These are intriguing data which could suggest a phenomenon in the early 
post-operative period of diminished PGb production which could affect platelet 
aggregability and be implicated in the multi-factorial prothrombotic state seen in the 
early post-operative period.
These findings were not confirmed using the radio-immunoassay without an 
extraction step where no 6-keto PGFio at all was detected in peripheral plasma 
samples. This raises the question as to what was been measured by the radio­
immunoassay using the extraction procedure? Clearly conclusions regarding PGb 
production from the extraction RIA cannot be made but the similarity in fall of 
apparent 6-keto PGFio at day two in all types of operation studied is an interesting 
one with regards to the aetiology of the post-surgical prothrombotic state. As a result 
of these major discrepancies in measured 6-keto PGFio in the same samples using 
the two radio-immunoassays, the use of the extraction process and the Wellcome 
antiserum was discontinued after only 15 samples were studied.
Portal vein plasma 6-keto PGFiq measured by both assays was significantly higher 
than in peripheral plasma. There could be several explanations for this 
phenomenon. Firstly, the degree of manipulation or trauma to the intestine or portal
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structures may be greater than that involved in taking a peripheral blood sample. 
However, great care was taken to minimize direct trauma and handling of the tissues 
prior to blood sampling and in addition, the first 2ml of blood were always discarded. 
Possibly the trauma of induction of anaesthesia and the laparotomy incision might 
contribute to this effect. Unfortunately, the design of this study did not involve the 
taking of peripheral venous samples during anaesthesia or any of the procedures in 
any of the groups studied. However, in the previously described studies, PGb 
production from venous tissue samples revealed significantly greater levels 
produced from portal compared to peripheral veins. It is therefore likely that these 
elevated portal plasma levels are real and that there is elevated PGb production in 
the portal system in man. No difference between 6-keto PGFiq levels in portal 
normotensive and portal hypertensive patients could be found however in this small 
group of patients.
In conclusion, the logistics of obtaining portal samples have proved to be major and 
had limited the sample size of these clinical studies. Furthermore, the levels of PGb 
produced in man are much lower than pig and rat. Thus reliable measurement using 
the available radioimmunoassays was also problematical with measured levels 
without the extraction process being at the very lower range of accuracy of the 
Cardeza radioimmunoassay. RIA with extraction leads to falsely elevated levels of 6- 
keto PGFiq like compounds and RIA without extraction is not sensitive enough to 
measure levels in peripheral blood and only just so in portal plasma. In order to 
study PGb production in the portal circulation in man, a more sensitive assay method 
was required.
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6.4 Plasma 6-keto PGFia Levels Measured by Gas Chromatography 
/ Mass Spectrometry
5.4.1 Introduction
The use of RIA in measuring plasma 6-keto PGFia in human samples was 
abandoned in 1982 because of the poor sensitivity of this assay for prostanoids in 
the very low levels produced by man. In 1983 a collaboration was set up with the 
Department of Clinical Pharmacology at the Royal Postgraduate Medical School, 
London (RPMS) to investigate PGb production measuring 66-keto PGFio using gas 
chromatography / gas spectrometry. Dollery’s group at the RPMS had shown that 
this method could accurately measure 6-keto PGFia down to levels of less than 
2pg/ml (Blair lA et al, 1982). Samples of peripheral and portal blood from patients at 
the Royal Free Hospital were collected and transported to the RPMS where 6-keto 
PGFia measurements were made under the supervision of Dr’s Sue E Barrow and J 
M Ritter (now Professor J M Ritter at Guys Hospital).
5.4.2 Methods
5.4.2.1 Subjects
Blood samples were taken from the following groups of patients:
group I Peripheral blood samples were taken from six patients with established 
cirrhosis and portal hypertension. These patients were stable and 
were not actively bleeding from oesophageal varices. They were in­
patients undergoing investigation of their liver disease.
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group 11 Six patients with portal hypertension and active bleeding from 
oesophageal varices requiring emergency surgery to stop the bleeding 
were studied. In three out of the six, pre-operative peripheral blood 
samples were taken. In all of the six patients, intra-operative peripheral 
blood samples and portal venous blood samples were collected in the 
standard manner.
group III Eight patients without liver disease or portal hypertension, but who 
were undergoing abdominal surgery for benign conditions (peptic 
ulceration, cholecystectomy), underwent portal venous sampling during 
surgery to provide a control group to establish 6-keto PGFia levels in 
the portal plasma. Peripheral samples were not taken from these 
patients during surgery.
5 4.2.2 Blood sampling
Peripheral samples were taken from an antecubital vein. Intra-operative peripheral 
and portal samples were taken simultaneously immediately on opening the 
abdomen. The portal samples were taken before any handling of the intestine or 
other intra-abdominal organs. A 21G needle was used to draw 20ml samples which 
were placed into ice cold lithium heparin tubes and mixed by gentle inversion. The 
heparinised tubes were stored in ice and transported to the laboratory for processing 
within 15 minutes of collection. The blood was Immediately centrifuged at 4°C at 
lOOOg. Plasma was aspirated using a plastic pipette and an exact volume (10ml or 
to the nearest 1 decimal place) was placed in a steralin container containing 2pg of
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tetradeuterated 6-keto PGFia in distilled water as an internal standard. After mixing 
well and recording the exact plasma volume and patient’s details on the container, 
the sample was stored at -20®C until transfer for assay. Samples were dispatched 
from the Royal Free Hospital to the RPMS on dry ice within one week of collection.
5.4.2.3 Assay by GC/MS
The assay method used at the RPMS was gas chromatography / negative ion 
chemical ionisation mass spectrometry (GC/NICIMS) previously validated as highly 
specific and sensitive (Blair lA et al, 1982).
Results were analysed using Wilcoxon’s non paired rank sum test and for paired 
samples, Wilcoxon's paired sum rank test.
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5.4.3 Results
These results are shown in table 5.4.3.
Patient Number No surgery Pre-op Intra-op Intra-op
group peripheral peripheral peripheral portal
1 Stable 1 <2
1 Stable 2 <2
1 Stable 3 <2
1 Stable 4 <2
1 Stable 5 <2
1 Stable 6 <2
II Bleeding 7 --- 740 796
II Bleeding 8 --- 748 1820
II Bleeding 9 --- 99 411
II Bleeding 10 25 1842 11485
II Bleeding 11 26 440 177
II Bleeding 12 31 137 217
III Normal 13 51
III Normal 14 1874
III Normal 15 97
III Normal 16 96
III Normal 17 152
III Normal 18 81
III Normal 19 <5
III Normal 20 524
Table 5.4.3 6-keto PGFiO levels (pg/ml) in peripheral and portal venous blood 
In stable and bleeding portal hypertensives, and in normai portal venous blood
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group I All six stable patients with portal hypertension had levels of 6-keto 
PGFiq of <2pg/ml in their peripheral blood.
group II In the pre-surgery samples taken from three patients actively bleeding 
from oesophageal varices, the peripheral 6-keto PGFiQ levels were 
significantly higher than the stable portal hypertensive patients (median 
26 pg/ml versus <2 pg/ml; p<0.024). Very high concentrations were 
found in both the peripheral and portal venous samples during surgery 
for the six patients who were actively bleeding. Five out of six of these 
patients had higher portal levels than peripheral but this difference was 
not statistically significant.
group III Portal venous samples taken from the eight non portal hypertensive 
patients undergoing abdominal surgery contained high levels of 6-keto 
PGFiQ (range 0-1874 pg/ml, median 96.5 pg/ml). These were lower 
than those found in portal samples from the portal hypertensive 
patients (median 604 pg/ml -  range 177-11485 pg/ml); this difference 
was significant, (p<0.04, Mann-Whitney test).
5.4.4. Discussion
Assay of 66-keto PGFio using the GC/NICIMS detected much lower levels in 
peripheral blood samples with the vast majority of patients having virtually no 6-keto 
PGFiq detectable. These results were comparable to those observed in the previous 
clinical studies using the Cardeza antiserum without the extraction process. This
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finding confirms the unreliability of RIA with extraction for prostanoids and confirms 
the findings of others (Morris HG et al, 1981).
Peripheral 6-keto PGFia levels in patients with portal hypertension who were not 
bleeding and in a stable condition were similarly very low at <2pg/ml. These levels 
fell within the normal range detected using this assay and were not different from 
patients with accelerated hypertension or coronary arterial disease in addition (Blair 
la et al, 1982 & Ritter JM et al, 1986). Pre-operative peripheral plasma samples 
from the three actively bleeding patients however contained higher levels of 6-keto 
PGFia (median 26 pg/ml, range 25 -  31 pg/ml). Although these are very small 
numbers, comparison with the peripheral plasma levels of the non bleeding portal 
hypertensive patients reveals that this difference is significant at p<0.02. Few 
conclusions can be made from such a small albeit homogenous sample. This 
elevation could either result from increased PGb production in the splanchnic 
circulation in these bleeding patients spilling over into the general circulation, or 
result from the traumas of resuscitation. These could include central venous 
cannulation, the administration of blood transfusions and various vaso-active 
substances, multiple peripheral venous cannulations for blood sampling etc.
The very high levels found during surgery, both in peripheral and portal samples in 
these acutely bleeding portal hypertensive patients, were not significantly different 
but the elevation overall was striking. In five out of the six patients, the portal levels 
were higher than in the peripheral plasma. The 6-keto PGFiO levels in portal blood 
in these actively bleeding patients were significantly increased in comparison to 
portal plasma obtained from patients without portal hypertension undergoing surgery.
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This significant difference supports the experimental findings in this work relating 
increased portal pressure to increasing PGb production
general abdominal surgery. This depletion of PGb production in response to major
Major surgery seems to increase dramatically peripheral plasma levels of 6-keto 
PGFi a. This effect was seen not only in these liver patients, but also in patients 
having coronary artery surgery (Ritter JM et al, 1986). This raises the possibility that 
the administration of general anaesthetic agents and or the traumas of the various 
cannulations, incision and handling of tissues, causes a massive release of PGb 
This could be a direct effect of trauma on endothelial cells and blood vessels since 
endothelial cells in culture have been shown to produce more PGb when exposed to 
cyclical stress (Okahara K et al 1998). A further possibility is that PGb is released as 
a reactive physiological mechanism to ‘quench’ the coagulation cascade thus 
preventing thrombus extension from haemostasis occurring in areas of sharp trauma 
to blood vessels. Alternatively, this may be a counteractive response to the massive 
platelet activation and release of TXA2 occurring from the multiple sites of trauma 
from a major operation. Increased levels of PGb would counteract the resultant 
vaso-constriction and increase platelet aggregation. This outpouring of PGb during 
surgery may exhaust temporarily the endothelial cells’ capacity for production of PGb
and explain the fall in PGb activity found during the first 48 hours after hip and
surgery may be a possible contributor to the post-operative hyper coagulable state.
These studies using a reliable assay of 6-keto PGFi a and hence PGb production on 
small numbers of patients, provide clinical evidence to support the hypothesis that 
PGb production is increased in the porta! circulation in portal hypertension in man.
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The trauma of surgery contributes to these elevated levels and the true magnitude of 
the increased PGb production from portal hypertension could only be studied using 
less invasive methods of portal venous blood sampling.
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CHAPTER 6: GENERAL D ISCUSSIO N
Variceal haemorrhage commonly complicates liver diseases which lead to portal 
hypertension. The haemorrhage, typically spectacular and life threatening, is now 
dealt with satisfactorily by volume and blood replacement, correction of clotting 
abnormalities, administration of agents to reduce portal blood flow, and injection 
sclerotherapy. Long-term control is now achieved by pharmacotherapy with agents 
such as beta-blockers, and the use of Transjugular Intra hepatic Portasystemic 
Shunt (TIPS). In the modern age therefore, surgical involvement and treatment of 
this condition is now limited essentially to liver transplantation. At the time of the 
production of this work, namely the early 80's, it was quite a different situation. 
Injection sclerotherapy was in its early stages of clinical introduction and 
assessment, (Burroughs AK et al, 1989), and the main treatment for acute and 
chronic variceal bleeding was overwhelmingly surgical.
J:,;:
In the acute situation, this was by emergency portasystemic disconnection 
procedures such as oesophageal transection, and less commonly emergency porta­
caval shunting. The major focus of surgical research into portal hypertension was 
therefore on the problem of control of haemorrhage in those patients where 
conservative treatment had failed. In the early 80’s, the eruptive theory of 
explanation of oesophageal rupture was widely accepted with recognition that larger 
varices were more likely to bleed. It was not clear however whether there was a 
relationship between higher portal pressure within the varix and bleeding. Reynolds 
in 1982 reported a review of studies relating portal pressure to oesophageal rupture.
I
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These measurements were mostly made by wedged hepatic venous pressure 
measurement and most reports showed no significant relationship between high 
portal pressure and bleeding, (Reynolds TB, 1982). Two further reports actually 
measured intra -variceal pressure by direct needle puncturing. In one the puncture 
was in the oesophageal variceal cord above the oesophago-cardiac junction and in 
the second, the puncture was directly into the varix at its point of potential 
haemorrhage although in this study the measurement was followed by injection 
sclerotherapy, (Palmer AD et al, 1956 and Westaby D et al, 1985). The fact that 
neither of these studies was complicated by significant oesophageal bleeding 
suggested that the relationship with oesophageal variceal pressure was not 
important. At the time of the work for this thesis, Groszmann had not yet elaborated 
the concept of variceal wall tension as the major factor in variceal rupture.
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The other major factor implicated in the severity of bleeding from ruptured 
oesophageal varices was disordered coagulation. In liver disease coagulopathy is 
frequent and multi-factorial. The patients presenting to the surgeon at the time of 
this work were those precisely who had undergone aggressive replacement therapy 
and correction of clotting deficiencies but in whom haemorrhage had not stopped, or 
where the benefit had only been temporary. Haemorrhage of such severity from a 
small hole in an oesophageal varix was therefore a major source of perplexity to the 
surgeon who had to deal with this problem. In the early 80’s it was felt that the 
inadequacies of conservative treatment of this condition reflected the current poor 
understanding of coagulation defects at that time rather than haemodynamic effects 
on the variceal wall. The recent discovery at that time of PGb and TXA2 and the
feeling that these prostanoids were important in regulation of platelet aggregability,
%I
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possibly coagulation and of vascular tone, led to my investigation of their possible 
role in the bleeding diathesis of portal hypertension leading to variceal haemorrhage. 
Indeed, there was widespread interest at that time in the possibility that disturbances 
in the balance between PGb and TXA2 might be centrally involved in the 
pathogenesis of several disorders. Mainly these were disorders of abnormal 
thrombosis or haemostasis such as arteriosclerosis, diabetes mellitus, the 
haemolytic uraemic syndrome and others (chapter 1).
Accurate measurement of PGb proved to be the most difficult part of these studies. 
Because of its evanescent nature, direct measurement of PGb in tissues and fluids 
was not possible. The initial bioassay for PGb-like activity using platelet 
nephetometry proved to reliable in measuring inhibition of platelet aggregation in 
tissues. This assay had the advantage of measuring a physiological effect but 
lacked specificity with regard to measurement of PGb itself. Testing for ADP-ase 
activity effectively excluded this physiological inhibitor but others such as PGA2, 
PGEi and PGD2 could not be excluded. Therefore the major deficiency in our use of 
this bioassay was in not using specific inhibitors of PGb production in controls in 
order to establish whether the effect measured was indeed due to the presence of 
PGb. Once the radio-immunoassay for 6-keto PGFiO was developed, an excellent 
correlation with PGb-like activity was found however, (R=0.95), indicating that the 
activity was indeed most likely due to PGb production by the tissues.
I
Our development of the radioimmunoassay for 6-keto PGFi a was driven mainly by 
the desire to have a more accurate and perhaps less cumbersome method of assay. 
The development however proved to be technically difficult with considerable
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modification of the methodologies required as the studies progressed. This 
endeavour alone involved a great deal of time and development since these studies 
predated the advent of commercially available radioimmunoassay kits for 6-keto 
PGFiO.
The major problem arose in the radioimmunoassay measurement of 6-keto PGFiO in 
serum. Initially because of the low levels detected, an extraction step was used 
which gave measured concentrations similar to many other published reports of that 
time. This was a time of excitement at the ability to measure significant levels of 6- 
keto PGFiO in the serum, leading to the hypothesis that PGb was a circulating 
hormone modulating vascular tone and coagulation (Moncada S etal, 1978[b]). The 
finding of elevated levels of 6-keto PGFia in portal venous samples also generated 
excitement in our laboratory which unfortunately proved to be almost as evanescent 
as the prostanoids. Once it was realised that artefactually high levels were being 
measured by the RIA, the extraction process was bypassed following the 
introduction of the high affinity Cardeza anti-serum. Using this anti-serum, 6-keto 
PGFi Q in normal serum was found to be either undetectable or below 10pg/ml. This 
finding was corroborated by others, leading to the conclusion that there was very 
little PGb in the circulating blood and that it did not have a role as a circulating 
hormone, (Greaves M et al, 1982). In the last part of these clinical studies, plasma 
measurements were made using GC/NICIMS in Professor Dollery’s Laboratories at 
the Hammersmith Hospital. This proved to be a method with high specificity and 
sensitivity providing accurate measurements of 6-keto PGFio in human serum, 
(Barrow SE et al, 1982). At that time however, this was a laborious and time- 
consuming assay involving equipment that occupied two laboratory rooms. Access
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to this facility was therefore limited resulting in the last clinical study being 
constituted of small numbers. Today this equipment is much more convenient and 
user friendly, occupying one laboratory bench surface. Thus in the early 80's, in the 
absence of RIA kits and sophisticated spectrometers, the logistical difficulties of 
performing studies on PGb and 6-keto PGFio were considerable.
s
For this work the model of partial portal vein ligation, (PPVL), to induce portal 
hypertension was chosen because of its convenience and the availability of the 
surgical expertise. Furthermore, this model had the advantage of causing portal 
hypertension without any iiver damage, thus removing a possible confounding factor 
in these early studies. This model had previously been described by Orda and Ellis,
(Orda R et al, 1978), and My king and Hatvorsen in the1970s, (Myking AO et al,
1973) who reported that it established portal hypertension by one week after PPVL.
There was little else in the literature about this model at the beginning of the work for 
this thesis. This model was further assessed and developed in this thesis, 
confirming the rapid establishment of portal hypertension in the size of rat that I 
chose (150-250g). This effect was established by 24 hours and lasted up to two 
weeks at the significant level. The gradual return to normal pressure thereafter was 
confirmed to be due to the opening up of collaterals by studies using splenic 
portography and resin corrosion cast studies. In particular, the left anterior lumbar 
vein, (LALV), was found to constitute a major collateral between the portal and 
systemic circulations. PPVL and simultaneous ligature of the LALV gave a reliable 
model for chronic portal hypertension. A subsequent study using a tighter stenosis 
of the portal vein, (8mm versus 1.2mm), also provided a chronic portal hypertension 
model. Induction of portal hypertension by injection with microspheres was also
I
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developed as a model specifically in order to avoid the potential trauma and 
inflammation of portal vein ligature. This proved to be effective but was associated 
with higher mortality and morbidity. Thus, I developed three simple and reliable 
models of portal hypertension using PPVL and microspheres, one giving acute portal 
hypertension which was limited to two weeks with return to normal pressure, the 
second giving chronic portal hypertension lasting over six weeks, and the third used 
in only one study because of its high morbidity and mortality. This allowed 
estimation of changes in PGb production in both acute and chronic situations.
The PPVL model has subsequently been used extensively, in particular to study 
development of the hyper-dynamic circulation of portal hypertension. Grozsmann’s 
group have shown that immediately after PPVL, there was resistance induced portal 
hypertension characterised by increased portal resistance, increased portal pressure 
and reduction of portal venous inflow. A series of changes occurred over the 
following seven days after ligation, namely extensive portasystemic shunting, a 
return of portal resistance to normal values, and increased portal venous inflow 
contributing to maintenance of elevated portal pressure, (Sikuler E et al, 1985). 
Subsequent work by this group confirmed that vasodilatation is the initiating event 
which together with subsequent plasma volume expansion results in the hyper­
dynamic state, (Colombato LA et al, 1992). The experimental studies on rats 
established a direct relationship between PGb production and pressure in the portal 
vein. Extensive comparison with controls excluded the effects of anaesthesia, 
surgical manipulation, and ligature related trauma and inflammation as possible 
causes. Furthermore, PGb production was shown to be significantly increased by as 
early as 24 hours. It remained so as long as portal hypertension was present, with
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circulatory vasodilator action to take place in the systemic circulation. Thus, it is 
probable that a systemic hyperdynamic circulation could only develop once 
significant shunting of portal blood containing active PGb has taken place.
The final part of my work focused on finding evidence for similar mechanisms in 
man. A significant difference in PGb production by venous tissue between man and
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return to normal levels even when previously established portal hypertension had 
resolved due to collateral development. This was the first report of increased PGb 
production in portal venous hypertension which other workers later confirmed to 
develop in rats and rabbits, (Sitzmann JV et al, 1991 and Oberti F et al, 1993).
Further confirmation of the role of prostacyclin in portal hypertension would be 
provided by studies using cyclooxygenase inhibitors; these would be NSAIDs such 
as indomethacin or the more recently available COX inhibitors. I did not undertake 
these experiments, but Sitzmann et al., confirmed that 6-keto PGFiO levels fell by 
50% after indomethacin blockade of PPVL rabbits. Furthermore, infusion of PGb 
resulted in a return to the previously raised levels of superior mesenteric artery 
resistance and blood flow seen in indomethacin blocked PPVL rabbits. These 
studies confirmed the importance of PGb release in experimental portal hypertension 
and its role in maintaining the haemodynamic changes in the splanchnic circulation. 
Subsequently increased PGb production was implicated by several workers in the 
development of porta-systemic collaterals. Once developed the rich collateral 
circulation may allow up to 90% of portal blood to be shunted away from the liver
"I
parenchyma, carrying with it PGb which will not have been inactivated by the liver. 
Unlike other prostaglandins, PGb is not metabolised by the lung, thus allowing a
"‘ i f
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animals was rapidly established. Bioassay of human venous tissues could not
detect any PGb-like activity at all, and RIA measurements of 6-keto PGFi Q in venous 
tissues confirmed lower production of PGb This was lower by an order of 
magnitude than those found in animal tissues, (pg rather than ng). In man 
mesenteric vein was found to have significantly greater production of PGb than hip
'Ï"
vein, a finding paralleling those in the rat and pig. Thus, in these species and in 
man, it is likely that a gradient of PGb production in venous tissue exists with the
greatest activity being present in veins (such as the portal circulation) exhibiting 
greater pressure.
No difference in 6-keto PGFiO production was found between 19 normotensive 
mesenteric veins from normal patients and six hypertensive mesenteric veins taken 
from patients with bleeding oesophageal varices. However, there was a 
considerably increased range of measurements in these normal veins in comparison 
to the six hypertensive veins. The standard deviation in the normotensive veins was 
fifty times greater than in the hypertensive veins. This suggests that a difference 
may be present but this could only be determined by a much larger study than was 
possible at this time.
■:i..
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Serum levels of 6-keto PGFiO using the RIA were significantly greater in portal vein 
compared to peripheral venous samples. This difference was present for both the 
anti-sera used but with no 6-keto PGFiq detected in any peripheral samples when 
using the Cardeza anti-serum. No difference between serum 6-keto PGFio levels 
was found between portal hypertensive and normotensive patients, confirming the 
finding in the incubated mesenteric human venous tissue samples.
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Therefore, these clinical studies confirmed increased PGb production in the portal 
system but that this activity was at much lower levels than in the rat, rabbit or pig 
with the average levels being <10pg/ml. After extraction, much greater levels of 
“apparent” PGb were measured with the intriguing finding of significant falls 
occurring during the second and third days after hip and abdominal surgery. It was 
not clear what was being measured in these “apparent” 6-keto PGFio samples, but 
presumably several members of the prostanoid family were being extracted. From 
all of the experimental and clinical studies, it is apparent that the trauma of surgery 
and general anaesthesia increases production of PGb and most probably, other 
prostaglandins. This fall detected in the early post-operative period may signify a 
degree of exhaustion of prostaglandin metabolism and it would be attractive to 
investigate this further as a possible contribution to the pro-thrombotic tendency 
which has long been recognized to occur in the post-operative period. These studies 
were on tissue and serum, therefore no contribution or effect arising from platelet 
prostaglandin substrates and in particular TXA2 can be implicated in this 
phenomenon. The finding of a major effect of surgery in the studies using gas 
chromatography/mass spectrometry (GC/MS), confirmed that there is a major 
outpouring of prostacyclin in major surgical interventions. This further supported the 
possibility that exhaustion of production of vasoactive prostaglandins does occur in 
the early post-operative period, an hypothesis which merits further study.
Gas chromatography/negative iron chemical ionisation mass spectrometry 
(GC/NICIMS) was used in the final part of the human studies to assay PGb 
production but this was possible only in a limited number of peripheral and portal
228
This highly specific and sensitive method of assaying PGb, (Blair lA et al, 1982), 
confirmed the findings using the Cardeza RIA that in man levels of circulating PGb 
are extremely low and indeed barely detectable, (<2pg/ml). The finding of increased 
levels in portal venous and peripheral samples in patients with portal hypertension 
undergoing surgery, must be interpreted with caution however because of the 
undoubted major effect of surgical trauma on PGb production. Further studies using 
this assay, but on samples collected less invasively, perhaps by portal venous 
cannulation during TIPS procedure would be an area of future study. It would be 
important in any such studies to exclude the effect of general anaesthesia. General 
anaesthesia has long been shown to affect splanchnic blood flow causing reductions 
of up to 30% in this vascular bed with 20-50% reduction in hepatic blood flow.
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venous samples. Once again, levels in samples obtained at laparotomy were found 
to be much higher than pre-operative peripheral venous samples. Similarly, 
increased levels of peripheral venous 6-keto PGFio were found in patients 
undergoing cardio-thoracic surgery. The trauma of general anaesthesia for major 
surgery with its multiple catheterisations, and the surgical handling of tissues is 
therefore implicated in this massive release of PGb In view of the limited access to 
this assay during these studies, limited comparison was possible between the 
normotensive and hypertensive portal venous samples. However, a significant 
increase in PGb production in portal hypertension was found in portal plasma from 
patients actively bleeding from oesophageal varices compared to normal. This is an
important finding in a small sample of 6 patients which provides clinical evidence to 
support my hypothesis that increased PGb production may be a factor in the 
severity of bleeding from ruptured varices.
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(Calverley RK et al, 1978, Eger El et al, 1970 and Gelman SI, 1976). Such a 
significant reduction in splanchnic blood and hepatic blood flow would reduce portal 
pressure, thus potentially causing diminished PGb production by the endothelial cells 
of the portal venous system. Future studies on portal venous tissues in addition to 
serum would also be of value (accepting the effect of general anaesthesia), but in 
the modern era the only readily available source of portal hypertensive samples 
would be in patients in end stage liver failure undergoing liver transplantation. 
Plasma measurements in such further studies must be using GC/MS methodologies 
rather than RIA which is undoubtedly unreliable in plasma measurements. As has 
been emphasized throughout this thesis, these facts were not recognized at the time 
of the studies and the logistics were such that GC/NICIMS was not readily available 
for larger studies than the one performed.
Thus the evidence gathered from this work in man indicates high levels of PGb 
production in the normal portal circulation but it remains unclear whether there is 
further elevation in portal hypertension. The generally undetectable levels of 
peripheral PGb in the plasma, even in patients with portal hypertension, would 
suggest that “spill-over” of PGb from the splanchnic circulation via collaterals is 
unlikely to contribute in man to the hyperdynamic circulation of portal hypertension. 
Infusion of PGb for treatment of disorders such as severe lower limb ischaemia is 
usually given at 8ng/min. This causes marked haemodynamic and platelet effects in 
man but results in peripheral plasma concentrations of 6-keto PGFiO of 291-510 
pg/ml, (Dollery CT et al, 1983). The levels of <2pg/ml in stable portal hypertensives, 
and 25-31 pg/ml in patients with bleeding oesophageal varices who are not
-.f
undergoing surgery, would not be expected to have any major haemodynamic effect.
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Possibly in man, PGb may play a role in the initial development of collaterals and the 
hyperdynamic circulation but not in its maintenance.
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In man therefore, PGb most probably acts at a local endothelial level rather than as 
a systemic hormone. All of my clinical studies have revealed elevated levels of PGb 
to be present in the portal circulation, both in the presence and in the absence of 
portal hypertension. These levels are within the range where significant effects on 
platelet aggregation can occur. Furthermore, there may be surges in PGb 
production as portal pressure changes. It is well recognised that portal pressure 
may increase significantly after meals and during infections. A recently proposed 
hypothesis implicates bacterial infection with portal endotoxaemia in the 
pathogenesis of variceal bleeding, (Goulis J et al, 1999). Endotoxin may mediate 
increased release of endothelin causing increased portal hypertension by stellate cell 
contraction. This may cause increased PGb production which also may be 
separately simulated by the action of the endotoxin. Furthermore, endothelin may
also mediate increased PGb production by the endothelium. Similar effects on 
increased nitric oxide production result and the combination of increased production
of PGb and nitric oxide could inhibit platelet aggregation resulting in disturbance of 
haemostasis at the site of variceal rupture.
There is scarce human data available to allow conclusions regarding the importance 
of PGb in development of the hyperdynamic circulation to be made. Further studies 
are required to investigate possible correlations between haemodynamic markers 
such as cardiac output, splanchnic blood flow, and accurate circulating PGb 
measurements.
,'ÿ
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Since this work was done, several other factors which cause vasodilatation have 
been proposed and Investigated using the model of PPVL. These include glucagon,
(Benoit JN et al, 1986, Kravetz D et al, 1988), adenosine (Murakami S et al, 1996), 
bile acids (Genecin P et al, 1990), endotoxin (Mehta R et al, 1990), nitric oxide 
(Sieber CC et al, 1992), and tumour necrosis factor (Lopez-Talavera JC et al, 1996).
Much current work is focusing on the concept that increased nitric oxide production 
plays an important role in the development of the vasodilatory changes in 
experimental portal hypertension. We have recently investigated the hypothesis that 
formation of reactive oxidant species causes oxidative stress in the portal circulation 
with activation of NF kappa-p resulting in synthesis of nitric oxide. Nitric oxide 
produced in the portal circulation and ‘spilling over' into the systemic circulation via 
collaterals, has been implicated as a causative factor in the development of the 
hyperdynamic circulation (Fernando BS, 1999).
Thus it is likely that the development of the hyperdynamic circulation results from an 
interplay of several factors which act to maintain it. The majority of evidence is 
based on experimental models with relatively little human data available at the 
present time. This accumulated experimental data suggests further future avenues 
of possible clinical intervention to modulate the development of portal hypertension.
Clinical trials of cyclooxygenase inhibitors are ethically difficult because of the likely 
effect of these agents on renal prostaglandin metabolism leading to hepato-renal 
syndrome and also because of the coronary complications reported with COX-2 
inhibitors. Specific PGb inhibitors which are safe are also not currently available.
The proposed prospective double-biinded randomised trial of antibiotic treatment
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versus placebo for prevention of variceal bleeding would be of great interest. This 
would test the hypothesis, (Goulis J et al, 1999), that endotoxaemia is the prime 
mediator for increases in portal hypertension and release of nitric oxide and 
prostacyclin which may result in deficient coagulation at the site of variceal rupture.
The model of partial portal vein ligation proved to be reliable and convenient but the 
initial model in rats of low weight proved to provide portal hypertension of only two
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Such a clinical study would involve large numbers of patients and in-vitro platelet 
studies to establish whether impaired platelet function is present in variceal bleeding 
would then be possible. If this effect was confirmed, it would also be possible to 
determine whether this was secondary to the effects of nitric oxide or PGb release. 
The logistics and ethics of obtaining portal venous samples would be most difficult 
however. If this study confirms the importance of the two mediators, the 
development of future inhibitors of nitric oxide synthase or cyclooxygenase may 
prove to be beneficial in the prevention of variceal bleeding.
Conclusion
Accurate measurement of PGb proved to be difficult from the beginning. The need 
for evolution of these assays from bioassay, through radioimmunoassay with and 
without an extraction process, and eventually to the gold standard of GC/NICIMS, in 
our laboratory paralleled the experience of others. The experimental studies in rat 
and pig revealed a high level of production of prostacyclin in all tissue studied with a 
consistent finding of the highest levels of PGb being produced in portal venous 
tissues.
1.
%
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weeks duration, identification of the important and major collateral channel via the 
left anterior lumbar vein allowed modification to provide a reliable model of chronic 
portal hypertension. It was also found that using a more severe degree of partial 
portal vein ligation also resulted in long lasting portal hypertension.
In the rat PPVL models, production of PGb by portal vein endothelium was found to 
be directly related to portal hypertension. This relationship was confirmed to be 
highly significant with significantly increased PGb production being present in all 
cases when portal hypertension had developed. In the first model, the return of 
portal vein pressure to normal with the opening up of collaterai circulation was 
accompanied by return of PGb production to normal levels. Correlation between 
measurements made using the bioassay in these experiments, and those using 
radioimmunoassay for 6-keto PGFio confirmed that the bioassay was measuring 
PGb production.
i
A significant but lesser effect on PGb production was confirmed to result from 
surgical intervention. This increased PGb production was confirmed to also happen 
in man.
Clinical studies on human venous tissues and plasma confirmed elevated PGb 
production by portal venous tissue and in the portal venous blood. Very low and in 
many cases undetectable levels of PGb in peripheral plasma was found in man 
using the more specific RIA with the Cardeza anti-serum, and the highly specific 
GC/NICIMS. No difference could be found in portal venous tissue between patients 
with or without portal hypertension, but higher levels were found in portal
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hypertensive venous plasma levels, and the highest levels of all were found in portal 
plasma samples from actively bleeding patients. The numbers studied however 
were small. .1
Several other vasoactive substances are now implicated in the pathophysiology of 
portal hypertension. The commonest among these currently is nitric oxide which 
also has an effect similar to prostacyclin, and seems to act synergistically with it. 
The rotes of nitric oxide and prostacyclin in the pathophysiology of portal 
hypertension and the possible effects on bleeding from oesophageal variceal rupture 
merit further study. The studies described here were the first to provide insight into 
the pathophysiology of portal hypertension relating to prostacyclin and endothelial 
function. Clinical evidence to support the hypothesis that increased prostacyclin 
release in portal hypertension may play a significant role in the severity of bleeding 
from oesophageal varices was found albeit in 6 patients. The hypothesis has 
therefore not been disproved and further clinical study certainly in larger numbers of 
patients, and possibly with selective COX-2 inhibitor drugs are required.
■5
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APPENDIX A
Reagents
Tris Buffer dH 8.0
Tris is Tris (hydroxymethly) methylamine.
Molecular weight = 121.14 (BDH, Analar).
6.057g in 1000ml. Of 0.9% sodium chloride gives 50mM solution.
Its pH, around 11 is then adjusted to ph 8.0 using concentrated hydrochloric acid. The same 
solution is adjusted to pH 7.5 when indicated.
Gleatin tris buffer pH 7.5 (GTB)
6.057g tris in 1000ml of 0.9% saline 
1g sodium azide (Sigma)
1 g gelatin (Sigma)
The pH of the solution is adjusted to 7.5 using concentrated hydrochloric acid.
Tris buffer containing 1% plasma v Globulin 
0.9ml GTB
0.1ml plasma (blood being collected in 0.38% trisodium citrate).
Tris buffer is used for the 6ketoPGFia RIA using the Cardeza antiserum.
Qwren's buffered saline pH 7.35 
20% Owren’s barbiturate buffer pH 7.35:
11.75 sodium diethylbarbiturate (Barbitone sodium)
14.67g sodium chloride
1570ml distilled water
430ml 0.1 N hydrochloric acid
80% isotonic saline (0.9% w/v sodium chloride).
Tritiated 6ketoPGF.„f(^H1 - 6ketoPGFi„)
This was bought from the Radiochemical Centre, Amersham, about once every four months and 
stored at less than -20°C.
Molecular weight with tritium = 380 
Specific activity = 150Ci/mMol = 395mCi/mg.
1 Ci (Curie) 2.22 x 10^  ^disintegrations per minute (dpm)
236
therefore 1 mg = 396 x 2.22 x 10® dpm 
1 ng = 395 x 2.22 x 10® dpm 
1 pg = 395 X 2.22 dpm = 876.9 dpm 
Activity in the stock = 0.1mCi/ml
0.005ml = 0.0005mCi 
Dissolved in 10m Tris = O.OOOOOSmCi
= 0.000005 X 2.22 x 10® dpm 
= 11.1 X 10^  dpm 
= 11000 dpm
Therefore, to prepare the labelled 6ketoPGFic solution, 6pl stock f  H) - 6ketoPGFia was dissolved 
in 10ml GTB and 0.1ml was used for each sample.
Dextran coated charcoal (DCC)
Charcoal (Norit A, Sigma) was washed several times over a period of days with distilled water, 
discarding any that did not precipitate and then dried in an oven. This procedure was to ascertain 
that the washed charcoal would all precipitate when centrifuged during the RIA. Dextran coated 
charcoal:
0.25g washed charcoal
0.025 Dextran T40 (Pharmacia Fine Chemicals)
100ml GTB
Scintillation Fluid forOketoPGFi»
20g butyl-PBD (Chemical and Services)
1400ml Toluene (BDH, Analar Grade)
600ml Triton X-100 (BDH, Analar Grade)
Antiserum to SketoPGFi» (Wellcome)
The antiserum was in a freeze-dried from and 5mg was weighed out and made up to 10mg in tris 
buffer pH 7.5. Aliquots of 0.75ml were made and stored at -40°C until used when the aliquot was 
made up to 9ml with GTB.
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APPENDIX B
Procedures
Total' and ‘Charcoal Blank' Samples
A ‘total’ sample measures the total amount of radioactivity present in each sample.
A 'charcoal blank’ sample measures the amount of non-specific binding in the radioimmunoassay 
system.
Both types of samples have:
0.3ml GTB
0.1ml fH) - 6ketoPGFia (ca. 10000 dpm)
However, 1ml of dextran coated charcoal is added to the ‘charcoal blank’ sample while 1ml of GTB 
is added to the ‘total’ sample at the end of the incubation period when bound f  H) - 6ketoPGFia is 
separated from free.
Calculation of bound fraction f%)
DCC bound to free ligand in the assay mixture can be precipitated by centrifugation, so that the
supernatant fraction consists of the bound ligand which is counted. The LKB scintillation counter
converts the count per minute (CPM) to disintegrations per minute (dpm). Expressing the dpm
obtained from the sample over the ‘total’ present having first excluded the amount found in the
charcoal blank for both samples, gives the percentage bound.
% bound = dom in supernatant of sample -  charcoal blank 
dpm in ‘total’ -  charcoal blank
APPENDIX 0
Calculations
Calculation on the relative cross-reactions of the Wellcome antiserum to prostaglandins
A) From standard curves (Fig 6.31:
At 50% total activity:
6ketoPGFia 251 pg
PGfza 7244 pg
238 '..Ï
' 4
PGA2
PGE2
PGAi
380189 pg 
758578 pg 
275423 pg
Therefore relative cross-reaction to
PGF2a
PGEi
PGA2
PGE2
B)
251
7244
251
275423
251
380189
251
758578
From Logit Plots (Fig 3.3.1.5.2.b):
At loge — -5
6ketoPGFia = log 1.6 i.e. 39.8 ng
PGFza = log 4.1 i.e. 12589.2 ng
PGA2, E2 and Ei are less than 10,000,000
Therefore relative cross-reaction to
PGF2a
C)
PGAz, Ezand Ei
From Logit Plots (Fig 3.3.1.5.2.cL 
At loge — -5
6ketoPGFia = 14700
PGI2 = 27000
39.8
12589.2
39.8
10,000,000
0.03
.0009
.0007
.0003
0.0032 
< 0.000004
i
■:S
Therefore relative cross-reaction to = 14700
27000
0.54
■ I-
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